

SOPHARMA AD**SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020**

SEPARATE STATEMENT OF COMPREHENSIVE INCOME	1
SEPARATE STATEMENT OF FINANCIAL POSITION	2
SEPARATE STATEMENT OF CASH FLOWS	3
SEPARATE STATEMENT OF CHANGES IN EQUITY	4
NOTES TO THE SEPARATE FINANCIAL STATEMENTS	
1. BACKGROUND CORPORATE INFORMATION	5
2. SUMMARY OF THE SIGNIFICANT ACCOUNTING POLICIES OF THE COMPANY	7
3. REVENUE	53
4. OTHER OPERATING INCOME AND LOSSES	56
5. RAW MATERIALS AND CONSUMABLES USED	58
6. HIRED SERVICES EXPENSE	59
7. EMPLOYEE BENEFITS EXPENSE	60
8. OTHER OPERATING EXPENSES	61
9. IMPAIRMENT OF CURRENT ASSETS	62
10. IMPAIRMENT OF NON-CURRENT ASSETS, OUTSIDE THE SCOPE OF IFRS 9	62
11. FINANCE INCOME	63
12. FINANCE COSTS	63
13. INCOME TAX EXPENSE	64
14. OTHER COMPREHENSIVE INCOME	65
15. PROPERTY, PLANT AND EQUIPMENT	66
16. INTANGIBLE ASSETS	69
17. INVESTMENT PROPERTY	70
18. INVESTMENTS IN SUBSIDIARIES	74
19. INVESTMENTS IN ASSOCIATES	77
20. OTHER LONG-TERM EQUITY INVESTMENTS	78
21. LONG-TERM RECEIVABLES FROM RELATED PARTIES	81
22. OTHER LONG-TERM RECEIVABLES	82
23. INVENTORIES	84
24. RECEIVABLES FROM RELATED PARTIES	87
25. TRADE RECEIVABLES	91
26(A). LOANS GRANTED TO THIRD PARTIES	94
26(B). OTHER RECEIVABLES AND PREPAYMENTS	95
27. CASH AND CASH EQUIVALENTS	97
28. EQUITY	98
29. LONG-TERM BANK LOANS	101
30. DEFERRED TAX LIABILITIES	103
31. GOVERNMENT GRANTS	105
32. LEASE LIABILITIES TO RELATED PARTIES	106
33. LEASE LIABILITIES TO THIRD PARTIES	106
34. RETIREMENT BENEFIT OBLIGATIONS	108
35. SHORT-TERM BANK LOANS	112
36. TRADE PAYABLES	113
37. PAYABLES TO RELATED PARTIES	114
38. TAX PAYABLES	115
39. PAYABLES TO PERSONNEL AND FOR SOCIAL SECURITY	116
40. OTHER CURRENT LIABILITIES	116
41. CONTINGENT LIABILITIES AND COMMITMENTS	117
42. FINANCIAL RISK MANAGEMENT	119
43. SEGMENT REPORTING	135
44. RELATED PARTY TRANSACTIONS	137
45. EVENTS AFTER THE REPORTING PERIOD	142

1. BACKGROUND CORPORATE INFORMATION

SOPHARMA AD is a business entity registered in Bulgaria with a seat and registered address of management: Sofia, 16, Iliensko Shousse St. The Company was entered in the Commercial Registry on 11 April 2008 with UIC 831902088.

The Company was registered with court on 15 November 1991 by Decision No 1/1991 of Sofia City Court.

1.1. Ownership and management

Sopharma AD is a public company under the Public Offering of Securities Act.

As at 31 December 2020, the structure of Company's joint-stock capital was as follows:

	%
Donev Investments Holding AD	26.54
Telecomplect Invest AD	20.68
Rompharm Company OOD	6.21
Mandatory Universal Pension Fund (MUPF) Allianz Bulgaria	5.10
Sopharma AD (treasury shares)	6.69
Other legal entities	26.38
Natural persons	8.40

Sopharma AD has a one-tier management system with a five-member Board of Directors. Company's management in the form of Board of Directors is composed as at 31 December 2020 as follows:

Ognian Donev, PhD	Chairperson
Vessela Stoeva	Member
Ognian Palaveev	Member
Alexander Chaushev	Member
Ivan Badinski	Member

The Company is represented and managed by its Executive Director Ognian Donev, PhD.

The Audit Committee supports the work of the Board of Directors and plays the role of those charged with governance that exercise monitoring and control over the internal control system, risk management and Company's system of financial reporting.

The composition of the Audit Committee is as follows:

Vasil Naidenov	Chairperson
Tsvetanka Zlateva	Member
Kristina Atanasova - Elliot	Member

Pursuant to a business management contract dated 9 June 2020, the Company's Procurator is Simeon Donev. The average number of Company's personnel for 2020 is 1,991 workers and employees (2019: 2,275).

1.2. Principal activities

The principal activities of the Company include the following types of transactions and deals:

- production and trade in medicinal substances and finished drug forms;
- research and development as well as engineering and implementation activities in the field of medicinal products.

The Company holds manufacturing / import authorisation for medicinal products No BG / MIA -0184 dated 16 September 2020, issued by the Bulgarian Drug Agency (BDA).

1.3. Main indicators of the economic environment

The main economic indicators of the business environment that have affected the Company's activities throughout the period 2017 – 2020 are presented in the table below:

Indicator	2017	2018	2019	2020
Nominal GDP in million levs*	102,345	109,743	119,772	117,520
Actual growth of GDP*	3.5%	3.1%	3.7%	-4.2%
Year-end inflation (HICP)	1.8%	2.3%	3.1%	-0.3%
Average exchange rate of USD for the year	1.73	1.66	1.75	1.72
Exchange rate of the USD at year-end	1.65	1.72	1.76	1.59
Basic interest rate at year-end	0.00	0.00	0.00	0.00
Unemployment rate (at year-end)**	7.1%	6.1%	5.9%	6.7%

* Note: BNB forecast for 2020, **According to data of the Employment Agency, Source: BNB

1.4. COVID-19 pandemic – impact, effects, actions and measures taken

On 11 March 2020 the World Health Organisation declared a COVID-19 pandemic, and on 13 March 2020 the Bulgarian Parliament imposed a state of emergency in Bulgaria, as a result of which a number of restrictive measures were taken.

On 24 March 2020, the State of Emergency Act was promulgated, imposing measures for the period of the pandemic state of emergency in various areas – employment relations and social security, taxation and annual financial closure, default and forced execution, deadlines, etc. Decisions and orders of the Council of Ministers and the Ministry of Health were adopted for introducing anti-epidemic measures on the territory of the country aimed to protect and preserve the population's life and health.

On 10 April 2020 the Bulgarian National Bank approved a "Procedure for deferral and settlement of payables due to banks and their subsidiaries – financial institutions, in relation to the state of emergency imposed on 13 March 2020 by the National Assembly.

As a result of the restrictions imposed in Bulgaria and in most countries around the world, the normal functioning of businesses in a number of sectors of the economy was disrupted. There were difficulties with the supplies of raw and other materials from suppliers, shipments to clients, and procuring workforce. Almost all entities, though to a different extent, had to impose certain actions and measures to reorganise business operations, work schedules, business communications and other aspects of their relations to counterparts, partners, and state institutions.

Impact on the Company's operations and financial position

The Company operates in the pharmaceutical sector. It continues to perform its operations without encountering significant difficulties in procuring asset supplies and performing sales to customers. No contracts with key suppliers and/or customers have been terminated.

The management did not dismiss personnel and did not take advantage of the measures introduced by the State of Emergency Act ("60:40", etc.).

The Company has sufficient financing to meet its liquidity needs.

Nevertheless, the Company's operating volumes in 2020 were affected by the pandemic in the country and in the other countries with which it has business connections and relations. Sales revenue in the country decreased by BGN 22,274 thousand or 24,31%, and export sales revenue – by BGN 2,094 thousand or 1,53% (*Note 3*).

2. SUMMARY OF THE SIGNIFICANT ACCOUNTING POLICIES OF THE COMPANY

2.1. Basis for preparation of the separate financial statements

The separate annual financial statements of SOPHARMA AD have been prepared in accordance with all International Financial Reporting Standards (IFRS), which comprise Financial Reporting Standards and the International Financial Reporting Interpretations Committee (IFRIC) interpretations, approved by the International Accounting Standards Board (IASB), as well as the International Accounting Standards (IAS) and the Standing Interpretations Committee (SIC) interpretations, approved by the International Accounting Standards Committee (IASC), which are effectively in force on 1 January 2020 and have been accepted by the Commission of the European Union. IFRSs as adopted by the EU is the commonly accepted name of the general-purpose framework – the basis of accounting equivalent to the framework definition introduced by § 1, p. 8 of the Additional Provisions of the Accountancy Act "International Accounting Standards" (IASs).

For the current financial year the Company has adopted all new and/or revised standards and interpretations, issued by the International Accounting Standards Board (IASB) and respectively, by the International Financial Reporting Interpretations Committee (IFRIC), which have been relevant to its activities.

The adoption of these standards and/or interpretations, effective for annual periods commencing on 1 January 2020, has not resulted in changes to the Company's accounting policy, with the exception of some new and the expansion of already introduced disclosures, without leading to other changes in the classification or measurement of individual reporting items and transactions.

The new and/or amended standards and interpretations include:

- *Amendments to the Conceptual Framework for Financial Reporting (the "Framework") and the respective references thereto in various IFRS (in force for annual periods beginning on or after 1 January 2020, endorsed by EC).* These amendments to the Framework include fully revised definitions of "asset" and "liability", as well as new guidance and concepts for their measurement, derecognition, presentation, and disclosure. The amendments to the Conceptual Framework are accompanied by amendments to some references thereto in the International Financial Reporting Standards, including IFRS 2, IFRS 3, IFRS 6, IFRS 14, IAS 1, IAS 8, IAS 34, IAS 37, IAS 38, IFRIC 12, IFRIC 19, IFRIC 20, IFRIC 22 and SIC 32. Some of the references state which version of the Conceptual Framework statements in the respective standards should refer to (the IASC framework adopted by IASB in 2001, the IASB framework of 2010, or the new revised framework dated 2018), while others specifically state that the standard's definitions have not been updated in accordance with the framework's latest amendments.
- *IFRS 3 (amended) "Business Combinations" (in force for annual periods beginning on or after 1 January 2020, endorsed by EC).* This change concerns the definition of "business" provided in the appendices to the standard and is related to the difficulties that acquiring entities experience when determining whether they have acquired a business or a group of assets. The amendment aims: (a) to clarify that to be considered a business, an acquired set of activities and assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs; (b) to narrow the definitions of a business and of outputs by focusing on goods and services provided to customers and by removing the reference to an ability to reduce costs; (c) to add guidance and illustrative examples to help entities assess whether a substantive process has been acquired; (d) to remove the assessment of whether market participants are capable of replacing any missing inputs or processes and continuing to produce outputs; and (e) to add an optional concentration test that permits a simplified assessment of whether an acquired set of activities and assets is a business, or not.
- *Amendments to IAS 1 "Presentation of Financial Statements" and IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors" (in force for annual periods beginning on or after 1 January 2020 – endorsed by EC).* These changes relate to providing a more precise definition of 'material' as stated in the two standards. According to them, the new definition of 'material' is: "Information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements, which provide

financial information about a specific reporting entity”. There are three new aspects of the definition which should be noted: (a) “Obscuring”. The existing definition only focused on omitting or misstating information, however, the IASB concluded that obscuring material information with information that can be omitted can have a similar effect. (b) “Could reasonably be expected to influence”. The existing definition referred to ‘could influence’ which the IASB felt might be understood as requiring too much information as almost anything ‘could’ influence the decisions of some users even if the possibility is remote; and (c) Primary users (existing or potential investors, lenders and other creditors) - the existing definition referred to ‘users’ which the IASB feared might be understood too broadly as requiring to consider all possible users of financial statements when deciding what information to disclose. Moreover, the amendments stress especially five ways material information can be obscured: (a) if the language regarding a material item, transaction or other event is vague or unclear; (b) if information regarding a material item, transaction or other event is scattered in different places in the financial statements; (c) if dissimilar items, transactions or other events are inappropriately aggregated; (d) if similar items, transactions or other events are inappropriately disaggregated; and (e) if material information is hidden by immaterial information to the extent that it becomes unclear which information is material. Moreover, the amendments clarify that referring to unclear information shall have the same effect as to omitted or missing information, and that materiality shall be assessed by the entity in the context of the financial statements taken as a whole.

- *Amendments to IFRS 9 “Financial Instruments”, IAS 39 “Financial Instruments: Recognition and Measurement” and IFRS 7 “Financial Instruments: Disclosures” (in force for annual periods beginning on or after 1 January 2020 – endorsed by EC)*. These amendments are related to the uncertainty ensuing from the interest rates benchmark reform undertaken by the Financial Stability Board of G20. This reform is aimed at replacing the existing interbank interest rates used as benchmarks in transactions with financial instruments (for instance: Libor, Euribor, Tibor) with alternative benchmarks based on interbank offered rates, and at developing alternative interest rates benchmark that are almost risk-free. The aim is to overcome consequences on the financial reporting resulting from the reform in interest rates benchmark in the period before the replacement of an existing interest rate benchmark with an alternative interest rate benchmark. The amendments envisage temporary and limited relief to the hedge accounting requirements in IFRS 9 and IAS 39 allowing entities to continue observing the two standards while ignoring the reform’s effect.

At the date when these financial statements have been approved for issue, with respect to the following new standards and interpretations as well as amended standards and interpretations, issued but not yet in force for annual periods beginning on or after 1 January 2020, the management has assessed and has concluded that these amendments would not affect materially the accounting policies and the classification of values of reporting items in the Company's financial statements, namely:

- *Amendments to IFRS 16 "Leases" (in force for annual periods beginning on or after 1 June 2020, endorsed by EC).* These amendments introduce a practical appropriate measure which exempts lessees from having to consider individual lease contracts to determine whether rent concessions occurring as a direct consequence of the COVID-19 pandemic are lease modifications. This measure applies when all of the following conditions are met: a) the change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change; b) any reduction in lease payments affects only payments due on or before 30 June 2021; and c) there is no substantive change to other terms and conditions of the lease. A lessee that uses the practical measure accounts for any change in lease payments resulting from the rent concession in the same way that it would account for the change applying IFRS 16 if the change were not a lease modification. It does not affect lessors. Earlier application is permitted.
- *IFRS 17 "Insurance Contracts" including amendments to IFRS 17 (in force for annual periods beginning on or after 1 January 2023, not endorsed by EC).* This is an entirely new accounting standard on all types of insurance contracts, including some guarantees and financial instruments, and includes rules on recognition and measurement, presentation and disclosure. It is not applicable to the Company's operations; therefore, the management has not assessed the application thereof.
- *IFRS 10 (amended) "Consolidated Financial Statements" and IAS 28 (amended) "Investments in Associates and Joint Ventures" – regarding the sale or contribution of assets between an investor and its associates or joint ventures (postponed effective date, to be determined by the IASB).* These amendments address the accounting treatment of the sale or contribution of assets between an investor and its associates or joint ventures. They confirm that the accounting treatment depends on whether the assets sold or contributed constitute in substance a business as defined in IFRS 3. If these assets as an aggregate do not meet the definition of a business, then the investor shall recognise gain or loss only to the extent of other unrelated investor's interests in the associate or joint venture. In cases of sale or contribution of assets, which as an aggregate constitute a business, the investor shall recognise the full gain or loss on the transaction. The amendments will be applied on a prospective basis. IASB postponed the initial date of application of these amendments for an indefinite period.

- *Amendments to IAS 1 “Presentation of Financial Statements” (in force for annual periods beginning on or after 1 January 2023, not endorsed by EC).* These amendments address the criteria for classification of liabilities as current or non-current. According to them, an entity classifies its liabilities as current or non-current depending on the rights that are in existence at the end of the reporting period, and the classification is unaffected by expectations about whether it will exercise its right to defer settlement of the liabilities. The amendments made clear that “settlement” refers to the transfer to a counterparty of cash, equity instruments, other assets or services. The classification does not address derivatives of convertible liabilities, which constitute equity instruments. The amendments are applied retrospectively.
- *Amendments to IFRS 3 “Business Combinations” (in force for annual periods beginning on or after 1 January 2022, not endorsed by EC).* These amendments update IFRS 3 by replacing an outdated reference to the Conceptual Framework for Financial Reporting with its latest updated 2018 version. They also add an exception from the principle for recognition of liabilities and contingent liabilities within the scope of IAS 37 “Provisions, Contingent Liabilities and Contingent Assets” and IFRIC 21 “Levies”, explicitly specifying that contingent liabilities are not recognized at the date of acquisition. The amendments are applied prospectively.
- *Amendments to IAS 16 “Property, Plant and Equipment” (in force for annual periods beginning on or after 1 January 2022, not endorsed by EC).* These amendments prohibit deducting from the cost for “testing whether the asset is functioning properly”, which is part of the direct costs attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management, net proceeds received from selling items produced while the entity is preparing the asset for its intended location and condition. Instead, the entity shall recognize this sales revenue for such items and the respective costs related thereto within profit or loss for the period, in accordance with the other applicable standards. The amendments specify that testing whether the asset is functioning properly is in fact an assessment of whether the technical and physical performance and capacity of the asset correspond to its intended use in production, supply of goods or services, lease, or for administrative purposes. Additionally, the amendment requires entities to separately disclose the amounts of proceeds and costs relating to items produced that are not an output of the entity’s ordinary activities. The amendments are applied retrospectively, but only for property, plant and equipment brought to the location and condition necessary for their intended use on or after the start of the earliest period presented in the financial statements for which the entity first applies the amendments.
- *Amendments to IAS 37 “Provisions, Contingent Liabilities and Contingent Assets” (in force for annual periods beginning on or after 1 January 2022, not endorsed by EC).* The amendments specify that the ‘cost of fulfilling’ a contract comprises the ‘costs that relate directly to the contract’, including: a) direct labour costs and direct cost of materials; and b) additional costs which related directly to fulfilling the contract – for instance, the allocation

of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract. Administrative and other general costs are excluded, unless specifically billable to the counterpart. The amendments also make a small adjustment to the clarifications for recognition of impairment losses before a separate onerous contract provision is created, by highlighting that these are assets used in fulfilling the contract rather than assets dedicated thereto, which was the requirement prior to the amendments' enforcement. An entity shall apply those amendments to contracts for which it has not yet fulfilled all its obligations at the beginning of the annual reporting period in which it first applies the amendments.

- *Annual Improvements to IFRSs 2018-2020 Cycle, to IFRS 1 "First-time Adoption of International Financial Reporting Standards", IFRS 9 "Financial Instruments", Illustrative Example 13 to IFRS 16 "Leases" and IAS 41 "Agriculture" (in force for annual periods beginning on or after 1 January 2022, not endorsed by EC).* These improvements introduce partial amendments to the following standards: a) the amendment to IFRS 1 grants a relief for a subsidiary in first-time adoption of IFRS at a date later than the parent. It measures in its separate financial statements the assets and liabilities at the carrying amounts that would be included in the parent's consolidated financial statements based on which the parent acquired the subsidiary. The subsidiary may, in its financial statements, measure the cumulative translation differences using the carrying amount stated in the parent's consolidated financial statements based on the date of the parent's date of transition to IFRS, unless adjustments have been made for the purpose of consolidation procedures or to account for the business combination's effects. This amendments will also be applied for associates and joint ventures which have elected the same relief under IFRS 1. Entities shall apply this amendments for annual reporting periods beginning on or after 1 January 2022. Earlier application is permitted; b) the amendment to IFRS 9 clarifies which fees an entity includes when it applies the '10 per cent' test in assessing whether in case of a modification of a financial liability the conditions of the new or amended financial liability significantly differ from the conditions of the initially recognized one. According to the amendment, the entity includes only fees paid or received between the entity (the borrower) and the lender, including fees paid or received by either the entity or the lender on the other's behalf. The entity applies the amendments to financial liabilities modified at or after the beginning of the annual reporting period in which it first applies these amendments; c) the amendment to Illustrative Example 13 to IFRS 16 removes from the example the illustration of the reimbursement of leasehold improvements by the lessor in order to resolve any potential confusion regarding the treatment of lease incentives. Since the amendment refers to an illustrative example accompanying the standard and is not a part thereof, no enforcement

date is specified; d) the amendment to IAS 41 removes the requirement for entities to exclude taxation cash flows when measuring the fair value of biological assets and agricultural production.

- *Amendments to IFRS 9 “Financial Instruments”, IAS 39 “Financial Instruments: Recognition and Disclosure”, IFRS 7 “Financial Instruments: Disclosure”, IFRS 4 “Insurance Contracts”, and IFRS 16 “Leases” related to Phase 2 of the Interest Rate Benchmark Reform (in force for annual periods beginning on or after 1 January 2021, not endorsed by EC).* The amendments to the standards related to Phase 2 of the Interest Rate Benchmark Reform constitute mainly two practical expedients: a) in identification and measurement of modification of contractual cash flows from financial assets, financial liabilities, and lease liabilities – the modifications to the interest rate benchmarks are accounted for by updating the effective interest rate; and b) in hedge accounting – by permitting an amendment (revision) in the identification of the hedging relationship and the measurement of the hedged item based on cash flows, due to and resulting from the substitution of the interest rate benchmarks applied with other alternatives. The amendments are applied retrospectively. Earlier application is permitted.
- *Amendments to IFRS 4 “Insurance Contracts” (in force for annual periods beginning on or after 1 January 2021, endorsed by EC).* The amendments allow entities primarily engaged with insurance activities, to defer the date of initial application of IFRS 9 “Financial Instruments” by two years, from 1 January 2021 to 1 January 2023, and continue to apply IAS 39 “Financial Instruments: Recognition and Measurement”. The aim of the amendment is to align the date of enforcement of IFRS 9 with the new IFRS 17 to overcome temporary accounting consequences from the different effective dates of the two standards. The amendment also introduces a temporary exemption from the requirements of IAS 28 “Investments in Associates and Joint Ventures”, with respect to the application of a uniform policy for entities using the equity method under IAS 28. For annual periods beginning before 1 January 2023, such entities are allowed, but not obliged, to retain the respective accounting policy applied by the associate or joint venture when using the equity method.
- *Amendments to IAS 1 “Presentation of Financial Statements” and IAS 8 “Accounting Policies, Changes in Accounting Estimates and Errors” (in force for annual periods beginning on or after 1 January 2023 – not endorsed by EC).*

- *Amendments to IAS 8 “Accounting Policies, Changes in Accounting Estimates and Errors” (in force for annual periods beginning on or after 1 January 2023 – not endorsed by EC).*
- *Proposed amendments to IFRS 16 “Leases” lease discounts in the context of COVID-19 after 30 June 2021 (in force for annual periods beginning on 1 April 2021, nor endorsed by EC).*

The separate financial statements of the Company have been prepared on a historical cost basis except for property, plant and equipment, investment property and financial assets constituting equity investments through other comprehensive income, which are measured at revalued amount and respectively, at fair value.

The Company keeps its accounting books in Bulgarian Levs (BGN), which is accepted as being its presentation currency. The data in the separate financial statements and the notes thereto is presented in thousand Bulgarian Levs (BGN'000) except where it is explicitly stated otherwise.

The presentation of financial statements in accordance with International Financial Reporting Standards requires the management to make best estimates, accruals and reasonable assumptions that affect the reported values of assets and liabilities, the amounts of income and expenses and the disclosure of contingent receivables and payables as at the date of the financial statements. These estimates, accruals and assumptions are based on the information, which is available at the date of the financial statements, and therefore, the future actual results might be different from them (whereas in the conditions of financial crisis the uncertainties are more significant). The items presuming a higher level of subjective assessment or complexity or where the assumptions and accounting estimates are material for the financial statements, are disclosed in *Note 2.32, Note 15, Note 17 and Note 20.*

2.2. Consolidated financial statements of the Company

The Company has started the process of preparation of its consolidated annual financial statements for year 2020 in accordance with IFRS effective for year 2020 whereas these separate annual financial statements will be included therein. In accordance with the planned dates, the management expects that the consolidated annual financial statements will be approved for issue by the Board of Directors of the Company not later than 30 April 2021 and after this date the financial statements will be publicly made available to third parties.

2.3. Comparatives

The Company usually presents comparative information for one prior year in its financial statements.

Where necessary, comparative data is reclassified (and restated) in order to achieve comparability in view of the current year presentation changes.

2.4. Functional currency and recognition of exchange differences

The functional and reporting (presentation) currency of the Company is the Bulgarian Lev. Starting from 1 July 1997 the Bulgarian Lev was fixed under the Bulgarian National Bank Act to the German Mark at the ratio of BGN 1 : DEM 1, and with the introduction of the Euro as the official currency of the European Union, it has been fixed to the Euro at a ratio of BGN 1.95583 : EUR 1.

Upon its initial recognition, a foreign currency transaction is recorded in the functional currency whereas the exchange rate to BGN at the date of the transaction or operation is applied to the foreign currency amount. Cash and cash equivalents, receivables and payables, as monetary reporting items, denominated in a foreign currency, are recorded in the functional currency by applying the exchange rate as quoted by the Bulgarian National Bank (BNB) for the last working day of the respective month. At 31 December, these amounts are presented in BGN at the closing exchange rate of BNB.

The non-monetary items in the statement of financial position, which have been initially denominated in a foreign currency, are accounted for in the functional currency by applying the historical exchange rate at the transaction date and are not subsequently revalued at the closing exchange rate.

Foreign exchange gains or losses arising on the settlement or recording of foreign currency transactions at rates different from those at which they were converted on initial recognition, are recognised in the statement of comprehensive income (within profit or loss for the year) in the period in which they arise and are treated as 'other operating income/(losses)' (within profit or loss for the year) and presented net.

2.5. Revenue***Revenue from contracts with customers***

The Company's usual revenue is from the activities disclosed in *Note 3.1*.

2.5.1. Recognition of revenue from contracts with customers

The Company's revenue is recognised when control over the goods promised in the *contract with the customer* is transferred to the customer. Control is transferred to the customer upon satisfaction of the contractual performance obligations through transfer of the promised goods and/or provision of the promised services.

Measurement of contracts with customers

The Company accounts for *a contract with a customer* only if upon its enforcement: a/ it has commercial essence and rationale; b/ the parties to the contract have approved the contract (in writing, orally or in accordance with other customary business practices) and are committed to perform it; c/ each party's rights and the d/ payment conditions can be identified; and e/ it is probable that the Company will collect the consideration to which it is entitled upon performing its performance obligations. In evaluating whether collectability of an amount of consideration is probable, the Company considers all relevant facts and circumstances of the transaction, including past experience, customary business practices, published rules and declarations made by the Company, collaterals and possibilities for satisfaction.

A contract for which any of the above criteria has not yet been met is subject to new assessment in each reporting period. The consideration received under such contracts shall be recognised as payable (*contract liability*) in the statement of financial position, until: a) all criteria for recognizing a contract with a customer are met; b) the Company meets its performance obligations and has received the whole or almost the whole remuneration (which is not recoverable); and/or c) when the contract is terminated and the remuneration received is not recoverable.

Upon the initial measurement of its contracts with customers, the Company makes additional analysis and judgement whether two or more contracts should be combined and accounted for as a single contract, respectively whether the products promised in each separate and/or combined contract should be accounted for as a single and/or multiple performance obligation(s).

Each promise to transfer goods which are distinct (in nature and in the context of the contract), is accounted for as a separate performance obligation.

The Company recognises revenue for *each separate performance obligation* at the level of *individual contracts with customers*, by analysing the type, term and conditions of each particular contract. For contracts with similar features, revenue is recognised on a portfolio basis, only if their grouping into a portfolio would not have a materially different impact on the financial statements.

When another (third) party is involved in the performance of obligations, the Company determines whether it acts in its capacity as principal or agent, by assessing the nature of its promise to the customer: to provide the finished goods or services on its own (principal) or to arrange for another party to provide them (agent). The Company is a principal and recognises as revenue the gross amount of remuneration if it controls the promised finished goods and/or services prior to their transfer to the customers. If however the Company does not obtain control over the promised goods and/or services and its obligation is only to organise for a third party to provide these finished goods and/or services, the Company is an agent and recognises as revenue the net amount it retains for the services granted in its capacity as agent.

2.5.2. Measurement of revenue under contracts with customers

Revenue is measured based on the *transaction price* determined for each contract.

The transaction price is the amount of consideration to which an entity expects to be entitled, excluding amounts collected on behalf of third parties. Upon determining the transaction price, the Company takes into consideration the contractual conditions and its customary business practices, including the impact of variable consideration, the existence of a significant financing component in the contract, non-cash consideration, consideration payable to the customer (if any). In contracts with more than one performance obligations, the transaction price is allocated between each performance obligation based on the standalone selling prices of each good and/or service determined based on one of the methods permitted under IFRS 15, priority being given to the method of “observable selling prices”.

The change in the scope or price (or both) of the contract is accounted for as a separate contract and/or as part of the existing contract, depending on whether the change is related to the addition of goods and/or services which are distinct, and on the price determined for them. Depending on that: a) the Company accounts for a contract modification as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct, and the price of the contract increases by an amount of consideration that reflects the entity's stand-alone selling prices of the additional promised goods or services; b) the Company accounts for the contract modification as if it were a termination of the existing contract and the creation of a new contract (future application), if the remaining goods and/or services are distinct from the goods and/or services transferred before the contract modification, but the change in the contract price does not reflect the standalone selling price of the goods and/or services added; c) the Company accounts for the contract modification as if it were a part of the existing contract (cumulative adjustment) if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied.

2.5.3. Performance obligations under contracts with customers

Revenue from the sale of products

Wholesales of medical substances and medical forms are made in the country and abroad, both based on the Company's specification (technology) and based on the customer's specification (technology). As a whole, the Company has concluded that it acts as principal in its contracts with customers, unless it has been explicitly stated otherwise for certain transactions, since usually the Company controls its goods and/or services prior to their transfer to the customer.

Sales of products based on the Company's specifications

Upon sales of products based on the Company's specifications, control is transferred to the customer *at a point in time*.

Upon *domestic sales*, this is usually upon handover of the products and the physical ownership of the customer thereof, when the customer may dispose of the finished goods by obtaining substantially all remaining rewards.

Upon *export sales*, the judgement on the point in which the customer obtains control over the finished goods is made based on the INCOTERMS applicable for the contract.

Sales of products based on the customer's specifications

Regarding products produced based on the customer's specifications, the Company has a legal and contractual restriction on direction for other use (sales to another party) and it has no alternative use. In these cases, the method of transfer is determined specifically for each contract with customers (at individual contract level). For this purpose, it is determined if the Company is entitled to payment for the work performed to date, which should at least compensate for the cost incurred, plus a reasonable margin should the contract be terminated for reasons other than the Company's default (legally exercisable right to payment).

If in the specific contract the Company has a legally exercisable right to payment, revenue is recognised *over time*, and the *output method* is used to measure progress (stage of completion) of the contract. This method has been determined as most suitable to measure progress, as the results achieved best describe the Company's activity towards complete satisfaction of the performance obligations. Progress is measured *based on the units produced versus the total number of units ordered by the customer*. The assessments of revenue, costs and/or stage of progress towards complete satisfaction of the performance obligations are reviewed at the end of each reporting period, incl. in case of change in the circumstance/occurrence of new circumstances. Each subsequent increase or decrease of expected revenue and/or costs is stated within profit or loss for the period in which the circumstances resulted in the review became known to the management.

If in the specific contract the *Company does not have a legally exercisable right to payment*, revenue is recognised *at a point in time*, when control over the products sold is transferred to the customer: when the products are handed over to the customer and it has physical title thereon (for domestic sales) and in accordance with the contract's applicable INCOTERMS (for export sales).

Transportation of the products sold

Usually, upon export sales, the Company is responsible for transporting the goods to the location agreed, and transport is organised by the Company, and the cost of transport is included (calculated) as part of the selling price. Depending on the transportation conditions agreed with the customer, it may be carried out also after control over the products sold has been transferred to the customer. Until the transfer of control over the products, the sales of products and the transportation service are accounted for as a *single performance obligation*, since they constitute parts of an integrated service.

The transportation service following transfer of control over the products sold is accounted for as a *separate performance obligation*, since the transportation can be provided by another supplier (i.e. the customer may use the products sold with easily accessible resources), and the transportation service does not modify or amend the products sold in any way. In this case, the remuneration the Company expects to be entitled to (the transaction price) is allocated between the separate performance obligations based on their standalone selling prices. The standalone selling price of the products sold is determined based on the price list effective at the transaction's date, and the standalone selling price of the transport service is determined in an approximate manner by using the cost plus margin approach.

To render the transportation service, the Company uses transportation companies – subcontractors. The Company has determined it controls the services prior to their provision to the customer and therefore it acts in its capacity as principal, since a) it bears the responsibility for rendering the services and that the services are acceptable to the customer (i.e. the Company is responsible for fulfilling the promise in the contract irrespective of whether it performs the services itself or hires a third-party service supplier to perform them); and b) it negotiates the service price independently, without interference by the customer.

Revenue from the sales of transportation services are recognised *over time*, since it is not necessary for the work performed to date to be repeated if another party has to perform the remaining work, therefore, the customer receives and consumes rewards simultaneously with the service rendition. In order to measure the

contract progress (stage of completion), the *input method* is used. This method has been determined as most appropriate to measure progress since it best describes the Company's activity regarding the transfer of control and satisfaction of obligations; respectively, it most accurately reflects the level of performance of obligations, in as far as the Company's efforts (costs incurred) are directly related to the transfer of the service to the customer. Progress is measured *based on the costs incurred versus the total costs planned for contract performance*.

Transaction price and payment terms

Selling prices are fixed based on a common or customer-specific price list and are individually determined for each product. The usual credit period is 30 to 270 days. In certain cases, the Company collects short-term advances from clients which do not have a significant financing component. The advances from clients are presented in the statement of financial position as contract liabilities.

Variable consideration

The variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The forms of variable consideration include:

- **Volume discounts:** Retrospective trade discounts provided to the customer upon reaching monthly, quarterly and/or annual turnover determined in advance, set as a uniform threshold and/or progressive bonus scheme. Upon measuring the variable consideration, the Company determines the customer's estimated turnover by using the most probable value method. The discounts granted are offset against the amounts due by the customer.
- **Price protection:** With regards to domestic sales, the Company is obliged, upon price reduction imposed by a state regulatory body, to compensate the buyer and/or its customers for finished goods purchased at a higher price and not yet sold to end clients. The payment of this consideration depends on the state policy on medicinal products price regulation and is beyond the Company's control.
- **Compensation for hidden flaws:** the customer may claim returns due to hidden flaws (quality claims) throughout the validity period of the finished goods sold, which may vary from one to five years. Quality claims are settled by the provision of new compliant goods or by recovery of the amount paid by the customer. Upon determining the compensations for hidden flaws due at the end of the reporting period, the Company takes into consideration the quality assurance system implemented thereby and the accumulated experience.
- **Compensations due to the customer:** in case of inaccurate performance of contractual obligations by the Company, usually in relation of failure to meet the negotiated delivery deadline. These are included within a decrease of the transaction price only if the payment is very likely. The Company's experience shows that historically, contract terms are complied with, and the Company has not charged payables for payment of compensations.
- **Compensations owed by the customer:** variable consideration in the form of compensations for delayed payment by the customer. Receiving such consideration depends on the customer's actions

and is beyond the Company's control. They are included within the transaction price only when the uncertainty regarding their receipt has been resolved.

Including compensations (owed by and due to the customer) within the transaction price is determined for each individual contract and is subject to review at the end of each reporting period.

The variable consideration expected in the form of various discounts, defaults and compensations is determined and measured based on the accumulated historical trade experience with customers and is recognised as adjustment for the purpose of the transaction price only and respectively the revenue (as an "increase" or a "decrease" component) only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur, including due to assessment restrictions. Any subsequent changes to amount of the variable consideration are recognised as adjustment of revenue (as an increase or a decrease) at the date of change and/or resolving the uncertainty. At the end of each reporting period, the Company updates the transaction prices, including whether the estimated price contains restrictions, so as to accurately present circumstances existing and occurring during the reporting period. Upon assessing the variable consideration, the Company uses the most likely value approach. Discounts accrued but not settled at the end of the reporting period, to which the customer still does not have unconditional right, are presented as refund obligations in the statement of financial position.

2.5.4. Contract costs

The Company treats as contract costs the following:

- the additional and directly related expenses it incurs upon concluding a contract with a customer, which it expects to recover over a period longer than twelve months (*costs to obtain a contract with a customer*) and
- the expenses it incurs to fulfil a contract with a customer and which are directly related to the specific contract, support the generation of resource to be used in the contract fulfilment and the Company expects to recover them over a period longer than twelve months (*costs to fulfil such contracts*).

In its usual activity, the Company does not incur direct and specific costs to enter contracts with customers or costs to fulfil contracts with customers which would not have occurred if the respective contracts had not been concluded.

2.5.5. Contract balances

Trade receivables and contract assets

A contract asset is the Company's right to consideration in exchange for goods or services that it has transferred to a customer but is not unconditional (receivable accrual). If by transferring the products and/or providing the services the Company performs its obligation to the customer to pay the respective consideration and/or before the payment is due, a contract asset is recognised for the consideration worked-out (which is conditional). Recognised contract assets are reclassified as trade receivables when the right to consideration becomes unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.

Contract liabilities

A contract liability is the consideration received from the customer and/or the unconditional right to receive consideration before it has performed its contractual obligations. Contract liabilities are recognised as revenue when (or as) the performance obligations are satisfied.

Contract assets and contract liabilities are stated within other receivables and payables in the statement of financial position. They are included within current assets when their maturity is within 12 months or are part of the Company's usual operating cycle, and the others are stated as non-current. Assets and liabilities from a single contract are stated net in the statement of financial position, even if they result from difference performance obligations in the contract.

Following their initial recognition, trade receivables and contract assets are subject to review for impairment pursuant to the conditions of IFRS 9 *Financial Instruments*.

2.5.6. Refund obligations under contracts with customers

The refund obligation includes the Company's obligation to reimburse a portion or the whole consideration received (or subject to receipt) from the customer under contracts with a right of return – for the expected retrospective discounts, rebates and discount volumes. The obligation is initially measured at the amount which the Company does not expect to be entitled to and which it expects to return to the customer. At the end of each reporting period, the Company updates the measurement of the refund obligations, respectively of the transaction price and of the recognised revenue.

Refund obligations under contracts with customers are stated within "other current liabilities" in the statement of financial position.

Other revenue

Other revenue comprises revenue from operating leases of investment property and non-current tangible assets and is stated within the statement of comprehensive income (within profit or loss for the year) in the "revenue" item.

2.6. Expenses

Company's expenses are recognised upon incurrence and based on the accrual and comparability principles to the extent at which this would not result in the recognition of assets/liabilities that do not meet the definitions for such under IFRS.

Deferred expenses are postponed for recognition as deferred expense in the period that contracts related thereto are performed.

Losses from the revaluation of investment property to fair value are stated in the statement of comprehensive income (within profit or loss for the year), within "other operating income/(losses)".

Losses from revaluation of agricultural produce upon initial fair value measurement are stated in the statement of comprehensive income (within profit or loss for the year), within "other operating income/(losses)".

2.7. Finance income

Finance income is included in the statement of comprehensive income (within profit or loss for the year) when earned, and comprises: interest revenue from loans granted and term deposits, interest revenue from receivables under special contracts, interest revenue for past due receivables, dividends on equity investments, net gains from exchange differences under loans denominated in a foreign currency, revenue from debt settlement transactions, gains from fair value measurements of investments in securities at fair value through profit or loss, or through other comprehensive income, gains from the fair value of long-term equity investments which constitute part of stage-by-stage acquisition of a subsidiary.

Interest income is calculated by applying the effective interest rate on the gross carrying amount of financial assets, with the exception of financial assets, which are credit-impaired (Stage 3), for which interest income is calculated by applying the effective interest rate on their amortised cost (i.e. the gross carrying amount after deducting the impairment allowance).

Finance income is stated separately from finance costs on the face of the statement of comprehensive income (within profit or loss for the year).

2.8. Finance costs

Finance costs are included in the statement of comprehensive income (within profit or loss for the year) when incurred, and are stated separately from finance income and comprise: interest expenses on loans, interest expenses on leases, bank charges and guarantees, net foreign exchange loss from loans in a foreign currency, and impairment of commercial loans granted.

Finance costs are stated separately from finance income on the face of the statement of comprehensive income (within profit or loss for the year).

2.9. Property, plant and equipment

Property, plant and equipment, including biological assets (carriers) are presented at revalued amount less the accumulated depreciation and impairment losses in value.

Initial acquisition

Upon their initial acquisition, non-current tangible assets are valued at acquisition cost (cost), which comprises the purchase price, including customs duties and any directly attributable costs of bringing the asset to working condition for its intended use. The directly attributable costs include the cost of site preparation, initial delivery and handling costs, installation costs, and professional fees for people involved in the project, non-refundable taxes, expenses on capitalised interest for qualifying assets, etc.

Upon acquisition of non-current tangible assets under deferred settlement terms, the purchase price is equivalent to the present value of the liability discounted on the basis of the interest level of the attracted by the Company credit resources with analogous maturity and purpose.

The Company has set a value threshold of BGN 500, below which the acquired assets, regardless of having the features of fixed assets, are treated as current expense at the time of their acquisition.

Subsequent measurement

The approach chosen by the Company for subsequent measurement of non-current tangible assets is the revaluation model under IAS 16, i.e. measurement at revalued amount less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The revaluation of property, plant and equipment is accepted to be performed by certified appraisers normally in a period of five years. Where the fair value changes materially in shorter periods, revaluation may be performed more frequently.

Subsequent costs

Repair and maintenance costs are recognised as current expenses as incurred. Subsequent costs incurred in relation to property, plant and equipment having the nature of replacement of certain components, significant parts and aggregates or improvements and restructuring, are capitalised in the carrying amount of the respective asset whereas the residual useful life is reviewed at the capitalisation date. At the same time, the non-depreciated part of the replaced components is derecognised from the carrying amount of the assets and is recognised in the current expenses for the period of restructure.

Depreciation methods

The Company applies the straight-line depreciation method for property, plant and equipment. Depreciation of an asset begins when it is available for use. Land is not depreciated. The useful life of the groups of assets is dependent on their physical wear and tear, the characteristic features of the equipment, the future intentions for use and the expected obsolescence.

The useful life per group of assets is as follows:

- for buildings – from 20 to 70 years;
- for facilities and transmitter devices – from 5 to 25 years;
- for machinery and equipment – from 6 to 34 years;
- for computers and mobile devices – from 2 to 5 years;
- for servers and systems – from 4 to 18 years;
- for motor vehicles – from 5 to 13 years;
- for furniture and fixtures – from 3 to 13 years;
- for biological assets (carriers) – from 10 to 12 years.

The term of use of right-of-use assets is as follows:

- for land – from 4 to 5 years;
- for buildings – from 2 to 8 years;
- for motor vehicles – from 2 to 5 years;
- for furniture and fixtures – from 2 to 3 years.

The useful life set for any tangible fixed asset is reviewed at the end of each reporting period and in case of any material deviation from the future expectations on the period of use, the latter is adjusted prospectively.

Impairment of assets

The carrying amounts of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying amount might permanently differ from their recoverable amount. If any indications exist that the estimated recoverable amount of an asset is lower than its carrying amount, the latter is adjusted to the recoverable amount of the asset. The recoverable amount of property, plant and equipment is the higher of fair value less costs to sell or the value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market conditions and assessments of the time value of money and the risks, specific to the particular asset. Impairment losses are recognised in the statement of comprehensive income (within profit or loss for the year) unless a revaluation reserve has been set aside for the respective asset. Then the impairment is at the expense of this reserve and is presented in the statement of comprehensive income (within other comprehensive income) unless it exceeds the reserve amount and the surplus is included as expense in the statement of comprehensive income (within profit or loss for the year).

Gains and losses on disposal (sale)

Tangible fixed assets are derecognised from the statement of financial position when they are permanently disposed of and no future economic benefits are expected therefrom or on sale, at the date of transfer of control to the asset recipient. The gains or losses arising from the sale of an item of 'property, plant and equipment' group are determined as the difference between the consideration the Company expects to be entitled to (sales revenue) and the carrying amount of the assets on the date when the recipient obtains control thereon. They are stated under 'other operating income/(losses), net' on the face of the statement of comprehensive income (within profit or loss for the year). The part of 'revaluation reserve' component attributable to the asset sold is directly transferred to 'retained earnings' component in the statement of changes in equity.

2.10. Biological assets (non-fruit-bearing) and agricultural produce

Upon initial acquisition, biological assets (non-fruit-bearing) are valued at acquisition cost (cost), which includes the purchase price and all direct costs necessary to align the asset to a fruit-bearing condition. Direct costs are mainly: costs for land preparation and processing, costs for planting, fertilization, irrigation and

other activities performed over a long period (4-5 years) in which biological assets (non-fruit-bearing) will be transferred into biological assets (bearer plants).

Agricultural produce is measured at fair value as at the date of acquisition, less the sales costs. The fair value of agricultural produce is determined, as follows:

- for milk thistle and yellow acacia crops – with support from a licensed appraiser;
- for wheat crops – based on information obtained from Sofia Commodity Exchange AD regarding the market value thereof in the crop period.

The agricultural produce – milk thistle seeds and yellow acacia seeds – is presented within the Company's inventories, on line "herbs", and wheat is presented within finished goods, on line "agricultural produce". Agricultural produce is subsequently measured according to the requirements of IAS 2 *Inventories*.

Gains on losses on measurement of agricultural produce at fair value, less sales costs, are recognized in the statement of comprehensive income (within profit or loss for the year) when incurred and are stated within "other operating income/(losses), net".

2.11. Intangible assets

Goodwill

Goodwill represents the excess of the cost of an acquisition (the consideration given) over the fair value of the share of Sopharma AD in the net identifiable assets of the subsidiaries (Bulgarian Rose - Sevtopolis AD, Medica AD and Unipharm AD) at the date of its acquisition (the business combination). This goodwill on the merger of the subsidiaries into the parent company is recognised in the separate statement of financial position of the parent. Goodwill is presented within the 'intangible assets' group.

Goodwill is measured at acquisition cost (cost), determined at the date of the actual business combination, less the accumulated impairment losses. It is not amortised. It is subject to annual review for existence of impairment indicators. Impairment losses on goodwill are presented in the separate statement of comprehensive income (within profit or loss for the year) in the item 'impairment of non-current assets'.

Other intangible assets

Intangible assets are stated in the financial statements at acquisition cost (cost) less accumulated amortisation and any impairment losses in value.

The Company applies the straight-line amortisation method for the intangible assets.

The useful life per group of assets is as follows:

- for software – from 2 to 12 years;
- for patents and licenses – from 2 to 10 years;
- for trademarks – from 5 to 13 years;
- for other intangible assets – from 5 to 7 years.

The carrying amount of the intangible assets is subject to review for impairment when events or changes in the circumstances indicate that the carrying amount might exceed their recoverable amount. Then impairment is recognised as an expense in the statement of comprehensive income (within profit or loss for the year).

Intangible assets are derecognised from the statement of financial position when they are permanently disposed of and no future economic benefits are expected therefrom or on sale, at the date of transfer of control to the asset recipient. The gains or losses arising from the sale of an item of intangible assets are determined as the difference between the consideration the Company expects to be entitled to (sales revenue) and the carrying amount of the assets on the date when the recipient obtains control thereon. They are stated under 'other operating income/(losses), net' on the face of the statement of comprehensive income (within profit or loss for the year).

2.12. Investment property

Investment property is property lastingly held by the Company to earn rentals and/or for capital appreciation. They are presented in the statement of financial position at fair value (*Note 2.31*). Gains or losses arising from a change in the fair value of investment property are recognised in the statement of comprehensive income (within profit or loss for the year) as 'other operating income/(losses), net' for the period in which they arise. The income gained on investment property is presented within “income” in the statement.

Investment property is derecognised from the statement of financial position when they are permanently disposed of and no future economic benefits are expected therefrom or on sale, at the date of transfer of control to the asset recipient. Gains or losses arising from the disposal of investment property are determined as the between the consideration the Company expects to be entitled to (sales revenue) and the carrying amount of the assets on the date when the recipient obtains control thereon. They are presented under 'other operating income/(losses), net' in the statement of comprehensive income (within profit or loss for the year).

Transfers to, or from, the group of ‘investment property’ is made only when there is a change in the function and purpose of a particular property. In case of a transfer from 'investment property' to 'owner-occupied property', the asset is recognised in the new group at deemed cost, which is its fair value at the date of transfer. To the opposite, in case of a transfer from 'owner-occupied property' to 'investment property' the asset is measured at fair value at the date of transfer while the difference to its carrying amount is presented as a component of the statement of comprehensive income (within other comprehensive income) and within 'revaluation reserve – property, plant and equipment' in the statement of changes in equity.

2.13. Investments in subsidiaries and associates

Long-term investments, in the form of stocks and shares in subsidiary and associate companies are presented in the financial statements at acquisition cost (cost) being the fair value of the consideration paid for the investment including any directly attributable costs incurred on the acquisition less accumulated impairment.

Company's investments in subsidiaries and associates are subject to annual review for impairment. Where conditions for impairment are identified, the impairment is recognised in the statement of comprehensive income (within profit or loss for the year).

In purchases and sales of investments in subsidiaries and associates the date of trading (conclusion of the deal) is applied.

Investments are derecognised when the rights related thereto are transferred to third parties as a result of occurrence of legal rights for that and thus the control over the economic benefits from the respective specific type of investments are being lost. Gain/(loss) on disposal is presented respectively as 'finance income' or 'finance costs' in the statement of comprehensive income (within profit or loss for the year).

2.14. Other long-term equity investments

The other long-term equity investments constitute non-derivative financial assets in the form of shares in the capital of other companies (minority interest), held for a long term.

Initial measurement

Equity investments are initially recognised at acquisition cost, which is the fair value of consideration paid, including direct costs to acquire the investment (financial asset) (*Note 2.25*).

All purchases and sales of equity instruments are recognised at the transaction's "trade date", i.e. the date on which the Company undertakes to purchase or sell the asset.

Subsequent measurement

The equity investments held by the Company are subsequently measured at fair value (*Note 2.31*) determined with support by an independent licensed valuator.

The effects from subsequent revaluation to fair value are carried within a separate component of the statement of comprehensive income (in other comprehensive income), respectively in the reserve for financial assets at fair value through other comprehensive income.

These effects are transferred to retained earnings upon disposal of the respective investment.

Dividend income

Dividend income related to long-term equity investments constituting shares in other entities (non-controlling interest) is recognised as current income and stated in the statement of financial position (within profit or loss for the year) in the "finance income" item.

Upon derecognising shares at disposal or sale, the average weighted price method is used, applying the price determined at the end of the month when the derecognition is performed.

2.15. Inventories

Inventories are valued in the financial statements as follows:

- raw materials, materials and goods – at the lower of acquisition cost (cost) and net realisable value;
- finished goods, semi-finished goods and work in progress – at the lower of production cost and net realisable value;
- agricultural produce – at the lower of fair value at initial acquisition and net realisable value.

Expenses incurred in bringing a certain product within inventories to its present condition and location, are included in the acquisition cost (cost) as follows:

- raw materials, materials and goods – all delivery costs, including the purchase price, import customs duties and charges, transportation expenses, non-refundable taxes and other expenses, incurred for rendering the materials and goods ready for usage/sale;
- finished goods, semi-finished goods and work in progress – all necessary expenses on production that constitute the production cost, which includes the cost of direct materials and labour and the attributable proportion of production overheads (both variable and fixed), but excluding administrative expenses, exchange rate gains and losses and borrowing costs. Fixed production overheads are included in the production cost of manufactured finished goods semi-finished goods and work in progress based on the normal operating capacity determined on the grounds of commonly maintained average volume of production confirmed by the production plan. The base, chosen for their allocation at unit-of-production level, is the standard rate of man-hours of directly engaged staff in the production of the particular unit.

The Company applies 'standard production cost' for current valuation of finished goods, semi-finished goods and work in progress, and respectively, 'standard purchase cost' for basic raw materials and other production materials. At the end of each reporting period the management performs analysis of factors leading to variances on: (a) the supply of raw materials and other production materials – by comparing the actual and standard acquisition costs, and (b) the production of finished goods, semi-finished goods and work in progress – by comparing the actual and standard production costs. Where necessary, the value of inventories, included in the financial statements, is adjusted. On the basis of research on the good reporting practices in the pharmaceutical industry, the Company has adopted materiality thresholds regarding: (a) variance on supply of raw materials and other production materials – up to 2%, and (b) variance on production – up to 1%, within which the current value of the existing closing stocks of raw and other materials, finished goods and work in progress are not adjusted for the purposes of the financial statements (*Note 2.32*).

Upon use (putting into production or sale) of inventories, they are currently expensed by applying the weighted average cost (cost) method.

The net realisable value represents the estimated selling price of an asset in the ordinary course of business less the estimated cost for completion of this asset and the estimated costs necessary to make the sale.

2.16. Trade receivables

Trade receivables constitute the Company's unconditional entitlement to consideration under contracts with customers and other counterparties (i.e. it is only dependent on the passage of time before payment of the consideration).

Initial measurement

Trade receivables are initially recognised and carried at fair value based on the transaction price, which is usually equal to the invoice amount, unless they contain a significant financial component, which is not additionally charged. In this case they are recognised at their present amount determined at a discount equal to the interest associated to the client - debtor.

Subsequent measurement

The Company holds trade receivables only for the purpose of collecting contractual cash flows and subsequently measures them at amortised cost less the amount of impairment accumulated for credit losses. (Note 2.25).

Impairment

The Company applies the expected credit losses model for the entire term of all trade receivables, using the simplified approach under IFRS 9, and based on the matrix model for loss percentage (Note 2.25 and Note 2.32).

Impairment of receivables is accrued through the respective corresponding allowance account for each type of receivable to the "other operating expenses" on the face of the statement of comprehensive income (within profit or loss for the year).

2.17. Interest-bearing loans and other financial resources granted

All loans and other financial resources granted are initially presented at acquisition cost (nominal amount), which is accepted to be the fair value of the amount given in the transaction, net of the direct costs related to these loans and granted resources. Following their initial recognition, interest-bearing loans and other funding granted is subsequently measured and stated in the statement of financial position at amortised cost, determined by applying the effective interest method. They are classified in this group since the Company's business model only aims to collect contractual cash flows of principal and interest. Amortised cost is calculated by taking into account all types of charges, commissions, and other costs, associated with these loans. Gains and losses are recognised in the statement of comprehensive income (within profit or loss for the year) as finance income (interest) or costs throughout the amortisation period, or when the receivables are settled, derecognised or reduced.

Interest income is recognised in accordance with the stage in which the respective loan or other receivables has been classified based on the effective interest method.

Interest-bearing loans and other financial resources granted are classified as current ones unless (and for the relevant portion thereof) the Company has unconditionally the right to settle its payable within a term of more than 12 months after the end of the reporting period (*Note 2.25*).

2.18. Cash and cash equivalents

Cash includes cash in hand and cash in current accounts, and cash equivalents – bank deposits with original maturity up to three months, and funds in deposits with longer maturity which are readily available to the Company under its agreements with the banks over the deposits' terms.

Subsequent measurement

Cash and cash equivalents at banks are subsequently measured at amortised cost, less the impairment accumulated for expected credit losses (*Note 2.25*).

For the purposes of the statement of cash flows:

- cash proceeds from customers and cash paid to suppliers are presented at gross amount, including value added tax (20%);
- interest on received investment purpose loans is reported as payments for financial activities while the interest on loans for current activities (for working capital) is included in the operating activities;
- interest received from bank deposits is included within cash flows from investing activities;
- VAT paid on fixed assets purchased from foreign suppliers is presented within the item 'taxes paid', while that paid on assets purchased from local suppliers is presented within the items 'purchase of PPE', 'purchase of intangible assets' and 'purchase of investment property' within cash flows from investing activities;
- overdraft proceeds and payments are stated net by the Company;
- permanently blocked funds for a period of more than 3 months are not treated as cash and cash equivalents.
- proceeds under factoring agreements are stated within cash flows from financing activities.

2.19. Trade and other payables

Trade and other current amounts payable in the statement of financial position are carried at original invoice amount (acquisition cost), which is the fair value of the consideration to be paid in the future for goods and services received. In case of payments deferred over a period exceeding the common credit terms, where no additional interest payment has been envisaged or the interest considerably differs from the common market interest rates, the payables are initially valued at their fair value based on their present value at a discount rate applicable for the Company, and subsequently – at amortised cost (*Note 2.25*).

2.20. Interest-bearing loans and other borrowings

In the statement of financial position, all loans and other borrowings are initially presented at acquisition cost (nominal amount) which is designated as the fair value of the transaction's deliverable, net of the direct costs related to these loans and borrowings. Following their initial recognition, interest-bearing loans and other borrowings are subsequently measured and presented in the statement of financial position at amortised cost, determined by means of the effective interest method. The amortised cost is calculated by considering all charges, commissions and other costs, including discounts and premiums associated with these loans. Gains and losses are recognised in the statement of comprehensive income (within profit or loss for the year) as finance income or finance expenses (interest) over the amortisation period or when the payables are written-off or reduced (*Note № 2.25*).

Interest costs are recognised for the term of the financial instrument based on the effective interest method.

Interest-bearing loans and other borrowings are classified as current, except from the portion thereof regarding which the Company has an unconditional right to settle its payable within over 12 months after the end of the reporting period.

2.21. Capitalisation of borrowing costs

Borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised as part of the cost of that asset. A qualifying asset is an asset that necessarily takes a period of at least 12 months to get ready for its intended use or sale.

The amount of borrowing costs eligible for capitalisation to the value of a qualifying asset is determined by applying a capitalisation rate. The capitalisation rate is the weighted average of the borrowing costs applicable to the borrowings of the Company that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset.

The capitalisation of borrowing costs as part of the cost of a qualifying asset commences when the following conditions are met: expenditures for the asset are being incurred, borrowing costs are being incurred and activities that are necessary to prepare the asset for its intended use or sale are in progress.

Borrowing costs are also reduced by any investment income earned on the temporary investment of those borrowed funds.

2.22. Leases***Lessee***

A contract is, or contains, a lease, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company has elected to state all lease payments under short-term leases (up to 12 months) as current expenses over a straight-line basis for the lease term.

Initial recognition

The Company recognises right-of-use assets in the statement of financial position at the commencement date of the lease (the date on which a lessor makes an underlying asset available for use by the lessee).

The acquisition cost of the right-of-use asset includes:

- the amount of the initial measurement of the lease liability;
- any lease payments made at or before the commencement date, less any lease incentives received;
- any initial direct costs incurred by the lessee;
- provisions for expenses related to dismantling and removing the underlying asset.

The Company depreciates the right-of-use asset to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term.

Right-of-use assets are presented in the statement of financial position, within 'property, plant and equipment', and depreciation thereof – in the statement of comprehensive income, within 'depreciation and amortisation expenses'.

The lease liabilities include the net present value of the following lease payments:

- fixed lease payments less any lease incentives receivable;
- variable lease payments that depend on an index or rate;
- the exercise price of the purchase options, if the lessee is reasonably certain to exercise this option;
- payments of penalties for terminating the lease;
- residual value guarantees.

Lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined, or the Company's incremental borrowing rate, which it would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.

Lease payments (instalments) contain a certain ratio of the finance cost (interest) and the respective portion of the lease liability (principal). Finance costs for the lease are presented in the statement of comprehensive income for the lease period on a periodic basis, so as to achieve constant periodic rate of interest on the remaining balance of the lease liability.

Subsequent measurement

The Company has elected to apply the acquisition cost model for all of its right-of-use assets. They are presented at acquisition cost less the depreciation accumulated, impairment losses and adjustments from restatement and adjustments to the lease liability.

The Company subsequently measures the lease liability by:

- increasing the carrying amount to reflect the interest on the lease liability;
- reducing the carrying amount to reflect the lease payments made;
- remeasuring the carrying amount to reflect any reassessment or lease modifications of the lease.

Accounting for revaluation and modifications to leases

As a result of revaluation, the lessee recognises the amount of revaluation of the lease liability as an adjustment to the right-of-use asset. If the carrying amount of the asset is lower, the residual amount of revaluations is recognised within profit or loss.

The Company remeasures the lease liabilities whenever:

- the modification increases the scope of the lease by adding another right-of-use of one or more additional underlying assets;
- the lease payment increases by an amount corresponding to the standalone price of the increase in the scope and potential adjustments reflecting circumstances of the respective lease.

Payments related to short-term leases and leases in which the underlying asset is of a low value, as well as variable lease payments are recognised directly as current expenses in the statement of comprehensive income on a straight-line basis over the lease term.

Lessor

Finance lease where a substantial portion of all risks and rewards incidental to the ownership of the leased asset is transferred outside the Company, is written-off from the assets of the lessor upon transfer to the asset's lessee and is presented in the statement of financial position as a receivable at an amount equal to the net investment in the lease. The net investment in the lease agreement represents the difference between the total amount of minimum lease payments under the finance lease agreement and the non-guaranteed residual value, accrued for the lessor and the non-earned finance income.

The difference between the carrying amount of the leased asset and the immediate (fair selling) value is recognised in the statement of comprehensive income (within profit or loss for the year) in the inception of the lease term (when the asset is delivered) as assets sales income.

The recognition of the earned finance income as current interest income is based on the application of the effective interest rate method.

In operating leases, the lessor continues to hold a significant part of all risks and rewards of ownership over the said asset. Therefore the asset is still included in its property, plant and equipment, while its depreciation for the period is included in the current expenses of the lessor.

Rental income from operating leases is recognised on a straight-line basis over the lease term. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight-line basis over the lease term.

2.23. Pensions and other payables to personnel under the social security and labour legislation

The employment and social security relations with the workers and employees of the Company are based on the provisions of the Labour Code and the effective social security legislation in Bulgaria.

Short-term benefits

Short-term benefits in the form of remuneration, bonuses and social payments and benefits (due for payment within 12 months after the end of the period when the employees have rendered the service or have satisfied the required terms) are recognised as an expense in the statement of comprehensive income (within profit or loss for the year) for the period when the service thereon has been rendered and/or the requirements for their receipt have been met, unless a particular IFRS requires capitalisation thereof to the cost of an asset, and as a current liability (less any amounts already paid and deductions due) at their undiscounted amount.

At the end of each reporting period, the Company measures the estimated costs on the accumulating compensated absences, which amount is expected to be paid as a result of the unused entitlement. The measurement includes the estimated amounts of employee's remuneration and the statutory social security and health insurance contributions due by the employer thereon.

Tantieme and bonus schemes

In accordance with Company's Articles of Association and upon a decision of the General Meeting of Shareholders, the Executive Director is entitled to one-off remuneration (tantieme) at the amount of up to 1% of Company's net profit and is empowered to determine the circle of employees among whom to distribute up to 2% of Company's profit for the year as a bonus for each calendar year. When a certain portion is required to be deferred for a period of more than 12 months, this portion is measured at present value at the reporting date and is stated within non-current liabilities in the statement of financial position in the item 'payables to personnel'.

Long-term retirement benefits

Defined contribution plans

The major duty of the Company as an employer in Bulgaria is to make the mandatory social security contributions for the hired employees to the Pensions Fund, the Supplementary Mandatory Pension Security (SMPS) Fund, to the General Diseases and Maternity (GDM) Fund, the Unemployment Fund, the Labour Accident and Professional Diseases (LAPD) Fund, the Guaranteed Receivables of Workers and Employees (GRWE) Fund and for health insurance. The rates of the social security and health insurance contributions are defined annually in the Law on the Budget of State Social Security and the Law on the Budget of National Health Insurance Fund for the respective year. The contributions are split between the employer and employee in line with rules of the Social Security Code (SSC).

These pension plans applied by the Company in its capacity as an employer are defined contribution plans. Under these plans, the employer pays defined monthly contributions to the government funds as follows: Pensions Fund, GDM Fund, Unemployment Fund, LAPD Fund as well as to universal and professional pension funds – on the basis of rates fixed by law, and has no legal or constructive obligation to pay further contributions if the funds do not hold sufficient means to pay the respective individuals the benefits they have worked-out over the period of their service. The obligations referring to health insurance are analogous.

There is no established and functioning private voluntary social security fund at the Company.

The contributions payable by the Company under defined contribution plans for social security and health insurance are recognised as a current expense in the statement of comprehensive income (within profit or loss for the year) unless a particular IFRS requires this amount to be capitalised to the cost of an asset, and as a current liability at their undiscounted amount along with the accrual of the respective employee benefits to which the contributions refer and in the period of rendering the underlying service.

Defined benefit plans

In accordance with the Labour Code, the Company in its capacity as an employer in Bulgaria is obliged to pay an indemnity to its personnel when coming of age for retirement, at an amount which, depending on the length of service with the entity, varies between two and six gross monthly salaries at the employment termination date. In their nature these are unfunded defined benefit schemes.

The calculation of the amount of these liabilities necessitates the participation of qualified actuaries in order to determine their present value at the date of the financial statements, at which they shall be presented in the statement of financial position, and respectively, the change in their value – in the statement of comprehensive income as follows: (a) current and past service costs, interest costs and the gains/losses on a curtailment and settlements are recognised immediately when incurred and are presented in current profit or loss under 'employee benefits expense'; and (b) effects from revaluation of obligations that in substance represent actuarial gains and losses are recognised immediately when occurred and are presented to other comprehensive income in the item 'revaluations of defined benefit pension plans'. Actuarial gains and losses arise from changes in the actuarial assumptions and experience adjustments.

At the end of each reporting period, the Company assigns certified actuaries who issue a report with their calculations about the long-term retirement benefit obligations to personnel. For this purpose, they apply the Projected Unit Credit Method. The present value of the defined benefit obligation is determined by discounting the estimated future cash flows, which are expected to be paid within the maturity of this obligation, and using the interest rates of long-term government bonds of similar term, quoted in Bulgaria where the Company itself operates.

Share-based payments

Share-based payments to employees and other persons rendering similar services are measured at the fair value of the equity instruments at the date of provision. For conditional share-based payments the fair value at the date of share-based payment is measured so as to reflect these conditions without actual differences between the expected and actual results.

Termination benefits

In accordance with the local provisions of the employment and social security regulations in Bulgaria, the Company as an employer is obliged, upon termination of the employment contracts prior to retirement, to pay certain types of indemnities.

The Company recognises employee benefit obligations on employment termination before the normal retirement date when it is demonstrably committed, based on a publicly announced plan, including for restructuring, to terminating the employment contract with the respective individuals without possibility of withdrawal or in case of formal issuance of documents for voluntary redundancy. Termination benefits due more than 12 months are discounted and presented in the statement of financial position at their present value.

2.24. Share capital and reserves

The Company is a joint-stock one and is obliged to register with the Commercial Register a specified ***share capital***, which should serve as a security for the creditors of the Company for execution of their receivables. Shareholders are liable for the obligations of the Company up to the amount of the capital share held by each of them and may claim returning of this share only in liquidation or bankruptcy proceedings. The Company reports its share capital at the nominal value of the shares registered in the court.

According to the requirements of the Commercial Act and the Articles of Association, the Company is obliged to set aside a ***Reserve Fund*** by using the following resources:

- at least one tenth of the profit, which should be allocated to the Fund until its amount reaches one tenth of the share capital or any larger amount as may be decided by the General Meeting of Shareholders;
- any premium received in excess of the nominal value of shares upon their issue (share premium reserve);
- other sources as provided for by a decision of the General Meeting.

The amounts in the Fund can only be used to cover annual loss or losses from previous years. When the amount of the Fund reaches the minimum value specified in the Articles of Association, the excess may be used for share capital increase.

Treasury shares are presented in the statement of financial position at cost (acquisition price) and their gross amount is deducted from Company's equity. Gains or losses on sales of treasury shares are at the account of retained earnings and are carried directly to Company's equity in the 'retained earnings' component.

Revaluation reserve – property, plant and equipment is set aside from:

- the revaluation surplus between the carrying amount of property, plant and equipment and their fair values at the date of each revaluation; and
- gain from the difference between the carrying amount of property, stated within the group 'owner occupied property', and their fair value at the date on which they are transferred to the group 'investment property'.

Deferred tax effect on the revaluation reserve is directly carried at the account of this reserve.

Revaluation reserve is transferred to the 'accumulated profits' component when the assets are derecognised from the statement of financial position or are fully depreciated.

The revaluation reserve covers the impairment of the assets with which it relates. It may be used in the implementation of Company's dividend and capital policies only after it is transferred to the 'retained earnings' component.

The reserve for financial assets at fair value through other comprehensive income is formed by the effects of fair-value measurement of other long-term equity investments. Upon derecognition of these investments, the reserve form is transferred to 'retained earnings'.

2.25. Financial instruments

A financial instrument is any contract that simultaneously gives rise to a financial asset at one entity and a financial liability or equity instrument at another entity.

Financial assets

Initial recognition, classification and measurement

Upon initial recognition, the Company's financial assets are classified in three groups, based on which they are subsequently measured: at amortised cost; at fair value through other comprehensive income, and at fair value through profit or loss.

The Company initially measures financial assets at fair value, and in the case of financial assets which are not stated at fair value through profit and loss, the direct transaction costs are added. An exception to this rule are trade receivables that do not contain a significant financing component – they are measured based on the transaction price determined under IFRS 15 (*Note 2.5.1.*).

The purchases and sales of financial assets whose conditions require asset delivery within a certain period, usually pursuant to legislation or the effective practice of the respective market (regular way purchases), are recognised using trade date accounting, i.e. on the date when the Company committed to purchase or sell the asset.

The classification of financial assets upon their initial recognition depends on the characteristics of the contractual cash flows of the respective financial asset and on the Company's business model for management thereof. In order for a financial asset to be classified and measured at amortised value or at fair value through other comprehensive income, its conditions should give rise to cash flows that are "solely payments of principal and interest (SPPI)" on the principal amount outstanding. For this purpose, analysis is performed by means of SPPI test at instrument level.

The Company's business model for the management of financial assets reflects the way the Company manages its financial assets to generate cash flows. The business model determines if cash flows are generated by the collection of contractual cash flows, the sale of financial assets, or both.

Subsequent measurement

For the purpose of subsequent measurement, the Company's financial assets are classified in the following categories:

- Financial assets at amortised cost (debt instruments)
- Financial assets at fair value through other comprehensive income without "recycling" of cumulative gains or losses (equity instruments).

*Classification groups**Financial assets at amortised cost (debt instruments)*

The Company measures a financial asset at amortised cost if both of the following conditions are met:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets at amortised cost are subsequently measured using the effective interest method. They are subject to impairment. Gains and losses are recognised in the statement of comprehensive income (within profit or loss for the year) upon asset disposal, modification or impairment.

The Company's financial assets at amortised cost include: cash and cash equivalents at banks, trade receivables, including from related parties, loans to related and third parties (*Note 21, Note 22, Note 24, Note 24, Note 26 (a) and Note 27*).

Financial instruments at fair value through other comprehensive income (equity instruments)

Upon their initial recognition, the Company may make an irrevocable choice to classify certain equity instruments as financial instruments at fair value through other comprehensive income, but only if they meet the equity definition under IAS 32 *Financial Instruments*. The classification is determined at the level of individual instruments.

Upon derecognition of these assets, gains and losses from measurement to fair value, recognised in other comprehensive income, are not stated (recycles) through profit or loss. Dividends are recognised as "finance income" in the statement of comprehensive income (within profit or loss for the year) when the right to payment is established, with the exception of cases when the Company obtains rewards from these proceeds as compensation of a portion of the financial asset's acquisition price – in this case, gains are stated in other comprehensive income. Equity instruments designated as financial instruments at fair value through other comprehensive income are not subject to impairment test.

The Company has made an irrevocable commitment to classify into this category minority equity investments which it holds in the long term and in relation to its business interests in these entities. Some of these instruments are traded on stock exchanges, and some aren't. They are stated in the statement of financial position within the „other long-term equity investments" item.

Derecognition

A financial asset (or, when applicable, a portion of a financial asset or a group of similar financial assets) is derecognised from the Company's statement of financial position, when:

- the rights to cash flows from the asset have expired, or
- the rights to cash flows from the asset have been transferred or the Company has assumed an obligation to pay in full the cash flows received, without undue delay, to a third party under a transfer agreement, in which: a) the Company has transferred substantially all risks and rewards from ownership of the asset; or b) the Company has neither transferred nor retained substantially all risks and rewards from ownership of the asset, but has transferred control thereon.

When the Company has transferred its right to obtain cash flows from the asset or has concluded a transfer agreement, it assesses the extent to which it has retained the risks and rewards of ownership. When the Company has neither transferred, nor retained substantially all risks and rewards from ownership of the financial assets, it continues to recognise the asset transferred to the extent of its continuing interest therein. In this case, the Company also recognises the respective liability. The transferred asset and the related liability are measured on a basis reflecting the rights and obligations that the Company has retained.

Continuing involvement in the form of a guarantee on the transferred asset is measured at the lower of the two values: the initial carrying amount of the asset and the maximum amount of consideration that the Company may be required to pay.

Impairment of financial assets

The Company recognises an allowance (impairment provision) for expected credit losses for all debt instruments which are not carried at fair value through profit or loss. Expected credit losses are calculated as the difference between the contractual cash flows due under the contractual conditions, and all cash flows the Company expects to receive, discounted at the initial effective interest rate. Expected cash flows also include cash flows from the sale of collateral held or other credit enhancements that constitute an integral part of the contractual conditions.

To calculate the expected credit losses for *loans to related and third parties, incl. cash and cash equivalents at banks*, the Company applies the general impairment approach defined by IFRS 9. Under this approach, the Company applies a 3-stage impairment model based on changes versus the initial recognition of the credit quality of the financial instrument (asset).

Expected credit losses are recognised at two stages:

- a. A financial asset which is not credit impaired upon its initial recognition/acquisition is classified in Stage 1. These are loans granted: to debtors with a low risk of default with stable key indicator (financial and non-financial) trends, regularly services and without any outstanding past due amounts. Since its initial recognition, its credit risk and characteristics are subject to continuous monitoring and analyses. The expected credit losses for the financial assets classified in Stage 1 are determined based on credit losses resulting from probable events or default, which could occur over the next 12 months of the respective asset's lifetime (12-month expected credit losses for the instrument).

- b. When there has been a significant increase in credit risk since the initial recognition of a financial asset, and as a result its characteristics deteriorate, it is transferred to Stage 2. Expected credit losses for financial assets classified in Stage 2 are determined for the remaining lifetime of the respective asset, irrespective of the point of default (lifetime expected credit loss (ECL)).

The Company's management has developed a policy and a set of criteria to analyse, ascertain and assess the occurrence of a condition of "significant increase in credit risk". The main aspects related thereto are disclosed in *Note 2.32*.

In the cases when the credit risk of a financial instrument increases to a level that indicates default, the financial asset is considered to be impaired, and is classified in Stage 3. At this stage, the losses incurred for the lifetime of the respective asset are identified and calculated.

The Company's management has performed the respective analyses, based on which it has determined a set of criteria for default events, in accordance with the specifics of the respective financial instrument. One of them is delay in contract payments by over 90 days, unless circumstances exist for a certain instrument that make such claim refutable. Along with that, there are other events, based on internal and external information, which indicate that the debtor is not able to repay all contract amounts due, including in consideration of all loan collaterals and reliefs held by the Company. The main aspects of the policy and the set of criteria are disclosed in *Note 2.32*.

The Company adjusts expected credit losses determined based on historical data, with forecast macroeconomic indicators for which it has been established that correlation exists and which are expected to impact the amount of future credit losses.

In order to calculate expected credit losses for *trade receivables and contract assets* the Company has elected and applies a simplified approach based on an expected credit losses calculation matrix and does not monitor subsequent changes in their credit risk. In this approach, it recognises an allowance (impairment provision) based on lifetime expected credit losses at each reporting date. The Company has developed and applies a provisioning matrix based on its historical experience with credit losses, adjusted with forecast factors specific for debtors and the economic environment, for which a correlation has been established with the percentage of credit losses (*Note 42*).

Derecognition

Impaired financial assets are derecognised when no reasonable expectation exists to collect contractual cash flows.

Financial liabilities

Initial recognition, classification and measurement

The Company's financial assets include trade and other payables, loans and borrowings, including bank overdrafts. Upon their initial recognition, financial assets are usually classified as liabilities at amortised cost.

All financial liabilities are initially recognised at fair value, and in the case of loans and borrowings and trade and other payables, net of direct transaction costs.

Subsequent measurement

The subsequent measurement of financial liabilities depends on their classification. They are usually classified and measured at amortised cost.

Classification groups

Loans and borrowing

Following their initial recognition, the Company measures interest-bearing loans and borrowings at amortised cost, applying the effective interest method. Gains and losses are recognised in the statement of comprehensive income (within profit or loss for the year) when the respective financial liability is derecognised, as well as through amortisation based on the effective interest rate.

The amortised cost is calculated by taking into consideration any discounts or premiums at acquisition, as well as fees or costs that constitute an integral part of the effective interest rate. Amortisation is stated as a “finance expense” in the statement of comprehensive income (within profit or loss for the year).

Derecognition

Financial liabilities are derecognised when the obligation specified in the contract is discharged or cancelled or expires. An exchange between an existing borrower and lender of debt instruments with substantially different terms is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the respective carrying amounts is recognised in the statement of comprehensive income (within profit or loss for the year).

Offsetting (netting) of financial instruments

Financial assets and liabilities are offset and the net amount reported in the statement of financial position, if a legally enforceable right exists to offset the recognised amounts and if there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously.

This requirement results from the concept of the actual economic nature of the Company’s relations with a given counterpart stating that in the simultaneous presence of these two requirements the expected actual future cash flow and rewards for the Company is the net flow, i.e. the net amount reflects the Company’s actual right and obligation resulting from these financial instruments – in all cases to only receive or pay the net amount. If the two conditions are not simultaneously met, it is assumed that the Company’s rights and obligations with respect to these offsetting financial instruments are not exhausted in all situations by only the payment or receipt of the net amount.

The offsetting policy is also related to the measurement, presentation and management of actual credit risk and the liquidity risk pursuant from these offsetting instruments.

The criteria applied to establish the “current and legally enforceable entitlement to offsetting” are:

- lack of dependence on a future event, i.e. it should not only be applicable upon the occurrence of a future event;
- the offsetting should be enforceable and legally defensible during (cumulatively):
 - the Company’s usual business operations;
 - in case of default/delay, and
 - in case of insolvency.

The applicability of criteria is measured against the requirements of the Bulgarian legislation and the contractual relations between the parties. The condition of “presence of current and legally enforceable right to offsetting” is always and mandatorily assessed together with the second condition – for “mandatory settling of these instruments on a net basis”.

2.26. Financial guarantee contracts

A financial guarantee contract is a contract that requires the issuer to make certain payments to recover the holder’s loss incurred when a debtor failed to make payment when due, in accordance with the initial or amended conditions of a debt instrument.

Financial guarantee contracts are recognised as financial liabilities at guarantee issuance. The liability is initially measured at fair value, and subsequently – at the higher of the following:

- the amount determined in accordance with the expected credit losses model, and
- the initially recognised amount, less the cumulative amount of the revenue (where applicable) recognised under the principles of IFRS 15 *Revenue from Contracts with Customers*.

The fair value of financial guarantees is determined based on the present value of the difference in cash flows between contract payments required under the debt instrument, and payments that would be required without a guarantee payable to a third party upon commitment.

The subsequent measurement of financial guarantee liabilities at the amount of expected losses under financial guarantee contracts is included in the statement of financial position, within “other current liabilities”.

2.27. Income taxes

Company's *current income taxes* are determined in accordance with the requirements of the Bulgarian tax legislation – the Corporate Income Taxation Act. The nominal income tax rate in Bulgaria for 2020 is 10% (2019: 10%).

Deferred income taxes are determined using the liability method on all of Company's temporary differences between the carrying amounts of the assets and liabilities and their tax bases, existing at the date of the financial statements.

Deferred tax liabilities are recognised for all taxable temporary differences, with the exception of those originating from recognition of an asset or liability, which has not affected the accounting and the taxable profit/(loss) at the transaction date.

Deferred tax assets are recognised for all deductible temporary differences and the carry-forward of unused tax losses, to the extent that it is probable they will reverse and a taxable profit will be available or taxable temporary differences might occur, against which these deductible temporary differences can be utilised, with the exception of the differences arising from the recognition of an asset or liability, which has affected neither the accounting nor taxable profit /(loss) at the transaction date.

The carrying amount of all deferred tax assets is reviewed at each reporting date and reduced to the extent that it is probable that they will reverse and sufficient taxable profit will be generated or taxable temporary differences will occur in the same period, whereby they could be deducted or compensated.

Deferred taxes related to items that are accounted for as other components of comprehensive income or an equity item in the statement of financial position, are also reported directly in the respective component of the comprehensive income or the equity item in the statement of financial position.

Deferred tax assets and liabilities are measured at the tax rates and on the bases that are expected to apply to the period and type of operations when the asset is realised or the liability – settled (repaid) on the basis of the tax laws that have been enacted or substantively enacted, and at tax rates of the country (Bulgaria) under the jurisdiction of which the respective deferred asset or liability is expected to be recovered or settled.

The deferred tax assets of the Company are presented net against its deferred tax liabilities when and as much as it is the tax payer for them in the respective jurisdiction (Bulgaria), and this is only in cases where the Company is legally entitled to perform or receive net payments of current tax liabilities or income tax receivables.

The deferred income tax liabilities of the Company as at 31 December 2020 were assessed at a rate valid for 2021, at the amount of 10% (31 December 2019: 10%).

2.28. Government grants

Government grants represent various forms of providing gratuitous resources by a government (local and central bodies and institutions) and/or intergovernmental agreements and organisations.

Government grants (municipal, government and international, including under the procedure of using the European funds and programmes) are initially recognised as deferred income (financing) when there is reasonable assurance that they will be received by the Company and that the latter has complied and complies with the associated thereto requirements.

A government grant that compensates the Company for expenses incurred is recognised in current profit or loss on a systematic basis in the same period in which the expenses are recognised.

A government grant that compensates investment expenses incurred to acquire an asset is recognised in current profit or loss on a systematic basis over the useful life of the asset proportionately to the amount of the recognised depreciation charge.

2.29. Net earnings or loss per share

The base net earnings or loss per share are calculated by dividing net profit or loss attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period.

The weighted average number of ordinary shares outstanding during the period is the number of ordinary shares outstanding during at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor. This factor represents the number of days that the shares are outstanding as a proportion of the total number of days in the period.

In case of a capitalisation, bonus issue or split, the number of the outstanding ordinary shares as at the date of such event, is adjusted as to reflect the proportional change in the number of outstanding ordinary shares as if the event has occurred in the beginning of the earliest presented period.

The diluted net earnings or loss per share are not calculated because no dilutive potential ordinary shares have been issued.

2.30. Segment reporting

The Company identifies its reporting segments and discloses segment information in accordance with the organisational and reporting structure used by the management. Operating segments are business components, which are regularly measured by members of the management who take operating decisions by using financial and operating information prepared specifically on the segment for the purposes of current monitoring and assessment of results and allocating Company's resources.

Company's operating segments are currently monitored and directed separately as each of them represents a separate business area that offers various products and bears various business risks and rewards. Company's operating segments include the business fields by individual lines of medicinal forms production – tablets, ampoules, medical products, other forms and other revenue.

Information by operating segments

The Company uses one basic measuring unit – gross margin (profit) for measuring the results in the operating segments and allocation of resources between them. The gross margin is defined as the difference between segment revenue and segment expenses directly attributable to the respective segment.

Segment assets, liabilities, respective revenue, expenses and results include those that are and can be directly attributable to the respective segment as well as such that can be allocated on a reasonable basis. Usually they include: (a) for revenue - sales of finished goods; (b) for expenses - raw materials and consumables used, depreciation and amortisation and production staff remuneration; (c) for assets - property, plant and equipment, investment property and inventories; (d) for liabilities – government grants, payables to personnel and for social security. Capital expenditures (investments) by business segments are differentiated expenses incurred in the period of acquisition or construction of segment non-current assets, which are expected to be used for more than one period.

The Company manages its investments in securities, trade accounts and financial resources granted/received as well as taxes at entity's level and they are not allocated at segment level.

The results of the operations regarded as accidental ones compared to the main types of operations (activities) of the Company as well as revenue, expenses, liabilities and assets that are not subject to allocation are stated separately in the item 'total at Company level'. In general, these amounts include: other operating income unless originating from the operation of a particular segment, administrative expenses, interest income and expenses, realised and unrealised gains and losses from foreign currency transactions and investments, investments in other companies, trade and other receivables, trade payables and loans received, tax accounts, general-purpose production and administrative equipment.

The applied accounting policy for segment reporting is based on that used by the Company for the preparation of its statutory financial statements for public purposes.

2.31. Fair value measurement

Some of Company's assets and liabilities are measured and presented and/or just disclosed at fair value for financial reporting purposes. Such are: (a) on a recurring (annual) basis – other *long-term equity investments, investment property, bank loans to/from third parties, certain trade and other receivables and payables; and other* (b) on a non-recurring (periodical) basis – *non-financial assets such as property, plant and equipment*.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair value is an exit price and is based on the assumption that the sale transaction will take place either in the principal market for this asset or liability or in the absence of a principal market – in the most advantageous market for the asset or liability. Both the designated as a principal market and the most advantageous market are markets to which the Company must have an access.

Fair value is measured from the perspective of using the assumptions and judgments that potential market participants would use when pricing the respective asset or liability assuming that market participants act in their economic best interest.

In measuring the fair value of non-financial assets the starting point is always the assumption what would be the highest and best use of the particular asset for the market participants.

The Company applies various valuation techniques that would be relevant to the specific features of the respective conditions and for which it has sufficient available inputs while trying to use at a maximum the publicly observable information, and respectively, to minimize the use of unobservable information. It uses the three acceptable approaches – *the market approach, the income approach and the cost approach* – whereas the most frequently applied valuation techniques include directly quoted and/or adjusted quoted market prices, market comparables (analogues) and discounted cash flows, including based on capitalised rental income.

All assets and liabilities that are measured and/or disclosed in the financial statements at fair value, are categorised within the following fair value hierarchy, namely:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 — Valuation techniques that use inputs other than directly quoted prices but are observable, either directly or indirectly, including where the quoted prices are subject to certain adjustments; and

- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised at fair value in the financial statements on a recurring basis, the Company determines at the end of each reporting period whether transfers between levels in the fair value hierarchy are deemed to be made for a particular asset or liability depending on the inputs available and used at that date.

The Company has developed internal rules and procedures for measuring the fair value of various types of assets and liabilities. For the purpose, a specifically designated individual, subordinated to the Company's Finance Director, organised the performance of the overall valuation process and also coordinates and observes the work of the external valuers.

The Company uses the expertise of external certified appraisers to determine the fair value of the following assets and liabilities: *financial assets at fair value through other comprehensive income* Level 1 and Level 2, *investment property* – Level 2, *property, plant and equipment* – Level 2 and Level 3. The choice of licensed appraisers is made on an annual basis using the following criteria: applied professional standards, professional experience and knowledge, reputation and market status. The need for rotation of external appraisers is periodically assessed – every three to five years. The applied valuation approaches and techniques as well as the used inputs for each case of fair value measurement are subject to mandatory discussion and coordination between the external experts – appraisers and the specifically designated individual, engaged with measurements, and so is the acceptance of the issued appraiser's reports – especially with regard to the significant assumptions and the final conclusions and proposals for the fair value amount. The final fair value measurements are subject to approval by Company's Finance Director and/or Chief Accountant, Executive Director and the Board of Directors.

In accordance with Company's accounting policy, at the end of each reporting period the specifically designated individual, engaged with measurements, performs a general analysis of collected in advance information about the movement in the values of the Company's assets and liabilities that are subject to valuation or to a disclosure at fair value, the type of available data and the possible factors for the observed changes, and proposes for approval to the Finance Director, the approach for measuring the fair value of the respective assets and liabilities at that date. Where necessary, this is explicitly consulted with the involved external appraisers.

The results from the process of fair value measurement are presented to the audit committee and to Company's independent auditors.

For the purposes of fair value disclosures, the Company has determined the respective assets and liabilities on the basis of their nature, basic characteristics and risks as well as of the fair value hierarchical level.

2.32. Critical accounting judgments on applying the Company's accounting policies. Key estimates and assumptions of high uncertainty.

Fair value measurement of equity investments

When the fair value of equity investments carried in the statement of financial positions cannot be obtained based on quoted prices on active markets, their fair value is determined by using other valuation models and techniques, including the discounted cash flows model. The input used in these models is obtained from observable markets, where possible, but when this cannot be done, significant judgement is applied to determine fair values. Such judgement involves the review, analysis and assessment of input, for instance regarding liquidity risk, credit risk, and volatility. The changes in assumptions for these factors may impact the amount of the fair value of financial instruments stated. The main key assumptions and components of the model are disclosed in *Note 20*.

Calculation of expected credit losses for loans and guarantees granted, trade receivables, incl. from related parties, and cash and cash equivalents

The measurement of expected credit losses for financial assets stated at amortised cost (loans granted, contract receivables and assets, cash and cash equivalents), as well as for financial guarantees granted is an area that requires the use of complex models and material assumptions for future economic conditions and the credit behaviour of customers and debtors (for instance, the probability of counterparties not meeting their obligations and the pursuant losses).

In order to apply these requirements, the Company's management makes a number of material judgements, such as: a) determining criteria to identify and measure significant credit risk increases; b) selection of suitable models and assumptions to measure expected credit losses; c) establishing groups of similar financial assets (portfolios) for the purpose of measuring expected credit losses; d) establishing and assessing the correlation between historical default rates and the behaviour of certain macro indicators to reflect the effects of forecasts for these macro indicators in the calculation of expected credit losses. (*Note 42*).

Regarding trade receivables, including from related parties

The Company uses provisioning matrixes calculate expected credit losses from trade receivables and contract assets. The provision rates are based on days past due for groups from different customer segments (portfolios) sharing similar loss models (type of client sector).

Each provisioning matrix is initially based on detailed historical observation of default rates in the Company's receivables and the movement of receivables by delay groups. Usually, historical data is used for at least three years as per the financial statement's date. Moreover, the Company calibrates the matrix so as to adjust historically ascertained dependence for credit losses with forecast information by also using probability scenarios. If certain forecast economic conditions, measured by means of certain macro indicators, are expected to aggravate or improve in the next year, which might result in established correlational increase in payment delays for a certain sector (type of client), the historic default rates are adjusted. At each reporting date, the observable historical default rates are updated and the effects of changes in the estimates are accounted for.

The assessment of the relation between observable historical default rates, the forecast economic conditions and expected credit losses is a significant accounting judgement. The amount of expected credit losses is sensitive to changes in circumstances and forecast conditions. The Company's historical credit losses and the forecast economic conditions may deviate from actual collection rates in the future.

Information about expected credit losses from trade receivables and contract losses is disclosed in *Note 22, Note 24 and Note 25*.

In 2020, an impairment was accrued for trade receivables, including from related parties, at the amount of BGN 873 thousand (2019: reversed credit losses at the amount of BGN 214 thousand) (*Note 8, Note 9, Note 22, Note 24 and Note 25*).

Regarding loans and guarantees granted:

The Company has adopted the general approach for calculating impairment based expected credit losses of the loans granted, pursuant to IFRS 9. For this purpose, the Company applies a model of its choice. Its application goes through several stages. First, the debtor's credit rating is determined by means of several rating agencies' methodologies for the respective economic sectors and ratios, quantitative and qualitative parameters and indicators of the entity. Second, by using statistical models including historical default probability data (PD), transfer between ratings, macro-economic data and forecast, the relevant marginal PD are calculated by year for each rating. Third, based on this analysis and the determined rating, and based on a set of indicators for the instrument's characteristics at the date of each financial statements, the following parameters are determined: instrument stage (Stage 1, Stage 2 or Stage 3), PD needed for the instrument's lifetime, as well as loss given default (LGD). The main formula used to calculate expected credit losses is: $ECL = EAD \times PD \times LGD$, where:

ECL is the expected credit losses indicator;

EAD is the exposure at default indicator;

PD is the probability of default indicator;

LGD is the loss given default indicator.

Upon determining losses, all guarantees and/or collaterals and/or insurances are taken into consideration. Thus, in the final step, by using all these parameters and following discount, the expected credit loss for the respective period of the respective financial assets is calculated.

Stage 1 includes loans granted which are classified as "regular" according to the internal risk classification scheme developed. These are loans granted to debtors with low default rates, regular servicing, without considerable aggravation of key indicators (financial and non-financial), and without amounts past due. The expected impairment loss for such loans is calculated based on default probability for the next 12 months and the Company's expectation for loss amount upon exposure default over the next 12 months.

Stage 2 includes granted loans classified as “renegotiated”. These are loans with respect to which (based on a set of indicators) a significant aggravation of the credit risk related to the debtor has been established as compared to the exposure’s initial recognition. The expected impairment loss for these loans is calculated based on the default probability for the lifetime of the loan which is considered to be credit-unimpaired, and the Company’s expectations for loss amount upon exposure default over the lifetime.

Stage 3 includes granted loans which are classified as “underperforming”. These are loans for which evidence exists that the asset is credit-impaired, i.e. a credit event has occurred (according to the policy on default event eligibility). Therefore, an analysis is performed of a system of indicators used to identify the occurrence of credit losses. Impairment losses for such loans are calculated based on probability-weighted scenarios for the Company’s expectations for the loss amount of the non-performing credit-impaired exposure throughout its lifetime.

A granted loan, respectively financial assets, is credit-impaired when one or more events have occurred which have an adverse effect on expected future cash flows from this loan, accordingly financial assets.

The Company applies the same model with respect to expected credit losses from guarantees granted and certain individual receivables.

The main matters related to the policy and set of criteria to assess the Company’s exposure to credit risk related to loans granted are disclosed in *Note 42*.

Information about expected credit losses from loans and guarantees is disclosed in *Note 21, Note 22, Note 24, Note 26(a), and Note 40*.

In 2020, a provision for impairment of expected credit losses was accrued at the amount of BGN 3,551 thousand, net of impairment of expected credit losses reserved (2019: provision for impairment of expected credit losses of BGN 526 thousand, net of impairment of expected credit losses reversed) (*Note 12, Note 21, Note 22, Note 24, Note 26(a)*).

In 2020, a provision for impairment of expected credit losses was accrued for dividend receivables at the amount of BGN 1,293 thousand (2019: none) (*Note 12 and Note 24*).

In 2020, expected credit losses were accrued on guarantees, at the amount of BGN 46 thousand (2019: BGN 54 thousand) (*Note 12 and Note 40*).

Cash

To calculate expected credit losses for cash and cash equivalents at banks, the Company applies the general “three-stage” impairment model under IFRS 9. For this purpose, it applies a model based on the bank’s public ratings as determined by internationally recognised rating firms like Moody’s, Fitch, S&P, BCRA and Bloomberg. Based on this, on the one hand, PD (probability of default) indicators are set by using public data

about PD referring to the rating of the respective bank, and on the other hand, through the change in the rating of the respective bank from one period to the next, the Company assesses the presence of increased credit risk. Loss given default is measured by using the above formula. Upon determining LGD, the presence of secured amounts in the respective bank accounts is taken into consideration.

Leases

The application of IFRS 16 requires the management to perform various assessments, estimates and assumptions that impact the accounting for right-of-use assets and lease liabilities. The main key assessments concern determining an appropriate discount rate and determining the term of each lease, including whether it is reasonably certain that the extension/termination options will be exercised. As a result of the uncertainty regarding these assumptions and estimates, significant adjustments may be made to the respective assets and liabilities in the future, respectively the revenue and expenses stated (*Note 32 and Note 33*).

Revenue from contracts with customers

Upon revenue recognition and preparation of the annual financial statements, the management performs various judgements, estimates and assumptions that impact the revenue, costs, assets and liabilities accounted for and the respective disclosures thereto. As a result of the uncertainty regarding these assumptions and estimates, significant adjustments may occur in the carrying amount of the assets and liabilities concerned in the future, respectively the costs and revenue stated.

The key judgements and assumptions that materially impact the amount and term for recognition of revenue from contracts with customers are related to determining the point in time when control over the goods and/or services promised in the contract is transferred to the customer and assessment of the variable consideration for returned goods and volume rebates (*Note 2.5.1.*).

Inventories

Normal capacity

Company's normal production capacity is determined on the basis of management assessments (made after relevant analyses) for optimum load of the production facilities and return on the investments made therein, with structure of the manufactured finished goods accepted as being common for the Company. When the actually achieved volume for individual articles is below the volume at the normal production capacity, set by the Company, the relevant recalculation are made for the fixed overheads, included in the cost of stocks of finished goods and work in progress.

Allowance for impairment

At the end of each financial year, the Company reviews the state, useful life and usability of the existing inventories. In case of identified inventories bearing a potential of not being realised at their current carrying amount in the following reporting periods, the Company impairs these inventories to net realisable value.

As a result of the reviews and analyses made in 2020, impairment of inventories was stated at the amount of BGN 2,813 thousand (2019: BGN 1,932 thousand) (*Note 5 and Note 8*).

Revaluation of property, plant and equipment

The Company uses the expertise of external licensed valuers to determine the fair values of property, machines and equipment. The selection of such valuers is done on an annual basis by using the following criteria: professional standards applied, professional experience and expertise, reputation and market status. On a periodic basis (once every three to five years), the need of external valuers rotation is assessed. The application of valuation approaches and techniques, as well as the input used for each instance of fair value measurement, are subject to mandatory discussion and coordination between the external expert valuers and a person designated as responsible for valuation and the approval of the valuation reports issued – especially with respect to the material assumptions and final conclusions and suggestions for the fair value amount. The final fair value measurement is subject to approval by the Company’s Finance Director and Executive Director.

At the date of each financial statements, as per the Company’s accounting policies, a person specially designated performs general analysis of information collected in advance on the movement in the values of assets and liabilities which are subject to measurement or fair value disclosure, on the type of data available and the possible factors for observable changes, and proposes to the Finance Director the approach to measuring the fair values of the respective assets and liabilities at this date. If necessary, this is expressly coordinated with the external valuers appointed.

The outcomes of the fair value measurement process are presented to the Company’s Audit Committee and independent auditors.

In 2020 there was a change in the price levels and behaviour of the markets for certain assets at the Company and it was determined necessary to recognize impairment at the amount of BGN 1,072 thousand (2019: BGN 3 thousand) (*Note 10 and Note 15*).

Goodwill impairment

At each reporting date, the management determines whether indicators exist for goodwill impairment. The calculations are made by the management with support from independent licensed appraisers.

As a result of the calculations made, in 2020 it was determined that goodwill impairment had to be stated at the amount of BGN 3,389 thousand (2019: BGN 2,541 thousand) (*Note 10 and Note 16*).

Impairment of investments in subsidiaries

At each reporting date, the management makes an assessment about whether indicators for impairment exist in respect of its investments in subsidiaries. The calculations were made by the management with the assistance of independent certified appraisers.

As a result of the calculations made in 2020, the Company found it necessary to recognise impairment of particular investments in subsidiaries at the amount of BGN 2,912 thousand (2019: BGN 12,591 thousand) (*Note 10 and Note 18*).

Actuarial calculations

Calculations of certified actuaries have been used when determining present value of long-term payables to personnel upon retirement on the basis of assumptions for mortality rate, staff turnover rate, future salaries level and discount factor. They are disclosed in *Note 34*.

Long-term retirement benefit obligations to personnel at the amount of BGN 4,478 thousand (31 December 2019: BGN 4,345 thousand) have been stated as a result of these calculations (*Note 34*).

Deferred tax assets

There are unrecognised deferred tax assets at the amount of BGN 4,837 thousand (31 December 2019: BGN 4,545 thousand), related to impairment of investments in subsidiaries because the management is not planning to dispose of these investments and has concluded that it is unlikely the temporary difference to be manifested in a foreseeable future. The temporary difference on which no tax asset is recognised amounts to BGN 48,366 thousand (31 December 2019: BGN 45,454 thousand).

Litigation provisions

With regard to the pending litigations against the Company, the management, jointly with Company's lawyers, has decided that at this stage the probability and risks of a negative outcome therefrom is still below 50% and therefore, it has not included provisions for litigation payables in the statement of financial position as at 31 December 2020.

3. REVENUE

Company's revenue includes:

	2020 BGN '000	2019 BGN '000
Revenue from contracts with customers	204,546	228,914
Other revenue	2,191	1,777
Total	206,737	230,691

3.1. The revenue from contracts with customers is from sales of medication produced and includes:

	2020 BGN '000	2019 BGN '000
Export	135,178	137,272
Domestic market	69,368	91,642
Total	204,546	228,914

Revenue from export sales by product includes:

	2020 BGN '000	2019 BGN '000
Tablet dosage forms	105,919	108,750
Ampoule dosage forms	10,126	10,011
Ointments	7,382	7,531
Syrup dosage forms	7,376	7,511
Medical cosmetics	1,261	732
Lyophilic products	1,245	811
Suppositories	780	677
Drops	527	468
Wound dressings	274	347
Plasters	251	307
Sanitary and hygienic products	3	4
Substances	34	123
Total	135,178	137,272

Revenue from domestic sales by product:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Tablet dosage forms	36,167	50,735
Ampoule dosage forms	13,540	18,659
Wound dressings	5,899	6,261
Lyophilic products	5,260	3,862
Plasters	2,730	2,873
Haemodialysis concentrates	1,367	1,571
Ointments	1,056	2,239
Drops	701	659
Syrup dosage forms	675	2,106
Inhalers	640	1,226
Sanitary and hygienic products	567	692
Sachets	444	38
Suppositories	201	532
Medical cosmetics	120	188
Substances	1	1
Total	69,368	91,642

The breakdown of sales by geographic region is as follows:

	<i>2020</i> <i>BGN '000</i>	<i>Relative share</i>	<i>2019</i> <i>BGN '000</i>	<i>Relative share</i>
Europe	114,554	56%	118,380	52%
Bulgaria	69,368	34%	91,642	40%
Other countries	20,624	10%	18,892	8%
Total	204,546	100%	228,914	100%

The total revenue from transaction with the largest clients of the Company is as follows:

	<i>2020</i> <i>BGN '000</i>	<i>% of</i> <i>revenue</i>	<i>2019</i> <i>BGN '000</i>	<i>% of</i> <i>revenue</i>
Client 1	69,192	34%	90,642	40%
Client 2	60,453	30%	76,786	34%
Client 3	32,908	16%	22,742	10%

Contract balances are as follows:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Receivables under contracts with customers – related parties, net of impairment (<i>Note 24</i>)	100,126	78,094
Receivables under contracts with customers – third parties, net of impairment (<i>Note 25</i>)	17,843	26,114
	<u>117,969</u>	<u>104,208</u>

The increase/decrease in trade receivables under contracts with customers, including receivables from related parties, is the result of an increase/decrease in operating volumes.

Reimbursement obligations as at 31 December 2020: none (31 December 2019: BGN 65 thousand). These include liabilities under retrospective trade volume discounts payable under contracts with customers which will be reimbursed over the next reporting period. (*Note 40*).

3.2. *The Company's other revenue* is as follows:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Revenue from right-of-use assets	1,897	1,760
Revenue from sales of agricultural produce	294	17
Total	<u>2,191</u>	<u>1,777</u>

4. OTHER OPERATING INCOME AND LOSSES

	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Services rendered	2,262	2,792
Income from government grants under European projects	540	540
<i>Sales of non-current assets</i>	<i>1,257</i>	<i>159</i>
<i>Carrying amount of non-current assets sold</i>	<u><i>(877)</i></u>	<u><i>(44)</i></u>
Gain on sale of non-current assets	<u>380</u>	<u>115</u>
Income from penalties and fines	293	10
<i>Sales of goods</i>	<i>1,642</i>	<i>1,674</i>
<i>Carrying amount of goods sold</i>	<u><i>(1,379)</i></u>	<u><i>(1,489)</i></u>
Gain on sale of goods	<u>263</u>	<u>185</u>
Income from grants for agricultural produce	242	-
Awarded amounts	166	53
<i>Sales of materials</i>	<i>1,310</i>	<i>1,277</i>
<i>Cost of materials sold</i>	<u><i>(1,173)</i></u>	<u><i>(1,216)</i></u>
Gain on sale of materials	<u>137</u>	<u>61</u>
Payables written-off	130	746
Gains/ (losses) on revaluation of investment property to fair value (<i>Note 23</i>)	68	(139)
<i>Lease liabilities written-off</i>	<i>82</i>	<i>428</i>
<i>Carrying amount of lease assets written-off</i>	<u><i>(86)</i></u>	<u><i>(431)</i></u>
Losses on leases	<u>(4)</u>	<u>(3)</u>
Losses on revaluation of investment property to fair value (<i>Note 17</i>)	(92)	(99)
Net loss on exchange differences under trade receivables and payables and current accounts	(390)	(311)
Other income	<u>193</u>	<u>184</u>
Total	<u>4,188</u>	<u>4,134</u>

The *liabilities written-off* comprise mostly tantieme written-off in 2020, at the amount of BGN 99 thousand (2019: 673 thousand).

The *sales of materials* comprise mainly: sales of substances, chemical products and packaging materials.

Services rendered include:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Manufacturing services	1,565	1,285
Social activities	219	918
Gamma irradiation	177	219
Laboratory analyses	148	97
Regulatory services	52	56
Transport services	17	23
Other	84	194
Total	2,262	2,792

Sales of goods include:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Foodstuffs	1,464	1,412
Medical products	171	133
Goods with technical designation	7	61
Cosmetics	-	68
Total	1,642	1,674

The book value of goods sold by types of goods is as follows:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Foodstuffs	1,241	1,275
Medical products	132	96
Goods with technical designation	6	57
Cosmetics	-	61
Total	1,379	1,489

5. RAW MATERIALS AND CONSUMABLES USED

The raw materials and consumables used include:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Basic materials	52,417	55,079
Electric energy	5,429	5,822
Laboratory materials	3,020	3,627
Heat power	2,714	3,587
Auxiliary materials	1,218	1,679
Spare parts	1,211	1,300
Working clothes and personal protective equipment for labour	937	771
Technical materials	756	1,462
Water	643	727
Fuels and lubricating materials	377	418
Impairment of materials (Note 9)	1,308	848
Scrapped materials	84	166
Total	70,114	75,486

Expenses on basic materials include:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Substances	20,870	22,156
Packaging materials	11,530	11,966
Liquid and solid chemicals	8,905	8,534
Sanitary-hygienic and dressing material	2,638	3,020
Herbs	2,235	2,989
Ampoules	1,943	1,980
Tubes	1,452	1,543
Vials	1,410	1,386
Aluminium and PVC foil	1,372	1,354
Materials for agricultural production	62	151
Total	52,417	55,079

6. HIRED SERVICES EXPENSE

Hired services expense includes:

	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Manufacturing of medical products	6,849	4,151
Advertising and marketing services	6,463	8,535
Transportation and spedition services	3,570	3,435
Consulting services	2,898	2,018
Building and equipment maintenance	2,867	2,993
Logistic services – domestic market	2,046	2,137
Security	1,441	1,369
Local taxes and charges	1,427	1,385
State and regulatory charges	1,170	1,375
Subscription fees	1,106	1,069
Medical services	830	817
Services under civil contracts	668	886
Registration services	632	307
Insurance	588	536
Licence fees and patent fees	522	506
Vehicles repair and maintenance	402	398
Translation of documentation	388	333
Taxes on expenses	378	412
Communications	335	311
Logistic services (export)	294	201
Clinical trial services	179	43
Agricultural land processing services	168	345
Rentals	147	144
Courier services	127	139
Fees and charges on current bank accounts	116	177
Destruction of pharmaceuticals	106	75
Commissions	18	34
Other	703	843
Total	36,438	34,974

The Company has long-term rental agreements for agricultural land (for 10 and 15 years), which have variable payment over the years and are therefore not included within the scope of IFRS 16.

The payments due under these agreements are currently stated in the statement of comprehensive income as “rentals”.

Rental costs comprise:

	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Rentals related to variable consideration under long-term leases	114	99
Rentals related to short-term leases	26	38
Rentals related to low-value leases	<u>7</u>	<u>7</u>
Total	<u>147</u>	<u>144</u>

The expenses accounted for the year on statutory audit of the separate annual financial statements amount to BGN 73 thousand (2019: BGN 92 thousand).

7. EMPLOYEE BENEFITS EXPENSE

Employee benefits expense includes:

	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Current wages and salaries	37,525	36,082
Social security/health insurance contributions	7,090	6,914
Social benefits and payments	2,037	3,266
Tantieme	1,211	1,005
Accruals for unpaid leaves	1,211	1,201
Social security/health insurance contributions on leaves	211	208
Accruals for long-term retirement benefit obligations (<i>Note 34</i>)	<u>519</u>	<u>527</u>
Total	<u>49,804</u>	<u>49,203</u>

8. OTHER OPERATING EXPENSES

Other expenses include:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Scrapped non-current assets	3,135	129
Entertainment events	1,556	1,564
Impairment of finished products and work in progress (<i>Note 9</i>)	1,505	1,084
Charged/(reversed) impairment for credit losses of receivables, including from related parties, net (<i>Note 9</i>)	873	(214)
Unrecognised input tax under VAT	787	282
Donations	465	299
Business trips	253	682
Trainings	123	183
Scrapped finished goods and work in progress	86	305
Other taxes and payments to the state budget	44	148
Scrapped goods	-	9
Other	65	123
Total	8,892	4,594

In 2020, the Company realized a loss of BGN 2,878 thousand from the liquidation of 749,987 yellow acacia trees (*Note 15*) and BGN 575 thousand from unrecognized VAT upon liquidation thereof.

9. IMPAIRMENT OF CURRENT ASSETS

Impairments of current assets comprise:

	2020	2019
	BGN '000	BGN '000
Impairment of finished goods and work in progress (<i>Note 8</i>)	1,505	1,084
Impairment of materials (<i>Note 5</i>)	1,308	848
<i>Impairment of credit losses for receivables, including from related parties</i>	4,370	3,532
<i>Reversed impairment of credit losses for receivables, incl. from related parties</i>	<u>(3,497)</u>	<u>(3,746)</u>
Net change in the provision for impairments of credit losses, including for related parties (<i>Note 8</i>)	<u>873</u>	<u>(214)</u>
Total	<u>3,686</u>	<u>1,718</u>

10. IMPAIRMENT OF NON-CURRENT ASSETS, OUTSIDE THE SCOPE OF IFRS 9

Impairment losses on non-current assets include:

	2020	2019
	BGN '000	BGN '000
Impairment of goodwill (<i>Note 16</i>)	3,389	2,541
Impairment of investments in subsidiaries (<i>Note 18</i>)	2,912	12,591
Impairment of property, plant and equipment (<i>Note 15</i>)	<u>1,072</u>	<u>3</u>
	<u>7,373</u>	<u>15,135</u>

11. FINANCE INCOME

Finance income includes:

	2020 BGN'000	2019 BGN'000
Income from shareholding	9,661	10,653
Interest income on loans granted	3,189	3,342
Income from issued and granted guarantees	368	-
Net gain on transactions with investments in securities	132	2,924
<i>including gain on sale of investments in subsidiaries</i>	<i>131</i>	<i>242</i>
Net gain on foreign exchange differences under leases	38	-
Reversed impairment of credit losses on cash	12	-
Net foreign exchange gain on receivables from sale of subsidiary	-	47
Total	13,400	16,966

12. FINANCE COSTS

Finance costs include:

	2020 BGN'000	2019 BGN'000
<i>Impairment of credit losses under loans granted</i>	<i>3,793</i>	<i>1,736</i>
<i>Reversed impairment of credit losses on receivables under loans granted</i>	<i>(242)</i>	<i>(1,210)</i>
Net change in the impairment of loans granted	3,551	526
Interest expense on loans received	1,467	1,698
Impairment of credit losses on dividend receivables	1,293	-
Bank charges on loans and guarantees	317	267
Net loss from exchange differences from receivables under subsidiary sale	294	-
Interest charges under leases	91	58
<i>Provision accrued under financial guarantees</i>	<i>249</i>	<i>54</i>
<i>Reversed provision under financial guarantees</i>	<i>(203)</i>	<i>-</i>
Net provision under financial guarantees	46	54
Deregistered company capital from the scope of long-term equity investments	26	-
Net loss from exchange differences from leases	-	8
Total	7,085	2,611

13. INCOME TAX EXPENSE

Statement of comprehensive income (profit or loss for the year)	2020 BGN '000	2019 BGN '000
Taxable profit for the year under tax return	42,564	49,205
Revaluation reserve included as an increase in the annual tax return	(474)	(505)
Taxable profit for the year	42,090	48,700
Current income tax expense for the year - 10% (2019: 10%)	4,209	4,870
<i>Deferred income taxes related to:</i>		
Origination and reversal of temporary differences	(799)	5
Tax expense for past periods	(309)	1
Total income tax expense carried to the statement of comprehensive income (within profit or loss for the year)	3,101	4,876
 <i>Reconciliation of income tax expense applicable to the accounting profit or loss</i>		
<i>Accounting profit for the year</i>	31,765	45,258
Income tax – 10% (2019: 10%)	3,177	4,526
 <i>From unrecognised amounts as per tax returns related to:</i>		
increases – BGN 11,242 thousand (2019: BGN 16,523 thousand)	1,124	1,652
decreases – BGN 9,507 thousand (2019: BGN 13,313 thousand)	(951)	(1,331)
Recognised deferred taxes originated in prior years	60	28
Tax expense for past periods	(309)	1
Total income tax expense carried to the statement of comprehensive income (within profit or loss for the year)	3,101	4,876

The tax effects *related to other components of comprehensive income* are as follows:

	2020 BGN '000			2019 BGN '000		
	Pre-tax amount	Tax effects recognised in equity	Amount net of tax	Pre-tax amount	Tax effects recognised in equity	Amount net of tax
Items that will not be reclassified to profit or loss						
Gains/(losses) on revaluation of property, plant and equipment	(41)	4	(37)	196	(20)	176
Subsequent revaluations of liabilities under defined benefit pension plans	(158)	-	(158)	16	-	16
Net change in the fair value of equity investments at FVOCI	(637)	-	(637)	(60)	-	(60)
Total other comprehensive income for the year	(836)	4	(832)	152	(20)	132

14. OTHER COMPREHENSIVE INCOME

Other comprehensive income includes:

	2020 BGN '000	2019 BGN '000
Subsequent revaluation of property, plant and equipment	(41)	196
Subsequent revaluations of liabilities under defined benefit pension plans	(158)	16
Net change in the fair value of equity investments measured at FVOCI	(637)	(60)
	(836)	152
Income tax relating to items of other comprehensive income	4	(20)
Total comprehensive income for the year	(832)	132

15. PROPERTY, PLANT AND EQUIPMENT

The Company's property, plant and equipment is as follows:

	<i>Land and buildings</i>		<i>Plant and equipment</i>		<i>Other</i>		<i>Assets in progress</i>		<i>Total</i>	
	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
<i>Book value</i>										
Balance at 1 January	171,672	165,305	194,600	190,190	22,771	21,013	4,848	5,712	393,891	382,220
Impact of adoption of IFRS 16 as at 1 January 2019	-	4,053	-	-	-	1,642	-	-	-	5,695
Additions	165	379	646	1,313	1,457	533	7,262	7,652	9,530	9,877
Transfer to property, plant and equipment	516	2,426	5,883	5,507	26	455	(6,425)	(8,388)	-	-
Effect from revaluation to fair value	(30)	-	-	-	-	196	-	-	(30)	196
Impairment	(1,072)	-	-	-	-	(3)	-	-	(1,072)	(3)
Disposals	(1,906)	(491)	(1,608)	(2,410)	(2,225)	(1,065)	(3,105)	(128)	(8,844)	(4,094)
Balance at 31 December	169,345	171,672	199,521	194,600	22,029	22,771	2,580	4,848	393,475	393,891
<i>Accumulated depreciation</i>										
Balance at 1 January	37,695	31,988	113,972	106,498	17,570	16,778	-	-	169,237	155,264
Depreciation charge for the year	5,804	5,760	9,565	9,877	1,930	1,820	-	-	17,299	17,457
Effect of revaluation to fair value	11	-	-	-	-	-	-	-	11	-
Depreciation written-off	(1,018)	(53)	(1,596)	(2,403)	(2,139)	(1,028)	-	-	(4,753)	(3,484)
Balance at 31 December	42,492	37,695	121,941	113,972	17,361	17,570	-	-	181,794	169,237
Carrying amount at 31 December	126,853	133,977	77,580	80,628	4,668	5,201	2,580	4,848	211,681	224,654
Carrying amount at 1 January	133,977	133,317	80,628	83,692	5,201	4,235	4,848	5,712	224,654	226,956

The Company's *land and buildings* as at 31 December include:

- buildings of carrying amount BGN 83,270 thousand (31 December 2019: BGN 89,634 thousand);
- land amounting to BGN 43,583 thousand (31 December 2019: BGN 44,343 thousand).

The Company's *other PPE* as at 31 December includes:

- Motor vehicles with carrying amount BGN 2,467 thousand (31 December 2019: BGN 2,508 thousand);
- Fixtures and fittings with carrying amount BGN 1,886 thousand (31 December 2019: BGN 2,338 thousand);
- Biological assets (carriers) with carrying amount BGN 315 thousand (31 December 2019: BGN 355 thousand).

Tangible fixed assets in progress as at 31 December include:

- advances for the purchase of machines and equipment – BGN 840 thousand (31 December 2019: BGN 1,177 thousand);
- biological assets (non-fruit-bearing) - BGN 318 thousand (31 December 2019: BGN 2,497 thousand);

- expenses on new buildings - BGN 816 thousand (31 December 2019: BGN 1,110 thousand);
- buildings reconstruction – BGN 545 thousand (31 December 2019: BGN 18 thousand);
- other – BGN 61 thousand (31 December 2019: BGN 46 thousand).

As at 31 December, the carrying amount of property, plant and equipment includes machinery and equipment, purchased using Grant Agreements under Operational Programme “Development of the Competitiveness of the Bulgarian Economy” 2007 – 2013 and Operational Programme “Energy Efficiency” (Note 31) as follows:

- for a tablet production facility at the amount of BGN 6,513 thousand (31 December 2019: BGN 7,428 thousand);
- for ampoule production at the amount of BGN 3,840 thousand (31 December 2019: BGN 4,244 thousand).
- combined exchange ventilation and air conditioning installation for the production of medical products at the amount of BGN 595 thousand (31 December 2019: BGN 655 thousand).
- for the production of innovative eye drops, “artificial tears” type, at the amount of BGN 186 thousand (31 December 2019: BGN 212 thousand).

Leases

The Company’s right-of-use assets are as follows:

	Land		Buildings		Motor vehicles		Furniture and fixtures		Total	
	2020	2019	2020	2019	2020	2019	2020	2019	2020	2019
	BGN'000	BGN '000	BGN'000	BGN '000	BGN '000	BGN '000	BGN '000	BGN '000	BGN '000	BGN '000
Book value										
Balance at 1 January	29	-	3,910	-	1,763	-	174	-	5,876	-
Effect of adoption of IFRS 16 as at 1 January 2019	-	-	-	4,053	-	1,642	-	-	-	5,695
Additions	9	29	156	341	1,056	121	2	174	1,223	665
Disposals	-	-	(49)	(484)	(48)	-	(45)	-	(142)	(484)
Balance at 31 December	38	29	4,017	3,910	2,771	1,763	131	174	6,957	5,876
Accumulated depreciation										
Balance at 1 January	1	-	1,053	-	511	-	29	-	1,594	-
Depreciation charge for the year	7	1	1,150	1,106	762	511	61	29	1,980	1,647
Depreciation written-off	-	-	(12)	(53)	(4)	-	(40)	-	(56)	(53)
Balance at 31 December	8	1	2,191	1,053	1,269	511	50	29	3,518	1,594
Carrying amount on 31 December	30	28	1,826	2,857	1,502	1,252	81	145	3,439	4,282
Carrying amount on 1 January	28	-	2,857	-	1,252	-	145	-	4,282	-

The Company has included its right-of-use assets within the same item in which the assets would have been stated if they were the Company's own.

The Company has leased PPE to related parties with carrying amount as at 31 December 2020 – BGN 15 thousand (31 December 2019: BGN 16 thousand). It has also leased to third parties PPE with carrying amount as at 31 December 2020 BGN 1,278 thousand (31 December 2019: BGN 238 thousand).

Other data

The book value of fully depreciated tangible fixed assets, used in the Company's activities by group, is as follows:

- Buildings – BGN 885 thousand (31 December 2019: BGN 743 thousand);
- Plant and equipment – BGN 61,420 thousand (31 December 2019: BGN 58,140 thousand);
- Other – BGN 12,164 thousand. (31 December 2019: BGN 11,820 thousand).

The following encumbrances were constituted on Company's tangible fixed assets as at 31 December 2020 in relation to received loans:

- Land and buildings with a carrying amount of BGN 27,268 thousand and BGN 48,433 thousand, respectively (31 December 2019: respectively, BGN 20,828 thousand and BGN 42,513 thousand) (*Note 29, Note 35 and Note 41*);
- Pledges on equipment – BGN 47,455 thousand (31 December 2019: BGN 36,604 thousand) (*Note 29, Note 35 and Note 41*).

Periodical revaluation to fair value

Revaluation of Company's property, plant and equipment was performed as at 31 December 2016 with the assistance of independent certified appraisers for the purpose of determining the fair value of the assets in accordance with the requirements of IFRS 13 and IAS 16. Based on the judgement applied the Company recognised a revaluation reserve at the amount of BGN 2,629 thousand, net of impairment.

As at 31 December 2020 there was a change in the price levels and behaviour of the markets for certain assets at the Company and it was determined necessary to recognize impairment at the amount of BGN 1,072 thousand (2019: BGN 3 thousand) (*Note 10*).

16. INTANGIBLE ASSETS

The Company's intangible assets are as follows:

	<i>Goodwill</i>		<i>Intellectual property rights</i>		<i>Software</i>		<i>Assets in progress</i>		<i>Total</i>	
	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
<i>Book value</i>										
Balance at 1										
January	6,698	6,698	11,538	11,697	4,429	4,501	163	7	22,828	22,903
Additions	-	-	1	55	8	6	131	273	140	334
Transfer to intangible assets	-	-	5	117	4	-	(9)	(117)	-	-
Written-off	-	-	(368)	(331)	(4)	(78)	(7)	-	(379)	(409)
Balance at 31										
December	6,698	6,698	11,176	11,538	4,437	4,429	278	163	22,589	22,828
<i>Accumulated amortisation and impairment</i>										
Balance at 1										
January	2,541	-	8,429	7,940	3,334	3,082	-	-	14,304	11,022
Amortisation charge for the year	-	-	778	820	325	330	-	-	1,103	1,150
Impairment	3,389	2,541	-	-	-	-	-	-	3,389	2,541
Amortisation written-off	-	-	(346)	(331)	(4)	(78)	-	-	(350)	(409)
Balance at 31										
December	5,930	2,541	8,861	8,429	3,655	3,334	-	-	18,446	14,304
Carrying amount at										
31 December	768	4,157	2,315	3,109	782	1,095	278	163	4,143	8,524
Carrying amount at										
1 January	4,157	6,698	3,109	3,757	1,095	1,419	163	7	8,524	11,881

Goodwill impairment

The goodwill which results from the merger of subsidiaries (Bulgarian Rose – Sevtopolis AD, Medica AD and Unipharm AD) into the parent and is recognised in the Company's separate statement of comprehensive income (*Note 2.11*).

At each date of the statement of financial position, the management assesses if indicators exist for impairment of the existing goodwill, with the support of independent licensed appraisers.

The key assumptions used in the calculation in the recoverable amount at 31 December 2020 are:

- growth rate – 1.34%;
- growth in the post-forecast period at terminal value calculation – 2.02%;
- interest rate /debt price/ - 2.12%, based on Company funding;
- discount rate (WACC-based) – from 7.9%.

For 2020, a need was identified to recognise impairment of goodwill stated, at the amount of BGN 3,389 thousand (2019: BGN 2,541 thousand) (*Note 10*).

The rights on intellectual property include mainly products of development activities and trademarks.

Intangible assets in progress as at 31 December include:

- expenses on software implementation, at the amount of BGN 149 thousand (31 December 2019: BGN 117 thousand);
- expenses on licenses and permits for use of medicinal products – BGN 129 thousand (31 December 2019: BGN 46 thousand).

The book value of fully amortised intangible fixed assets, used in the Company's activities according to their groups, is as follows:

- rights on intellectual property – BGN 6,598 thousand (31 December 2019: BGN 4,403 thousand);
- software – BGN 1,853 thousand (31 December 2019: BGN 1,806 thousand).

17. INVESTMENT PROPERTY

Investment property represents buildings and the land they stand on, differentiated parts of buildings for independent use, intended for long-term lease to subsidiaries and third parties.

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Balance at 1 January	<u>39,329</u>	<u>37,451</u>
Additions	5,522	1,977
Net profit/(loss) on adjustment to fair value measurement included in profit or loss	<u>(92)</u>	<u>(99)</u>
Balance at 31 December	<u><u>44,759</u></u>	<u><u>39,329</u></u>

The investment property per groups of assets is as follows:

<i>Group of assets</i>	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Warehouse premises	34,627	29,259
Offices	3,189	3,049
Production buildings	1,003	1,066
Social objects	441	416
Investment property in progress	5,499	5,539
Total	44,759	39,329

There are established encumbrances as at 31 December 2020 on investment property as follows:

- mortgage of warehouse premises – BGN 13,214 thousand (31 December 2019: BGN 13,142 thousand) (*Note 35 and Note 41*);
- pledges on attached equipment – BGN 4,517 thousand (31 December 2019: BGN 4,764 thousand) (*Note 35*).

Fair value measurement

Fair value hierarchy

The fair values of the groups of investment properties are categorised as Level 2 fair values based on the inputs to the valuation technique used.

The investment property revaluation to fair value is recurring (annual) and is due to the application of the fair value model under IAS 40. It is performed regularly at the end of each reporting period. Fair value is determined with the assistance of independent certified appraisers.

The table below shows reconciliation between the opening and closing balances of the fair values of investment properties measured at Level 2:

	<i>Warehouse premises</i>	<i>Offices</i>	<i>Production buildings</i>	<i>Social objects</i>	<i>Assets in progress</i>	<i>Total</i>
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Balance at 1 January 2019	29,271	2,847	1,010	416	3,907	37,451
Additions	-	-	15	-	1,962	1,977
Transfer	330	-	-	-	(330)	-
Revaluation to fair value through profit or loss – unrealised	(342)	202	41	-	-	(99)
Balance at 31 December 2019	29,259	3,049	1,066	416	5,539	39,329
Additions	-	-	-	-	5,522	5,522
Transfer	5,562	-	-	-	(5,562)	-
Revaluation to fair value through profit or loss – unrealised	(194)	140	(63)	25	-	(92)
Balance at 31 December 2020	34,627	3,189	1,003	441	5,499	44,759

The expenses for acquisition of investment property as at 31 December include:

- advances granted for logistics system building – BGN 5,453 thousand (31 December 2019: BGN 5,440 thousand);
- advances granted for purchases of machinery and equipment – BGN 46 thousand (31 December 2019: BGN 99 thousand).

At the date of each statement of financial position, the management analyses and assesses the fair value of the group of assets in the scope of investment property. The calculations are made by the management with the support of independent licensed appraisers.

Valuation techniques and significant unobservable inputs

The table below shows a description of the valuation techniques, used in measuring the fair value of all groups of Level 2 investment properties as well as the used significant unobservable inputs:

Groups of assets Level 2	Valuation approaches and techniques	Significant unobservable inputs
Warehouse premises	<i>a. Income approach</i> Valuation technique: Method of capitalised rental income as application of discounted cash flows (main valuation technique)	a. Weighted rate of return b. Term to entrance into rental deals
	<i>b. Cost approach</i> Valuation technique: Method based on the costs of construction or replacement – depreciated replacement cost (supportive valuation technique)	* Adjusted prices for construction of identical properties and purchase prices of analogues of the respective type of machinery and equipment
Offices, production buildings and social objects	<i>Income approach</i> Valuation technique: Method of capitalised rental income as application of discounted cash flows (main valuation technique)	a. Weighted rate of return b. Term to entrance into rental deals

Key assumptions used in the calculation of the fair value of investment properties as at 31 December 2020:

- rate of return – from 3.50% to 9%;
- term to entrance into rental deals – from 6 to 12 months;

As a result of the calculations made in 2020, it was necessary to recognise losses on revaluation to fair value, at the amount of BGN 92 thousand (2019: net loss of BGN 99 thousand) (*Note 4*).

18. INVESTMENTS IN SUBSIDIARIES

The carrying amount of the investments by company is as follows:

		<i>31.12.2020</i>	<i>Interest</i>	<i>31.12.2019</i>	<i>Interest</i>
		<i>BGN '000</i>	<i>%</i>	<i>BGN '000</i>	<i>%</i>
Sopharma Trading AD	Bulgaria	43,974	76.17	40,551	74.23
Briz SIA	Latvia	11,347	100.00	11,347	68.14
Sopharma Ukraine EOOD	Ukraine	9,669	100.00	9,669	100.00
Biopharm Engineering AD	Bulgaria	7,111	97.15	7,111	97.15
Veta Pharma AD	Bulgaria	6,754	99.98	9,666	99.98
Momina Krepost AD	Bulgaria	2,755	60.93	2,853	63.12
Vitamina AD	Ukraine	1,283	100.00	1,283	100.00
Rap Pharma International OOD	Moldova	1,183	80.00	1,183	80.00
Pharmalogistica AD	Bulgaria	961	89.39	961	89.39
TOO Sopharma Kazakhstan	Kazakhstan	502	100.00	502	100.00
Sopharma Buildings REIT	Bulgaria	459	40.38	459	40.38
Electroncommerce EOOD	Bulgaria	384	100.00	384	100.00
Sopharma Warsaw EOOD	Poland	323	100.00	323	100.00
Phyto Palauzovo AD	Bulgaria	104	95.00	104	95.00
Aromania AD	Bulgaria	-	-	750	76.00
Total		<u>86,809</u>		<u>87,146</u>	

In 2020, the company Pharmachim EOOD, Serbia was established (2019: none). Sopharma AD holds 100% of the company's shares. The amount of the investment as at 31 December 2020 is below BGN 1 thousand.

As at 31 December 2020, the composition of investments in the subsidiaries includes the investment in Sopharma Poland OOD – in liquidation, Poland, which is fully impaired (31 December 2019: fully impaired investment in Sopharma Poland OOD – in liquidation, Poland).

Sopharma AD exercises direct control on the above-mentioned companies.

The scope of activities of the subsidiaries and the dates of their acquisition are as follows:

- Pharmalogistica AD – Scope of activities: secondary packaging and real estate leases. Date of acquisition – 15 August 2002.
- Sopharma Poland OOD – in liquidation – Scope of activities: market and public opinion research. Date of acquisition – 16 October 2003. The company is in a procedure of liquidation.
- Electroncommerce EOOD – Scope of activities: trade, transportation and packaging of radioactive materials and nuclear equipment, household electronics and electrical equipment. Date of acquisition – 9 August 2005.
- Biopharm Engineering AD – Scope of activities: manufacture and trade in solutions for infusion. Date of acquisition – 10 March 2006.
- Sopharma Trading AD – Scope of activities: trade in pharmaceuticals. Date of acquisition – 8 June 2006.

- Momina Krepost AD – Scope of activities: development, implementation and production of medical goods for human and veterinary medicine. Date of acquisition – 1 January 2008.
- Vitamina AD – Scope of activities: production and trade in pharmaceuticals. Date of acquisition – 18 January 2008.
- Sopharma Buildings REIT – Scope of activities: investment of funds, accumulated by issuance of securities, in real estate (securitisation of real estate) through purchase of property and other proprietary over real estate, rent-out, lease, and/or sale. Date of acquisition – 4 August 2008.
- SIA Briz – Scope of activities: trade in pharmaceuticals; Date of acquisition – 10 November 2009.
- Sopharma Warsaw EOOD – Scope of activities: market and public opinion research. Date of acquisition – 23 November 2010.
- Sopharma Ukraine EOOD – Scope of activities: trade in pharmaceuticals; Date of acquisition – 7 August 2012.
- Phyto Palauzovo AD – Scope of activities: production, harvesting of crops and trade in herbs and medicinal plants. Date of acquisition (as from the merger of a subsidiary) – 1 January 2014.
- TOO Sopharma Kazakhstan – Scope of activities: trade in pharmaceuticals. Date of acquisition – 30 September 2014.
- Veta Pharma AD – Scope of activities: production of medicinal, non-medicinal and other products. Date of acquisition – 11 November 2016.
- Rap Pharma International OOD – Scope of activities: trade in pharmaceutical products. Date of acquisition – 14 April 2017.
- Aromania AD – Scope of activities: trade in finished goods, sale and management of real estate. Date of acquisition – 31 July 2017. The Company disposed of all of its investment in Aromania AD on 23 December 2020.
- Pharmachim EOOD – Scope of activities: consulting services. Date of incorporation: 14 April 2020.

The shares of Sopharma Trading AD are traded on the stock exchange, the average monthly price of realised transactions for December 2020 being BGN 5.65 per share (December 2019: BGN 5.76). The book value per share based on accounting net assets for 2020 is BGN 3.27 (2019: BGN 2.90).

The shares of Momina Krepost AD were not traded on the stock exchange in December 2020 (December 2019: BGN 3.16). The book value per share based on accounting net assets for 2020 is BGN 1.99 (2019: BGN 2.53).

The shares of Sopharma Buildings REIT were not traded on the stock exchange in 2019 and 2020. The book value per share based on accounting net assets for 2020 is BGN 1.86 (2019: BGN 1.75).

The movement of investments in subsidiaries is presented below:

	<i>Investments in subsidiaries</i>	
	<i>31.12.2020</i>	<i>31.12.2019</i>
<i>Acquisition cost</i>	<i>BGN '000</i>	<i>BGN '000</i>
Balance at 1 January	135,049	125,257
Additional interest acquired	3,474	1,832
Interest sold with loss of control	(800)	-
Interest sold without loss of control	(99)	(1,376)
Increase in the capital of subsidiaries	-	9,336
Balance at 31 December	137,624	135,049
 <i>Impairment charged</i>		
Balance at 1 January	47,903	35,312
Impairment charged	2,912	12,591
Balance at 31 December	50,815	47,903
Carrying amount at 31 December	86,809	87,146
Carrying amount at 1 January	87,146	89,945

Impairment of investments in subsidiaries

At each reporting date, the management makes an analysis and assessment about whether indicators for impairment exist in respect of its investments in subsidiaries. The following are accepted as main indicators for impairment: significant volume reduction (over 25%) and/or termination of activities of the investee; loss of markets, clients or technological problems, reporting of losses for a longer period of time (over three years), reporting of negative net assets or assets below the registered share capital, trends of deterioration of main financial ratios as well as a decrease in market capitalisation. The calculations were made by the management with the assistance of independent certified appraisers. As a base for projected pre-tax cash flows, the Company uses financial budgets developed by the respective companies that cover a 3- to 5-year period, as well as other average-term and long-term plans and intents for their development, including projections for basic economic ratios at national level and at the level of EU/the Balkans. The key assumptions used in the calculations of recoverable amount as at 31 December 2020 are as follows:

- growth rate – from 0.81% to 9.49%;
- growth after the projected period upon calculation of terminal value – 2% to 5%;
- interest rate (cost of debt) – from 2.12% to 14.24%;
- discount rate (based on WACC) – from 6.1% to 17.5%.

The key assumptions used in the calculations have been determined specifically for each company, treated as a separate cash-generating unit, and in line with the characteristic features of its operations, the business environment and risks.

The tests and assumptions of the management for impairment of investments are made through the prism of its projections and intents on the future economic benefits, which are expected from the subsidiaries, including trade and industrial experience, ensuring position in the Bulgarian and in foreign markets, expectations for future sales, etc. The calculations are performed with the assistance of an independent certified appraiser.

As a result of the calculations made in 2020, the Company found necessity to recognise impairment of particular investments in subsidiaries at the amount of BGN 2,912 thousand was necessary (2019: BGN 12,591 thousand) (*Note 10*).

19. INVESTMENTS IN ASSOCIATES

The investments in associates are as follows:

	<i>31.12.2020</i>	<i>Interest</i>	<i>31.12.2019</i>	<i>Interest</i>
	<i>BGN '000</i>	<i>%</i>	<i>BGN '000</i>	<i>%</i>
Doverie Obedinen Holding AD	6,062	24.98	6,062	24.98

As at 31 December 2020, the carrying amount of the investments in associates is BGN 6,062 thousand and includes interest at the rate of 24.98% of the capital of Doverie Obedinen Holding AD (31.12.2019: BGN 6,062 thousand and interest at the rate of 24.98%).

The principal activities of Doverie Obedinen Holding AD include acquisition, management, assessment and sale of shares in Bulgarian and foreign companies – legal entities.

The shares of Doverie Obedinen Holding are traded on the stock exchange, the average monthly price of realised transactions for December 2020 being BGN 3.24 per share (December 2019: BGN 3.09).

The book value per share based on accounting net assets for 2020 is BGN 1.93 (2019: BGN 1.95).

The movement of investments in associates is presented below:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Balance at 1 January	6,062	7,962
Shares acquired	-	192
Shares sold	-	(2,092)
Carrying amount at 31 December	6,062	6,062

Impairment of investments in associates

At each reporting date, the management makes an assessment about whether indicators for impairment exist in respect of its investments in associates.

The assessments of the management for impairment of investments are made through the prism of its projections and intents on the future economic benefits, which are expected from the associates, including trade and industrial experience, ensuring position in the Bulgarian and in foreign markets, expectations for future sales, etc.

The calculations have been made by the management with the support of independent licensed appraisers. The key assumptions used in the calculation in the recoverable amount at 31 December 2020 are:

- growth rate – 2.39%;
- growth in the post-forecast period at terminal value calculation – 2.02% ;
- discount rate (CAMP-based) – 12.52%.

In 2020, there was no need to recognise impairment of the investments in associates.

20. OTHER LONG-TERM EQUITY INVESTMENTS

The *other long-term equity investments* include the interest (shares) in the following companies:

	<i>31.12.2020</i>	<i>Interest</i>	<i>31.12.2019</i>	<i>Interest</i>
	<i>BGN '000</i>	<i>%</i>	<i>BGN '000</i>	<i>%</i>
Lavena AD	5,024	12.84	4,771	12.68
Sopharma Properties REIT	4,648	3.78	2,925	2.13
Olainfarm AD - Latvia	1,533	0.77	1,587	0.77
Chimimport AD	310	0.14	13	0.003
Imventure 1 KDS	50	1.36	50	1.36
Achieve Life Science Inc. – USA	23	0.03	44	0.12
Ecobulpack AD	7	0.74	7	0.74
Aroma AD	4	0.02	6	0.02
BTF Expat Bulgaria	3	0.01	5	0.01
UniCredit Bulbank AD	3	0.001	3	0.001
Industrial Holding Bulgaria AD	1	0.001	1	0.001
Expo Group AD	1	0.05	1	0.05
Todorov AD	-	-	208	12.45
Total	11,607		9,621	

All above companies except for Olainfarm AD, Latvia, and Achieve Life Science Inc. – USA, have their seat and operations in Bulgaria.

SOPHARMA AD**NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020**

The fair value per share at 31 December is as follows:

<i>Equity investments</i>	<i>Number of shares</i>	<i>31.12.2020</i>		<i>Number of shares</i>	<i>31.12.2019</i>	
		<i>Fair value per share</i>	<i>Fair value as per the statement of financial position</i>		<i>Fair value per share</i>	<i>Fair value as per the statement of financial position</i>
		<i>BGN</i>	<i>BGN '000</i>		<i>BGN</i>	<i>BGN '000</i>
Lavena AD	1,273,646	3.94	5,024	1,257,664	3.79	4,771
Sopharma Properties REIT	829,822	5.60	4,648	456,466	6.41	2,925
Olainfarm AD – Latvia	108,500	14.13	1,533	108,500	14.63	1,587
Chimimport AD	329,000	0.94	310	7,000	1.79	13
Achieve Life Science Inc. – USA	1,796	12.91	23	35,930	1.23	44
Aroma AD	2,371	1.84	4	2,371	2.65	6
BTF Expat Bulgaria	4,565	0.72	3	4,565	0.99	5
Industrial Holding Bulgaria AD	1,482	0.83	1	1,482	1.02	1
Todorov AD	-	-	-	423,431	0.49	208
Total			11,546			9,560

The table below presents Company's other equity investments, which are measured at fair value on a recurring basis in the statement of financial position:

<i>Equity investments</i>	<i>Fair value</i>	<i>Level 1</i>	<i>Level 2</i>
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Lavena AD	5,024	-	5,024
Sopharma Properties REIT	4,648	4,648	-
Olainfarm AD – Latvia	1,533	1,533	-
Chimimport AD	310	310	-
Achieve Life Science Inc. – USA	23	23	-
Aroma AD	4	-	4
BTF Expat Bulgaria	3	3	-
Industrial Holding Bulgaria AD	1	1	-
Total	11,546	6,518	5,028

<i>Equity investments</i>	<i>Fair value</i>	<i>Level 1</i>	<i>Level 2</i>
	31.12.2019		
	BGN'000	BGN'000	BGN'000
Lavena AD	4,771	-	4,771
Sopharma Properties REIT	2,925	2,925	-
Olainfarm AD – Latvia	1,587	1,587	-
Todorov AD	208	-	208
Achieve Life Science Inc. – USA	44	44	-
Chimimport AD	13	13	-
Aroma AD	6	-	6
BTF Expat Bulgaria	5	5	-
Industrial Holding Bulgaria AD	1	1	-
Total	9,560	4,575	4,985

The table below shows reconciliation between the opening and closing balances of the fair values at Level 1 and Level 2:

<i>Equity investments</i>	<i>Level 1</i>	<i>Level 2</i>	<i>Total</i>
	BGN '000	BGN '000	BGN '000
Balance at 1 January 2019	3,740	3,798	7,538
Purchases	554	494	1,048
Issue of shares	322	800	1,122
Sales	(85)	(3)	(88)
Transfer from Level 1 to Level 2	(4)	4	-
Unrealised gain/(loss), net, included in other comprehensive income (<i>Note 14</i>)	48	(108)	(60)
Balance at 31 December 2019	4,575	4,985	9,560
Purchases	2,119	88	2,207
Issue of shares	501	-	501
Sales	(15)	(44)	(59)
Capital deregistration	(26)	-	(26)
Unrealised gain/(loss), net, included in other comprehensive income (<i>Note 14</i>)	(636)	(1)	(637)
Balance at 31 December 2020	6,518	5,028	11,546

Valuation techniques and approaches

The market comparables approach was applied in the Level 2 fair value measurements. The valuation technique was based on the trading multiples method. Upon preparing fair value measurements, the Company has used the services of certified valuers.

For investments not traded on equity markets, the Company has used internal assessments by Company's specialists. Upon the analysis of the companies subject to these internal assessments the Company has determined that the fair value of these equity investments do not materially deviate from their carrying amounts.

21. LONG-TERM RECEIVABLES FROM RELATED PARTIES

The long-term receivables from related parties include:

	31.12.2020 BGN '000	31.12.2019 BGN '000
Long-term loans granted	59,843	91,723
Provision for impairment of credit losses	(118)	(118)
	59,725	91,605
Long-term rental deposit granted	-	189
Total	59,725	91,794

Long-term loans are granted to the following related parties:

	31.12.2020 BGN '000	31.12.2019 BGN '000
Companies controlled by an associate	59,725	84,715
Associate companies	-	6,890
Total	59,725	91,605

The terms and conditions of the long-term loans granted to related parties are as follows:

<i>Currency</i>	<i>Contracted amount</i>	<i>Maturity</i>	<i>Interest %</i>	<i>31.12.2020</i>		<i>31.12.2019</i>	
				<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
	<i>'000</i>				<i>including interest</i>		<i>including interest</i>
<i>To companies controlled by an associate</i>							
<i>BGN</i>	81,900	31.12.2025	3.00%	58,321	852	81,999	99
<i>EUR</i>	708	31.12.2022	3.33%	1,404	20	-	-
<i>BGN</i>	3,400	31.12.2021	3.00%	-	-	2,716	-
<i>To associates</i>							
<i>EUR</i>	31,194	31.12.2021	3.50%	-	-	6,890	13
				59,725	872	91,605	112

The movement in the allowance (provision) for impairment of receivables from related parties under long-term loans granted is as follows:

	2020 BGN '000	2019 BGN '000
Balance on 1 January	118	116
Increase in the credit loss allowance recognised in profit or loss for the year	-	111
Decrease in the credit loss allowance recognised in profit or loss for the year	-	(109)
Balance at 31 December	118	118

The long-term loans granted to related parties are intended to support the financing of these companies' activities under common strategic objectives. They are secured by pledges on securities (shares), pledges on receivables and promissory notes.

Long-term deposit to a company related through a main shareholder under a concluded rental contract for administrative offices valid until 1 August 2022, as at 31 December 2020: none (as at 31 December 2019: BGN 189 thousand).

22. OTHER LONG-TERM RECEIVABLES

Company's *other long-term receivables* include:

	31.12.2020 BGN '000	31.12.2019 BGN '000
<i>Granted long-term loans</i>	7,620	6,447
<i>Provision for impairment of credit losses</i>	(12)	(149)
Long-term loans granted, net	7,608	6,298
<i>Receivables under transactions in securities</i>	3,605	3,482
<i>Provision for impairment of credit losses</i>	(297)	(268)
Receivables under transactions in securities, net	3,308	3,214
Receivables under a long-term rental deposit	189	-
<i>Receivables under sales of non-current assets</i>	-	394
<i>Provision for impairment of credit losses</i>	-	(9)
Receivables on sales of non-current assets, net	-	385
Total	11,105	9,897

The conditions of the long-term loans granted to third persons are as follows:

<i>Currency</i>	<i>Contracted amount '000</i>	<i>Maturity</i>	<i>Interest rate</i>	<i>31.12.2020</i>		<i>31.12.2019</i>	
				<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
				<i>Incl. interest</i>		<i>Incl. interest</i>	
<i>EUR</i>	3,000	29.06.2023	3.05%	6,135	267	4,890	-
<i>EUR</i>	695	12.10.2022	3.05%	1,473	114	1,393	34
<i>BGN</i>	24	14.03.2023	5.00%	-	-	15	-
				7,608	381	6,298	34

The movement in the allowance (provision) for impairment of receivables from third parties under long-term loans granted is as follows:

	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Balance at 1 January	149	71
Increase in the credit loss allowance recognised within profit or loss for the year	-	78
Decrease in the credit loss allowance recognised within profit or loss for the year	(137)	-
Balance at 31 December	12	149

The long-term loans granted to third parties aim to support the financing of these companies for general strategic objectives. They are secured with pledges on securities (shares), pledged on receivables and promissory notes.

Receivables under transactions in securities comprise receivables under an investment in subsidiaries and are as follows:

<i>Currency</i>	<i>Receivables '000</i>	<i>Maturity</i>	<i>31.12.2020</i>	<i>31.12.2019</i>
			<i>BGN'000</i>	<i>BGN'000</i>
<i>USD</i>	2,000	31.03.2024	2,891	3,214
<i>BGN</i>	417	22.06.2022	417	-
			3,308	3,214

The deferred payment with maturity on 31 March 2024 is related to the completion of legal actions of registration of medical product permits.

The movement in the allowance (provision) for impairment of receivables under transactions in securities is as follows:

	2020 BGN '000	2019 BGN '000
Balance at 1 January	268	322
Increase in the allowance for credit losses recognized in profit or loss for the year	29	29
Decrease in the allowance for credit losses recognized in profit or loss for the year	-	(83)
Balance at 31 December	297	268

Receivables under sales with deferred payment of non-current assets at the amount of BGN 385 thousand have maturity on 20 April 2021 and are classified as trade receivables (*Note 25*) (31 December 2019: BGN 385 thousand).

The movement in the allowance (provision) for impairment of receivables under sales of non-current assets is as follows:

	2020 BGN '000	2019 BGN '000
Balance at 1 January	9	69
Transfer to trade receivables	(9)	-
Increase in the allowance for credit losses recognized in profit or loss for the year	-	9
Decrease in the allowance for credit losses recognized in profit or loss for the year	-	(69)
Balance at 31 December	-	9

23. INVENTORIES

Company's *inventories* include:

	31.12.2020 BGN '000	31.12.2019 BGN '000
Materials	32,934	29,850
Finished goods	20,874	15,921
Work in progress	7,598	8,219
Semi-finished goods	6,600	7,266
Goods	154	109
Total	68,160	61,365

Materials by type are as follows:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Basic materials	31,159	28,245
Materials in transit	742	678
Technical materials	499	475
Auxiliary materials	311	208
Spare parts	189	189
Other	34	55
Total	32,934	29,850

Basic materials by type are as follows:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Substances	17,118	14,562
Chemicals	4,572	5,149
Ampoules	3,950	2,466
PVC and aluminium foil	1,427	1,732
Sanitary hygienic and dressing materials	1,339	1,326
Packaging materials	1,317	1,174
Herbs	948	1,163
<i>Incl. own production</i>	2	33
Vials	271	426
Tubes	217	247
Total	31,159	28,245

The movement in herbs – own production (agricultural produce including milk whistle and yellow acacia seeds) is as follows:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Agricultural produce at 1 January	33	-
Used in production	(31)	(173)
Cost of produce yield in the year	-	319
Loss on fair value measurement	-	(36)
Loss on revaluation under IAS 2	-	(77)
Agricultural produce at 31 December	2	33

Finished goods existing at 31 December include:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Tablet dosage forms	10,634	8,186
Ampoule dosage forms	3,642	3,307
Ointments	2,147	1,028
Dressing products	1,167	1,209
Syrups	856	619
Plasters	449	363
Drops	433	104
Sachets	406	-
Inhalers	352	-
Haemodialysis concentrates	305	50
Sanitary-hygienic products	266	325
Suppositories	99	85
Medical cosmetics	76	228
Lyophilic products	42	417
Total	20,874	15,921

In 2020, the Company produced 529,270 kg of wheat and 174,920 kg sunflower (2019: 100,368 kg wheat).

The movement in agricultural produce (wheat and sunflower) is as follows:

	2020	2019
	BGN '000	BGN '000
Agricultural produce at 1 January	<u>-</u>	<u>-</u>
Cost of produce in the year	210	136
Gain/ (Loss) on fair value measurement	68	(103)
Produce sold	(293)	(17)
Produce used for sowing crop 2020	-	(9)
Lease paid on agricultural land used	-	(6)
Gain/ (Loss) on sale	15	(1)
Agricultural produce at 31 December	<u><u>-</u></u>	<u><u>-</u></u>

Goods by type are as follows:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Medicinal products	86	41
Foodstuffs	68	68
Total	154	109

Pledges were established on Company's inventories with carrying amount of BGN 26,874 thousand as at 31 December 2020 as collateral to bank loans received (31 December 2019: BGN 21,921 thousand) (*Note 35 and Note 41*).

24. RECEIVABLES FROM RELATED PARTIES

Receivables from related parties include:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Receivables from subsidiaries	117,668	94,914
<i>Provision for impairment of credit losses</i>	<i>(9,558)</i>	<i>(3,962)</i>
	108,110	90,952
Receivables from companies controlled by an associate	6,135	6,112
<i>Provision for impairment of credit losses</i>	<i>(76)</i>	<i>(50)</i>
	6,059	6,062
Total	114,169	97,014

The receivables from related parties by type are as follows:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
<i>Receivables under contracts with customers</i>	<i>102,760</i>	<i>80,095</i>
<i>Provision for impairment of credit losses</i>	<i>(2,634)</i>	<i>(2,001)</i>
Receivables under contracts with customers, net	100,126	78,094
<i>Trade loans granted</i>	<i>19,114</i>	<i>19,638</i>
<i>Provision for impairment of credit losses</i>	<i>(5,707)</i>	<i>(2,011)</i>
Trade loans granted, net	13,407	17,627
Receivables under issued and granted guarantees	368	-
Advances granted	268	-
<i>Dividend receivables</i>	<i>1,293</i>	<i>1,293</i>
<i>Provision for impairment of credit losses</i>	<i>(1,293)</i>	<i>-</i>
Dividend receivables, net	-	1,293
Total	114,169	97,014

The receivables under contracts with customers – related parties are interest-free and BGN 72,972 thousand of them are denominated in BGN (31 December 2019: BGN 65,356 thousand) and in EUR – BGN 27,154 thousand (31 December 2019: BGN 12,738 thousand).

The receivables from a subsidiary with principal activities in the field of trade in pharmaceuticals were the most significant and amounted to BGN 72,792 thousand as at 31 December 2020 or 72,70% of all receivables under contracts with customers - related parties (31 December 2019: BGN 65,172 thousand – 83,45%).

The Company usually negotiates with its subsidiaries payment terms ranging from 45 to 270 days for receivables on sales of finished goods and up to 90 days for receivables on sales of materials (incl. substances).

The movement in the allowance (provision) for impairment of trade receivables from related parties is as follows:

	2020	2019
	BGN '000	BGN '000
Balance at 1 January	2,001	1,797
Increase in the credit loss allowance recognised within profit or loss for the year	2,634	2,001
Decrease in the credit loss allowance recognised within profit or loss for the year	(2,001)	(1,797)
Balance at 31 December	2,634	2,001

The *age structure* of non-matured (regular) trade receivables from related parties is as follows:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
up to 30 days	19,150	15,358
from 31 to 90 days	25,169	31,367
from 91 to 180 days	22,839	26,364
from 181 to 365 days	5,651	1,154
over 365 days	4,092	-
<i>Gross amount of non-matured (regular) receivables from related parties</i>	<i>76,901</i>	<i>74,243</i>
<i>Provision for impairment of credit losses</i>	<i>(1,156)</i>	<i>(874)</i>
Non-matured (regular) receivables from related parties, net	75,745	73,369

The provision for impairment of credit losses of non-matured (regular) trade receivables from related parties is as follows:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
up to 30 days	281	181
from 31 to 90 days	383	379
from 91 to 180 days	344	301
from 181 to 365 days	86	13
over 365 days	62	-
Total	1,156	874

The age structure of the invoice date of past due trade receivables from related parties is as follows:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
from 31 to 90 days	1,669	33
from 91 to 180 days	1,935	363
from 181 to 365 days	21,441	4,480
over 365 days	814	976
<i>Gross amount of past due receivables from related parties</i>	<i>25,859</i>	<i>5,852</i>
<i>Provision for impairment of credit losses</i>	<i>(1,478)</i>	<i>(1,127)</i>
Past due receivables from related parties, net	24,381	4,725

The Company applies the simplified approach under IFRS 9 to measure expected credit losses for trade receivables by recognizing expected lifetime losses for all trade receivables (*Note 2.16*).

Based on that, the credit loss allowance as at 31 December is determined as follows:

<i>31 December 2020</i>		<i>Regular</i>	<i>Up to 90 days past due</i>	<i>Over 90 days past due</i>	<i>Over 180 days past due</i>	<i>Over 365 days past due</i>	Total
Expected average percentage of credit losses		2%	3%	6%	39%	98%	
Trade receivables from related parties (gross carrying amount)	<i>BGN '000</i>	76,901	17,936	6,846	876	201	102,760
Expected credit loss (Impairment allowance)	<i>BGN '000</i>	(1,156)	(513)	(426)	(343)	(196)	(2,634)

		<i>Regular</i>	<i>Up to 90 days past due</i>	<i>Over 90 days past due</i>	<i>Over 180 days past due</i>	<i>Over 365 days past due</i>	Total
31 December 2019							
Expected average percentage of credit losses		1%	3%	13%	38%	88%	
Trade receivables from related parties (gross carrying amount)	BGN '000	74,243	1,502	3,065	910	375	80,095
Expected credit loss (Impairment allowance)	BGN '000	(874)	(44)	(404)	(348)	(331)	(2,001)

Special pledges have been established as at 31 December 2020 on receivables from related parties at the amount of BGN 79,292 thousand as collateral under bank loans received (31 December 2019: BGN 71,672 thousand) (*Note 35*).

Loans granted to related parties by type of related party are as follows:

	31.12.2020 BGN '000	31.12.2019 BGN '000
Subsidiaries	13,037	13,584
<i>Provision for impairment of credit losses</i>	<u>(5,688)</u>	<u>(2,005)</u>
	7,349	11,579
Companies controlled by an associate	6,077	6,054
<i>Provision for impairment of credit losses</i>	<u>(19)</u>	<u>(6)</u>
	6,058	6,048
Total	<u>13,407</u>	<u>17,627</u>

The terms and conditions of the loans granted to related parties are as follows:

<i>Currency</i>	<i>Contracted amount '000</i>	<i>Maturity</i>	<i>Interest %</i>	<i>31.12.2020</i>		<i>31.12.2019</i>	
				<i>BGN '000</i>	<i>BGN '000 including interest</i>	<i>BGN '000</i>	<i>BGN '000 including interest</i>
<i>to subsidiaries</i>							
<i>BGN</i>	14,109	31.12.2021	4.10%	5,355	45	5,664	228
<i>BGN</i>	3,050	31.12.2021	3.50%	889	10	1,661	8
<i>EUR</i>	390	31.12.2021	3.95%	839	76	811	48
<i>EUR</i>	132	31.05.2021	5.00%	266	7	-	-
<i>EUR</i>	2,770	31.12.2019	4.70%	-	-	3,443	-
<i>to companies controlled by an associate</i>							
<i>EUR</i>	8,937	31.12.2021	3.10%	6,010	22	5,999	-
<i>BGN</i>	190	31.12.2021	3.50%	48	-	49	-
				<u>13,407</u>	<u>160</u>	<u>17,627</u>	<u>284</u>

The short-term loans granted to related parties are intended to support the financing of these companies' activities under common strategic objectives. They are secured by pledges on corporate shares and securities (shares), pledges on receivables and promissory notes.

The movement in the allowance (provision) for impairment of loans granted to related parties is as follows:

	2020	2019
	BGN '000	BGN '000
Balance at 1 January	2,011	938
Increase in the credit loss allowance recognised within profit or loss for the year	3,793	1,629
Decrease in the credit loss allowance recognised within profit or loss for the year	(97)	(556)
Balance at 31 December	5,707	2,011

25. TRADE RECEIVABLES

Trade receivables include:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
<i>Receivables under contracts with customers</i>	19,535	27,601
<i>Provision for impairment of credit losses</i>	(1,692)	(1,487)
Receivables under contracts with customers, net	17,843	26,114
Advances granted	539	1,098
Total	18,382	27,212

The *receivables under contracts with customers* are interest-free and BGN 895 thousand of them are denominated in BGN (31 December 2019: BGN 943 thousand), in EUR – BGN 14,753 thousand (31 December 2019: BGN 22,822 thousand), in USD – BGN 2,193 thousand (31 December 2019: BGN 2,349 thousand), and in other currencies – BGN 2 thousand (31 December 2019: none).

One main counterparty of the Company is accountable for about 66,59% of the receivables from clients (2019: one main counterparty accountable for 84,42%).

The Company usually agrees with its clients payment terms from 30 to 180 days for receivables under sales except for the cases when new markets and products are being developed and new trade counterparts are being attracted.

The movement in the allowance (provision) for impairment of trade receivables from third parties is as follows:

	2020 BGN '000	2019 BGN '000
Balance at 1 January	1,487	1,817
Increase in the credit loss allowance recognised within profit or loss for the year	1,692	1,487
Transfer from other long-term receivables	9	-
Decrease in the credit loss allowance recognised within profit or loss for the year	(1,496)	(1,817)
Balance at 31 December	1,692	1,487

The age structure of non-matured (regular) trade receivables is as follows:

	31.12.2020 BGN '000	31.12.2019 BGN '000
up to 30 days	5,582	4,226
from 31 to 90 days	10,919	11,143
from 91 to 180 days	515	435
over 365 days	394	-
<i>Gross amount of non-matured (regular) trade receivables</i>	<i>17,410</i>	<i>15,804</i>
<i>Provision for impairment of credit losses</i>	<i>(194)</i>	<i>(181)</i>
Non-matured (regular) trade receivables, net	17,216	15,623

The provision for impairment of credit losses of non-matured (regular) trade receivables is as follows:

	31.12.2020 BGN '000	31.12.2019 BGN '000
up to 30 days	57	47
from 31 to 90 days	126	129
from 91 to 180 days	6	5
over 365 days	5	-
Total	194	181

The *age structure* of the invoice date of past due but not impaired trade receivables is as follows:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
from 31 to 90 days	267	10,240
from 91 to 180 days	157	153
from 181 to 365 days	313	412
over 365 days	1,388	992
<i>Gross amount of past due trade receivables</i>	<u>2,125</u>	<u>11,797</u>
<i>Provision for impairment of credit losses</i>	<u>(1,498)</u>	<u>(1,306)</u>
Past due trade receivables, net	<u>627</u>	<u>10,491</u>

The Company applies the simplified approach under IFRS 9 to measure expected credit losses for trade receivables by recognizing expected lifetime losses for all trade receivables (*Note 2.16*) Based on that, the loss allowance as at 31 December is determined as follows:

		<i>Regular</i>	<i>Up to 90 days past due</i>	<i>Over 90 days past due</i>	<i>Over 180 days past due</i>	<i>Over 365 days past due</i>	<i>Total</i>
31 December 2020							
Expected average percentage of credit losses		1%	5%	51%	75%	98%	
Trade receivables (gross carrying amount)	BGN '000	17,410	451	278	173	1,223	19,535
Expected credit loss (Impairment allowance)	BGN '000	(194)	(21)	(143)	(130)	(1,204)	(1,692)
31 December 2019							
Expected average percentage of credit losses		1%	2%	28%	47%	97%	
Trade receivables (gross carrying amount)	BGN '000	15,804	10,398	130	367	902	27,601
Expected credit loss (Impairment allowance)	BGN '000	(181)	(224)	(37)	(173)	(872)	(1,487)

As at 31 December 2020, special pledges have been established as collateral of bank loans received on trade receivables at the amount of BGN 11,735 thousand (31 December 2019: BGN 11,735 thousand) (*Note 35 and Note 41*).

The *advances granted to suppliers* as at 31 December are for the purchase of:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Inventories	403	787
Services	136	311
Total	539	1,098

The *advances granted* are regular. They include: in BGN – BGN 298 thousand (31 December 2019: BGN 609 thousand), in EUR – BGN 57 thousand (31 December 2019: BGN 171 thousand), in USD: BGN 161 thousand (31 December 2019: BGN 317 thousand), and in other currency – BGN 23 thousand (31 December 2019: BGN 1 thousand).

26(A). LOANS GRANTED TO THIRD PARTIES

The *loans granted to third parties* are as follows:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Trade loans granted	3,903	6,052
<i>Provision for impairment of credit losses</i>	-	(8)
Total	3,903	6,044

The *loans granted to third parties* are intended to provide support for financing of activities, performed by these entities, but having common strategic objectives. They are secured through pledges on securities (shares) and pledges on receivables.

The terms and conditions under which loans are granted to third parties are as follows:

Currency	Contracted amount	Maturity	Interest %	31.12.2020		31.12.2019	
				BGN '000	BGN '000 including interest	BGN'000	BGN'000 including interest
BGN	4,511	31.12.2021	2.55%	3,158	2	4,549	-
BGN	832	31.12.2021	4.50%	443	-	496	-
BGN	4,184	31.12.2021	4.30%	199	-	889	-
BGN	949	31.12.2021	4.70%	103	1	110	-
				3,903	3	6,044	-

The movement in the allowance (provision) for impairment of loans to third parties is as follows:

	2020	2019
	BGN '000	BGN '000
Balance at 1 January	8	545
Increase in the credit loss allowance recognised within profit or loss for the year	-	8
Decrease in the credit loss allowance recognised within profit or loss for the year	(8)	(545)
Balance at 31 December	-	8

26(B). OTHER RECEIVABLES AND PREPAYMENTS

Other receivables and prepayments include:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Taxes refundable	4,910	5,027
Prepayments	747	957
Dividends receivables	180	-
Receivables under deposits granted as guarantees	131	119
Cash paid for dividends	40	-
Funds provided to an investment intermediary	3	1
Awarded receivables	20	5
Provision for impairment of credit losses from awarded receivables	(20)	(5)
Other	46	40
Total	6,057	6,144

Taxes refundable include:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Excise duties	4,910	5,027
Total	4,910	5,027

Prepayments include:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Subscriptions	394	424
Insurance	258	259
Licence and patent fees	66	82
Rentals	16	31
Vouchers	2	1
Advertisement	-	88
Consulting services	-	35
Other	11	37
Total	747	957

Deposits placed as guarantees include:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Guarantees under contracts for fuel supply	81	86
Guarantees under supply of medicinal products	15	13
Guarantees under contracts for rental	13	9
Guarantees under construction contracts	4	4
Guarantees under contracts for electricity supply	3	3
Other	15	4
Total	131	119

The movement in the allowance (provision) for impairment of court and awarded receivables is as follows:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Balance at 1 January	5	137
Increase in the credit loss allowance recognised within profit or loss for the year	15	5
Decrease in the credit loss allowance recognised within profit or loss for the year	-	(137)
Balance at 31 December	20	5

27. CASH AND CASH EQUIVALENTS

Cash includes:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
<i>Cash at current bank accounts</i>	3,668	4,062
<i>Impairment of cash at current bank accounts</i>	-	(166)
Cash at current bank accounts, net of impairment	3,668	3,896
Cash in hand	84	43
Blocked cash under issued bank guarantees	24	20
Total	3,776	3,959

Cash structure at current bank accounts is as follows: in BGN: BGN 1,819 thousand (31 December 2019: BGN 2,472 thousand), in EUR – BGN 1,541 thousand (31 December 2019: BGN 615 thousand), in USD – BGN 281 thousand (31 December 2019: BGN 784 thousand) and in other currency – BGN 27 thousand (31 December 2019: BGN 25 thousand).

Cash in hand is denominated in: BGN: BGN 83 thousand (31 December 2019: BGN 42 thousand), and other currencies: BGN 1 thousand (31 December 2019: BGN 1 thousand).

The cash blocked under bank securities issued is: in BGN – BGN 23 thousand (31 December 2019: BGN 18 thousand), and in EUR – BGN 1 thousand (31 December 2019: BGN 2 thousand).

As a result of the analyses made and the methodology applied to calculate expected credit losses for cash and cash equivalents, the management has determined that no impairment is necessary of cash and cash equivalents. Therefore, the Company has not recognised a provision for the impairment of expected credit losses on cash and cash equivalents as at 31 December 2020.

28. EQUITY

Share capital

As at 31 December 2020, the registered share capital of Sopharma AD amounted to BGN 134,798 thousand distributed in 134,797,899 shares of nominal value BGN 1 each.

<i>Ordinary shares issued and fully paid</i>	<i>Shares number</i>	<i>Share capital net of treasury shares BGN '000</i>
Balance at 1 January 2019	125,916,563	101,461
Treasury shares bought	(232,131)	(801)
Expense for treasury shares purchase	-	(4)
Balance at 31 December 2019	125,684,432	100,656
Treasury shares sold	253,748	949
Treasury shares bought	(151,748)	(461)
Expense on treasury shares purchase	-	(2)
Balance at 31 December 2020	125,786,432	101,142

The table below presents the paid joint-stock capital of the Company at 31 December:

	<i>31.12.2020 BGN '000</i>	<i>31.12.2019 BGN '000</i>
Share capital (registered), nominal	134,798	134,798
Share premium	8,785	8,785
Total paid capital	143,583	143,583

Company's shares are ordinary, non-cash, with right of dividend and liquidation share and are registered for trade in the Bulgarian Stock Exchange – Sofia AD and Warsaw Stock Exchange.

The *treasury shares* were 9,011,467 at the amount of BGN 33,656 thousand as at 31 December 2020 (31 December 2019: 9,113,467 shares at the amount of BGN 34,142 thousand). The number of shares purchased in the current year was 151,748 (2019: 232,131 shares) and the number of shares sold: 253,748 (2019: none).

Company's *reserves* are summarised in the table below:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Statutory reserves	63,335	59,297
Property, plant and equipment revaluation reserve	21,594	22,040
Reserve for financial assets at fair value through other comprehensive income	2,282	2,873
Additional reserves	321,596	298,339
Total	408,807	382,549

Statutory reserves at the amount of BGN 63,335 thousand (31 December 2019: BGN 59,297 thousand) represent the Reserve Fund, which is set aside under a requirement of the Commercial Act and Company's Articles of Association, and includes two components: (a) amounts from distribution of profit for the Reserve Fund – BGN 54,550 thousand (31 December 2019: BGN 50,512 thousand), and (b) share premium representing the excess of the issue value over the nominal value of the issued shares on the merger of a subsidiary into Sopharma AD – BGN 8,785 thousand (31 December 2019: BGN 8,785 thousand).

The movements of statutory reserves were as follows:

	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Balance at 1 January	59,297	55,967
Distribution of profit	4,038	3,330
Balance at 31 December	63,335	59,297

The *property, plant and equipment revaluation reserve*, amounting to BGN 21,594 thousand (31 December 2019: BGN 22,040 thousand), is set aside from the surplus between the carrying amount of property, plant and equipment and their fair value at the date of the respective revaluation. The deferred tax effect on the revaluation reserve was directly carried to this reserve.

The movements of property, plant and equipment revaluation reserve were as follows:

	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Balance at 1 January	22,040	22,433
Transfer to retained earnings	(409)	(569)
(Loss)/Gain on revaluation of property, plant and equipment, net	(41)	196
Deferred tax relating to revaluations	4	(20)
Balance at 31 December	21,594	22,040

The reserve of financial assets at fair value through other comprehensive income, amounting to BGN 2,282 thousand (31 December 2019: BGN 2,873 thousand) is formed of the effects of fair-value measurement of other long-term equity investments. Upon derecognition of these investments, the reserve formed is transferred to “retained earnings”.

The movements of the reserve of financial assets at fair value through other comprehensive income were as follows:

	2020	2019
	BGN '000	BGN '000
Balance at 1 January	2,873	2,933
Net change in the fair value of other long-term equity investments	(637)	(60)
Transfer to retained earnings	46	-
Balance at 31 December	2,282	2,873

Additional reserves at the amount of BGN 321,596 thousand (31 December 2019: BGN 298,339 thousand) are set aside from distribution of profits under a decision of shareholders and can be used for payment of dividend, share capital increase as well as to cover losses.

The movements of additional reserves are as follows:

	2020	2019
	BGN '000	BGN '000
Balance at 1 January	298,339	275,977
Distributed profit in the year	23,257	22,362
Balance at 31 December	321,596	298,339

Base net earnings per share

	31.12.2020	31.12.2019
Weighted average number of shares	125,754,274	125,896,515
Net profit for the year (BGN '000)	28,664	40,382
Base net earnings per share (BGN)	0.23	0.32

As at 31 December 2020, *retained earnings* amount at BGN 27,039 thousand (31.12.2019: BGN 39,439 thousand).

The movement in *retained earnings* is as follows:

	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Balance at 1 January	39,439	30,448
Net profit for the year	28,664	40,382
Transfer from revaluation reserve of property, plant and equipment	409	569
Profit distribution to reserves	(27,295)	(25,692)
2019 profit distribution for dividends	(8,798)	(6,284)
Distribution of advance dividend from profit for 2020	(5,032)	-
Actuarial loss on revaluation	(158)	16
Effect from treasury shares sold	(144)	-
Transfer from revaluation reserve of financial assets at fair value through other comprehensive income	(46)	-
Balance at 31 December	27,039	39,439

29. LONG-TERM BANK LOANS

Long-term bank loans include:

<i>Currency</i>	<i>Contracted loan amount</i>	<i>Maturity</i>	<i>Non-current portion</i>	<i>31.12.2020</i>			<i>31.12.2019</i>		
				<i>Current portion</i>	<i>Total</i>	<i>Non-current portion</i>	<i>Current portion</i>	<i>Total</i>	
	<i>'000</i>		<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	
<i>Investment-purpose loans</i>									
EUR	32,000	15.04.2021	-	2,389	2,389	2,386	7,160	9,546	
AZN	27	18.05.2023	14	7	21	-	-	-	
AZN	23	15.04.2022	1	5	6	8	7	15	
AZN	35	16.03.2021	-	3	3	4	14	18	
			15	2,404	2,419	2,398	7,181	9,579	

The investment-purpose loan received in Euro was agreed at interest rate based on three-month EURIBOR plus a mark-up of up to 1.7 points but not less than 1.7 points and fixed interest rate at the amount of 22% to 24.10% (2019: three-month EURIBOR plus a mark-up of up to 1.7 points, but not less than 1.7 points and fixed interest rate at the amount of 24.10%).

The following were established under the loans listed:

- Mortgages of real estate with a carrying amount of BGN 35,810 thousand as at 31 December 2020 (31 December 2019: BGN 37,505 thousand) (*Note 15*);
- Special pledges on machinery and equipment with a carrying amount of BGN 13,818 thousand as at 31 December 2020 (31 December 2019: BGN 14,889 thousand) (*Note 15*).

The long-term bank loan contracts include clauses with covenants for maintaining certain financial ratios. Company's management currently controls the observance of these financial ratios in communication with the respective creditor bank.

Reconciliation of the movement of liabilities from financing activities

The table below shows changes in liabilities from financing activities, representing both cash and non-cash changes. Liabilities from financial liabilities are those for which cash flows are or future cash flows will be classified in the Company's statement of cash flows as cash flows from financing activities.

	<i>01.01.2020</i>	<i>Changes in cash flows from financing activities</i>	<i>Newly arising liabilities over the year</i>	<i>Other non-cash changes</i>	<i>31.12.2020</i>
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Bank loans	109,938	(34,213)	28	1	75,754
Lease liabilities to related parties	2,609	-	-	(2,609)	-
Lease liabilities to third parties	1,677	(1,928)	1,223	2,462	3,434
Dividends	6,441	(19,944)	13,830	(2)	325
Total	120,665	(56,085)	15,081	(148)	79,513
Treasury shares	(34,142)	342	-	144	(33,656)
Net cash flows from financing activities	86,523	(55,743)	15,081	(4)	45,857
	<i>01.01.2019</i>	<i>Changes in cash flows from financing activities</i>	<i>Newly arising liabilities over the year</i>	<i>Other non-cash changes</i>	<i>31.12.2019</i>
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Bank loans	82,376	27,478	24	60	109,938
Lease liabilities to related parties	3,896	(1,038)	121	(370)	2,609
Lease liabilities to third parties	1,799	(672)	544	6	1,677
Dividends	271	(28)	6,244	(46)	6,441
Total	88,342	25,740	6,933	(350)	120,665
Treasury shares	(33,337)	(805)	-	-	(34,142)
Net cash flows from financing activities	55,005	24,935	6,933	(350)	86,523

30. DEFERRED TAX LIABILITIES

Deferred income taxes as at 31 December are related to the following items of the statement of financial position:

<i>Deferred tax (liabilities)/ assets</i>	<i>temporary difference</i>		<i>temporary difference</i>	
	<i>31.12.2020</i>	<i>31.12.2020</i>	<i>31.12.2019</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Property, plant and equipment	67,427	6,743	69,390	6,939
<i>including revaluation reserve</i>	19,828	1,983	20,323	2,032
Investment property	10,034	1,003	8,808	881
<i>including revaluation reserve</i>	516	52	516	52
Intangible assets	1,027	103	2,086	209
<i>Total deferred tax liabilities</i>	78,488	7,849	80,284	8,029
Payables to personnel	(8,179)	(818)	(7,859)	(786)
Receivables	(11,889)	(1,189)	(6,180)	(618)
Inventories	(4,073)	(407)	(3,261)	(326)
Accrued liabilities	(772)	(77)	(729)	(73)
Cash	-	-	(166)	(17)
<i>Total deferred tax assets</i>	(24,913)	(2,491)	(18,195)	(1,820)
Deferred income tax liabilities, net	53,575	5,358	62,089	6,209

On recognising deferred tax assets, the probability of a reversal of the individual differences and the abilities of the Company to generate sufficient taxable profit in the future, had been taken into account.

The change in the balance of deferred taxes for 2020 is as follows:

<i>Deferred tax (liabilities)/ assets</i>	<i>Balance at 1 January 2020</i>	<i>Recognised in the statement of comprehensive income</i>	<i>Recognised in equity</i>	<i>Recognised in the statement of changes in equity and the current tax return</i>	<i>Balance at 31 December 2020</i>
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Property, plant and equipment	(6,939)	144	4	48	(6,743)
Investment property	(881)	(122)	-	-	(1,003)
Intangible assets	(209)	106	-	-	(103)
Payables to personnel	786	32	-	-	818
Receivables	618	571	-	-	1,189
Inventories	326	81	-	-	407
Accrued liabilities	73	4	-	-	77
Cash	17	(17)	-	-	-
Total	(6,209)	799	4	48	(5,358)

The change in the balance of deferred taxes for 2019 is as follows:

<i>Deferred tax (liabilities)/ assets</i>	<i>Balance at 1 January 2019</i>	<i>Recognised in the statement of comprehensive income</i>	<i>Recognised in equity</i>	<i>Recognised in the statement of changes in equity and the current tax return</i>	<i>Balance at 31 December 2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Property, plant and equipment	(7,080)	110	(20)	51	(6,939)
Intangible assets	(230)	21	-	-	(209)
Investment property	(768)	(113)	-	-	(881)
Payables to personnel	742	44	-	-	786
Receivables	599	19	-	-	618
Inventories	424	(98)	-	-	326
Accrued liabilities	61	12	-	-	73
Cash	17	-	-	-	17
Total	(6,235)	(5)	(20)	51	(6,209)

31. GOVERNMENT GRANTS

The government grants are under concluded contracts with the Bulgarian Small and Medium Enterprises Promotion Agency for gratuitous financial aid under Operational Programme "Development of the Competitiveness of the Bulgarian Economy" 2007-2013 and Operational Programme "Energy Efficiency".

The current portion of the financing will be recognised as current income over the following 12 months from the date of the separate statement of financial position and presented as 'other current liabilities' (*Note 40*).

The table below presents the non-current and the current portion of the grants received by type:

	31.12.2020			31.12.2019		
	<i>Non-current portion</i> <i>BGN '000</i>	<i>Current portion</i> <i>BGN '000</i>	<i>Total</i> <i>BGN '000</i>	<i>Non-current portion</i> <i>BGN '000</i>	<i>Current portion</i> <i>BGN '000</i>	<i>Total</i> <i>BGN '000</i>
Acquisition of machinery and equipment for a new tablets production line	2,279	179	2,458	2,459	179	2,638
Implementation of innovative products in the production of ampoule dosage forms	1,700	200	1,900	1,900	200	2,100
Acquisition on non-current assets and building reconstruction	304	8	312	312	8	320
Implementation of innovative "artificial tears" eye drops production	61	24	85	84	24	108
Acquisition of combined exchange ventilation and air conditioning installation	83	9	92	93	9	102
Acquisition of machinery and equipment for technological renovation and modernisation of tablet production	-	10	10	10	120	130
	4,427	430	4,857	4,858	540	5,398

32. LEASE LIABILITIES TO RELATED PARTIES

The lease liabilities to related parties included in the statement of financial position have arisen in relation to building rentals and are stated net of the future interest due, as follows:

<i>Term</i>	31.12.2020 BGN '000	31.12.2019 BGN '000
Up to one year	-	999
Over one year	-	1,610
Total	-	2,609

Minimum lease payments to related parties are due, as follows:

<i>Term</i>	31.12.2020 BGN '000	31.12.2019 BGN '000
Up to one year	-	1,030
Over one year	-	1,635
	-	2,665
Future finance costs on finance leases	-	(56)
Present value of lease liabilities to related parties	-	2,609

Lease liabilities to related parties are denominated in EUR.

Instalments due over the next 12 months are presented in the statement of financial position as “payables to related parties” (Note 37).

33. LEASE LIABILITIES TO THIRD PARTIES

The lease liabilities to third parties included in the statement of financial position are presented net of future interest due, and are as follows:

<i>Term</i>	31.12.2020 BGN '000	31.12.2019 BGN '000
Up to one year	1,901	723
Over one year	1,533	954
Total	3,434	1,677

Minimum lease payments to third parties are due, as follows:

<i>Term</i>	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Up to one year	1,965	744
Over one year	1,617	990
	3,582	1,734
Future finance costs on finance leases	(148)	(57)
Present value of lease liabilities to third parties	3,434	1,677

The table below presents liabilities per types of leases to third parties:

	<i>31.12.2020</i>			<i>31.12.2019</i>		
	<i>Long-term portion</i> <i>BGN'000</i>	<i>Short-term portion</i> <i>BGN'000</i>	<i>Total</i> <i>BGN'000</i>	<i>Long-term portion</i> <i>BGN'000</i>	<i>Short-term portion</i> <i>BGN'000</i>	<i>Total</i> <i>BGN'000</i>
Leases of motor vehicles	777	703	1,480	695	544	1,239
Leases of buildings	717	1,129	1,846	147	125	272
Leases of apparatuses	20	62	82	95	48	143
Leases of land	19	7	26	17	6	23
Total	1,533	1,901	3,434	954	723	1,677

Lease liabilities to third parties in BGN amount to BGN 107 thousand (31 December 2019: BGN 166 thousand), in EUR – BGN 3,107 thousand (31 December 2019: BGN 1,343 thousand), in USD – BGN 152 thousand (31 December 2019: BGN 107 thousand), and in other currencies – BGN 68 thousand (31 December 2019: BGN 61 thousand).

The lease payments due over the next 12 months are presented in the statement of financial position as “other current payables” (Note 40).

34. RETIREMENT BENEFIT OBLIGATIONS

Long-term payables to personnel include:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Long-term retirement benefit obligations	4,478	4,345
Long-term benefit obligations for tantieme	280	293
Total	4,758	4,638

Long-term retirement benefit obligations

The long-term retirement benefit obligations to personnel include the present value of Company's liability at the date of the statement of financial position to pay indemnities to individuals of its employees upon coming of age for retirement.

In accordance with the Labour Code in Bulgaria, every employee is entitled to an indemnity on retirement at the amount of two gross monthly salaries, and if he or she has worked for the same employer during the last 10 years of their service the indemnity amounts to six gross monthly salaries at the time of retirement. This is a defined benefits plan (*Note 2.23*).

For the purpose of establishing the amount of these obligations to personnel, the Company has assigned an actuarial valuation as at 31 December 2020 by using the services of a certified actuary.

Movements in the present value of retirement benefit obligations to personnel are as follows:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Present value of the obligation at 1 January	4,345	4,100
Current service cost	509	476
Interest cost	27	44
Net actuarial loss recognised for the period	(17)	7
Payments made in the year	(544)	(266)
Revaluation gains or losses on the retirement benefit obligations, including:	158	(16)
<i>Actuarial losses arising from changes in demographic assumptions</i>	4	12
<i>Actuarial losses arising from changes in financial assumptions</i>	28	116
<i>Actuarial (gains)/losses arising from past experience adjustments</i>	126	(144)
Present value of the obligation at 31 December	4,478	4,345

The amounts of long-term retirement benefits of personnel accrued in the statement of comprehensive income are as follows:

	2020 BGN '000	2019 BGN '000
Current service cost	509	476
Interest cost	27	44
Net actuarial (gain)/loss recognised for the period	(17)	7
Components of defined benefit plan costs recognised in profit or loss (Note 7)	519	527
Revaluation gains or losses on the retirement benefit obligations, including:		
<i>Actuarial losses arising from changes in demographic assumptions</i>	4	12
<i>Actuarial losses arising from changes in financial assumptions</i>	28	116
<i>Actuarial losses/(gains) arising from past experience adjustments</i>	126	(144)
Components of defined benefit plans cost recognised in other comprehensive income (Note 14)	158	(16)
Total	677	511

The following actuarial assumptions were used in calculating the present value of the liabilities as at 31 December 2020:

- The discount factor is calculated by using as basis of 0.5% (2019: 0.6%). The assumption is based on yield data for long-term government securities with 10-year maturity;
- The assumption for the future level of the salaries is based on the information provided by the Company's management and amounts to 5% annual growth compared to the prior reporting period (2019: 5%);
- Mortality rate – in accordance with the table issued by the National Statistics Institute for the total mortality rate of the population in Bulgaria for the period 2017-2019 (2019: 2016 - 2018);
- Staff turnover rate – from 0% to 16% for the five age groups formed (2019: between 0% and 16%);
- Early retirement due to illness – between 0.03% and 0.32% for the five age groups formed (2019: between 0.03% and 0.32%).

This defined benefit plan exposes the Company to the following risks: investment risk, interest risk, longevity risk and salary growth related risk: The Company's management defines them as follows:

- investment risk – as far as this is unfunded plan, the Company should monitor and balance currently the forthcoming payments under it with the ensuring of sufficient cash resources. The historical experience and the liability structure show that the annual resource required is not material compared to the commonly maintained liquid funds;
- interest risk – any increase in the yield of government securities with similar term will increase the plan liability;

- longevity risk – the present value of the retirement benefit liability is calculated by reference to the best estimate and updated information about the mortality of plan participants. An increase in life expectancy would result in a possible increase in the liability. A relative stability of this indicator has been observed in the recent years; and
- salary growth related risk – the present value of the retirement benefit liability is calculated by reference to the best estimate of the future increase in plan participants' salaries. Such an increase would increase the plan liability.

The sensitivity analysis of the main actuarial assumptions is based on the reasonably possible changes of these assumptions at the end of the reporting period, assuming that all other assumptions are held constant.

The effects of the change (increase or decrease) by 1% of:

- salary growth*
- discount rate*
- staff turnover rate*

on the expenses and interest for current service, respectively on the present value of the obligation for payment of defined retirement benefits, are assessed as follows:

- *Impact on the amount of the present value of the obligation:*

	2020		2019	
	<i>Increase</i>	<i>Decrease</i>	<i>Increase</i>	<i>Decrease</i>
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Change in salary growth	353	(314)	370	(321)
Change in discount rate	(320)	368	(330)	390
Change in staff turnover rate	(343)	390	(349)	408

- *Impact on the amount of the expenses and interest for current service*

	2020		2019	
	<i>Increase</i>	<i>Decrease</i>	<i>Increase</i>	<i>Decrease</i>
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Change in salary growth	46	(40)	52	(45)
Change in discount rate	-	1	(6)	6
Change in staff turnover rate	(44)	51	(49)	58

The weighted average duration of the defined benefit obligation to personnel is 7.6 years (31 December 2019: 8.1 years).

The expected indemnity payments upon retirement under the defined benefit plan for the following five years are as follows:

	<i>Forecast payments</i>	<i>Old age and length of service retirement</i>	<i>Poor health retirement</i>	<i>Total</i>
	<i>BGN '000</i>		<i>BGN '000</i>	<i>BGN '000</i>
<i>Payments in 2021</i>	799		16	815
<i>Payments in 2022</i>	254		16	270
<i>Payments in 2023</i>	301		16	317
<i>Payments in 2024</i>	360		15	375
<i>Payments in 2025</i>	379		14	393
	2,093		77	2,170

Long-term benefit obligations for tantieme

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Long-term benefit obligations for tantieme with maturity in 2023	154	-
Long-term benefit obligations for tantieme with maturity in 2022	126	126
Long-term benefit obligations for tantieme with maturity in 2021	-	167
	280	293

35. SHORT-TERM BANK LOANS

Short-term bank loans include:

<i>Currency</i>	<i>Contracted amount '000</i>	<i>Maturity</i>	<i>31.12.2020 BGN '000</i>	<i>31.12.2019 BGN '000</i>
Bank loans (overdrafts)				
BGN	20,000	31.07.2021	19,987	20,009
EUR	10,000	31.07.2021	10,047	18,363
BGN	9,779	01.06.2021	9,518	9,704
BGN	5,000	31.07.2021	4,968	4,992
BGN	20,000	31.05.2021	4,966	987
BGN	20,000	31.07.2021	4,937	19,948
			54,423	74,003
Extended credit lines				
BGN	20,000	31.01.2021	17,613	19,782
EUR	10,000	31.08.2021	1,299	6,574
			18,912	26,356
Total			73,335	100,359

The bank loans received in EUR have been agreed at interest rate based on one-month EURIBOR plus a mark-up of 1.3 points, but not less than 1.3 points, one-month EURIBOR plus a mark-up of 1.5 points, and for those in BGN – from 1.3% to 1.45%, and average deposit index plus 1 point (2019: for loans in EUR - 1-month EURIBOR plus a mark-up of 1.3 points, but not less than 1.3 points and 1-month EURIBOR plus a mark-up of 1.5 points, and those in Bulgarian Levs – from 1.3% to 1.45%, and average deposit index plus 1 point). The loans are for working capital.

A portion of the loans drawn at 31 December at the amount of BGN 23 thousand (31 December 2019: BGN 130 thousand) are in the form of bank guarantees in favour of the National Health Insurance Fund (NHIF) and suppliers for covering obligations as follows.

The following collateral has been established in favour of the creditor banks:

- Mortgages of real estate with a carrying amount of BGN 28,617 thousand as at 31 December 2020 (31 December 2019: BGN 29,183 thousand) (*Note 15 and Note 17*);
- Special pledges on:
 - machinery and equipment with a carrying amount of BGN 15,871 thousand as at 31 December 2020 (31 December 2019: BGN 17,379 thousand) (*Note 15 and Note 17*);
 - inventories with a carrying amount of BGN 26,874 thousand as at 31 December 2020 (31 December 2019: BGN 21,921 thousand) (*Note 23*);

- receivables from related parties with a carrying amount of BGN 79,292 thousand as at 31 December 2020 (31 December 2019: BGN 71,672 thousand) (*Note 24*);
- trade receivables with a carrying amount of BGN 11,735 thousand as at 31 December 2020 (31 December 2019: BGN 11,735 thousand) (*Note 25*);
- trade receivables from third parties of a subsidiary with a carrying amount of BGN 7,823 thousand as at 31 December 2020 (31 December 2019: BGN 7,823 thousand).

The short-term bank loan contracts include clauses with covenants for maintaining certain financial ratios. Company's management currently controls the observance of these financial ratios in communication with the respective creditor bank.

36. TRADE PAYABLES

Trade payables include:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Payables to suppliers	7,016	5,472
Advances received	202	602
Total	7,218	6,074

Payables to suppliers by type are as follows:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Payables for supply of inventories	3,726	3,820
Payables for supply of services	2,901	1,513
Payables for supply for non-current assets	389	139
Total	7,016	5,472

Payables to suppliers are as follows:

	<i>31.12.2020</i> <i>BGN '000</i>	<i>31.12.2019</i> <i>BGN '000</i>
Payables to foreign suppliers	4,241	4,002
Payables to local suppliers	2,775	1,470
Total	7,016	5,472

The payables to suppliers are regular and interest-free. The payables in BGN amount to BGN 2,379 thousand (31 December 2019: BGN 1,470 thousand), in EUR – BGN 2,433 thousand (31 December 2019: BGN 2,695 thousand), in USD – BGN 2,202 thousand (31 December 2019: BGN 1,299 thousand), in PLN – none (31 December 2019: BGN 1 thousand), and in other currency – BGN 2 thousand (31 December 2019: BGN 7 thousand).

The common credit period for which no interest is charged on trade payables, is 180 days. The Company has no past due trade payables.

The advances from clients as at 31 December are current and are for purchase of finished goods. Of them, BGN 43 thousand are denominated in BGN (31 December 2019: none), BGN 158 thousand are denominated in EUR (31 December 2019: BGN 572 thousand) and BGN 1 thousand are denominated in USD (31 December 2019: BGN 30 thousand).

The Company has placed deposits as security for payables to suppliers under commercial transactions at the amount of BGN 343 thousand (31 December 2019: BGN 249 thousand) (*Note 22, 26b and Note 35*).

37. PAYABLES TO RELATED PARTIES

The *payables to related parties* refer to:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Payables to companies related through key management personnel	1,144	1,329
Payables to companies shareholders with significant influence	89	3,138
Payables to subsidiaries	40	133
Payables to companies related through a shareholder entities with significant influence	-	2,064
Total	1,273	6,664

The *payables to related parties by type* are as follows:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Payables for supply of inventories	1,144	1,064
Supply of services	129	1,123
Dividend payables	-	3,107
Advances received	-	60
Payables for supply of non-current assets	-	299
Payables under leases	-	999
Payables for increase in capital in subsidiary	-	12
Total	1,273	6,664

The trade payables to related parties are regular and interest-free. The payables in Bulgarian Levs amount to BGN 1,233 thousand (31 December 2019: BGN 5,604 thousand), in EUR – BGN 36 thousand (31 December 2019: BGN 1,006 thousand), and in PLN – BGN 4 thousand (31 December 2019: BGN 54 thousand).

The common credit period, for which no interest is charged on trade payables to related parties, is 90 days. The Company has no overdue trade payables to related parties.

The Company has not placed deposits as security for payables to related parties under commercial transactions (31 December 2019: BGN 189 thousand) (*Note 21*).

38. TAX PAYABLES

Tax payables include:

	<i>31.12.2020</i>	<i>31.12.2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
Value Added Tax	825	579
Individual income tax	489	568
Corporate tax	406	713
Taxes on expenses	372	469
Total	2,092	2,329

The following tax audits have been carried out of the Company and of the subsidiaries merged into it:

Sopharma AD:

- under VAT Act – until 31 December 2011;
- full-scope tax audit – until 31 December 2011;
- National Social Security Institute – until 30 September 2013.

Bulgarian Rose Sevtopolis (transforming company)

- under VAT Act – until 31 December 2014;
- full-scope tax audit – until 31 December 2013;
- National Social Security Institute – until 31 December 2013.

Medica AD (transforming company)

- under VAT Act – until 31 January 2013;
- full-scope tax audit – until 31 December 2002;
- National Social Security Institute – until 31 January 2016.

Unipharm AD (transforming company)

- under VAT Act – until 31 August 2018;
- full-scope tax audit – until 31 December 2017;
- National Social Security Institute – until 31 December 2017.

Tax audit is performed within a 5-year period after the end of the year when the tax return for the respective liability has been submitted. The tax audit confirms finally the tax liability of the respective company-tax liable person except in the cases explicitly stated by law.

39. PAYABLES TO PERSONNEL AND FOR SOCIAL SECURITY

Payables to personnel and for social security are as follows:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Payables to personnel, including:	6,329	5,797
<i>Tantieme</i>	3,369	3,077
<i>accruals on unused compensated leaves</i>	1,503	1,511
<i>current liabilities</i>	1,457	1,209
Payables for social security/health insurance, including:	1,178	1,469
<i>current liabilities</i>	916	1,217
<i>accruals on unused compensated leaves</i>	262	252
Total	7,507	7,266

40. OTHER CURRENT LIABILITIES

Other current liabilities are as follows:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Lease liabilities to third parties (<i>Note 33</i>)	1,901	723
Government grants (<i>Note 31</i>)	430	540
Provision for financial guarantees granted (<i>Note 2.26</i>)	427	381
Dividend payables	325	3,334
Awarded amounts under litigations	302	329
Deductions from work salaries	44	185
Liabilities under deposits received as guarantees	1	24
Refund obligations under contracts with customers (<i>Note 2.5.6</i>)	-	65
Total	3,430	5,581

The provision for financial guarantees granted, at the amount of BGN 427 thousand (31 December 2019: BGN 381 thousand), arises as a result of commitment undertaken by the Company to perform payments for a debtor which failed to make payment in accordance with a debt instrument (*Note 2.26*).

The movement in the provision for financial guarantees is as follows:

	2020 BGN '000	2019 BGN '000
Balance at 1 January	381	327
Increase in provision for financial guarantees recognised within profit or loss for the year	249	54
Decrease in provision for financial guarantees recognised within profit or loss for the year	(203)	-
Balance at 31 December	427	381

The commitments undertaken by the Company to make certain payments for a debtor that did not make payment in accordance with a debt instrument are as follows:

	2020 BGN '000	2019 BGN '000
Commitments to banks – creditors of debt instruments to related parties	426	379
Commitments to banks – creditors of debt instruments to third parties	1	2
Total	427	381

41. CONTINGENT LIABILITIES AND COMMITMENTS

Significant irrevocable agreements and commitments

The Company received government grants under Operational Programme "Development of the Competitiveness of the Bulgarian Economy" 2007 – 2013 and Operational Programme "Energy Efficiency" (Note 31 and Note 40), related to acquisition of non-current assets, buildings reconstruction and technological renovation and modernisation of tablet production facilities and implementation of innovative products in the ampoule production section and the acquisition of combined exchanger installations for ventilation and air conditioning in the production of medical products and implementation of innovative "artificial tears" eye drops (Note 15). The Company undertook a commitment that for a period of 5 years after the completion of the respective projects they shall not be subject to significant modifications affecting the essence and the terms and conditions for their execution or giving rise to unjustified benefits to the company, neither modifications resulting from a change in the nature of ownership over the assets acquired in relation to the grants. On non-compliance with these requirements, the financing shall be returned. At the date of preparation of the financial statements, all contractual requirements were being fulfilled.

Issued and granted guarantees

The Company has provided the following collateral in favour of banks under loans received by related parties:

(a) under loans of subsidiaries:

- Mortgages of real estate with a carrying amount of BGN 9,578 thousand as at 31 December 2020 (31 December 2019: BGN 9,795 thousand) (Note 15);
- Special pledges on:
 - machinery and equipment with a carrying amount of BGN 22,283 thousand as at 31 December 2020 (31 December 2019: BGN 9,100 thousand) (Note 15);
 - inventories with a carrying amount of BGN 17,000 thousand as at 31 December 2020 (31 December 2019: BGN 17,000 thousand) (Note 23);
 - trade receivables with a carrying amount of BGN 11,735 thousand as at 31 December 2020 (31 December 2019: BGN 11,735 thousand) (Note 25);

(b) under loans of associates:

- Mortgages of real estate with a carrying amount of BGN 14,910 thousand as at 31 December 2020 (31 December 2019: none) (Note 15).

The Company is a co-debtor and guarantor of loans received, bank guarantees issued and leases of the following companies:

Company	Maturity period	Currency	Contracted amount		Amount guaranteed as at
			Original currency	BGN'000	31.12.2020 BGN'000
Sopharma Trading AD	2021-2025	EUR	68,728	134,420	109,596
Sopharma Trading AD	2021-2024	BGN	50,625	50,625	42,471
Doverie Obedinen Holding AD	2027	BGN	30,000	30,000	30,000
Sopharma Trading doo, Belgrade	2023	EUR	8,000	15,647	14,062
Doverie Obedinen Holding AD	2021	EUR	5,000	9,779	9,779
Sopharma Trading Pharmaceuticals doo and Sopharma Trading doo	2026	EUR	5,210	10,190	8,885
PAT Vitamini and Sopharma	2022	EUR	7,000	13,691	5,350
Biopharm Engineering AD	2023-2028	BGN	7,750	7,750	3,574
Momina Krepost AD	2021-2026	BGN	5,000	5,000	3,722
Doverie Capital AD	2021	EUR	3,000	5,867	2,151
Energoinvestment AD	2021	BGN	2,000	2,000	798
Veta Pharma AD	2021	BGN	1,000	1,000	734
Pharmaplant AD	2023	EUR	235	460	163
Mineralcommerce AD	2021	BGN	451	451	42
Total					231,327

42. FINANCIAL RISK MANAGEMENT

In the ordinary course of business, the Company can be exposed to a variety of financial risks the most important of which are market risk (including currency risk, risk of a change in the fair value and price risk), credit risk, liquidity risk and risk of interest-bearing cash flows. The general risk management is focused on the difficulty to forecast the financial markets and to achieve minimizing the potential negative effects that might affect the financial results and position of the Company.

The financial risks are currently identified, measured and monitored through various control mechanisms in order to establish adequate prices for the Company's finished goods and services and the borrowed thereby capital, as well as to assess adequately the market circumstance of its investments and the forms for maintenance of free liquid funds through preventing undue risk concentrations.

Risk management is currently performed by Company's management following the policy adopted by the Board of Directors. The latter has approved the basic principles of general financial risk management, on the basis of which specific procedures have been established for management of the different types of specific risk such as currency, price, interest, credit and liquidity risk and the risk in using non-derivative instruments.

The structure of financial assets and liabilities is as follows:

<i>Financial assets</i>	31.12.2020	31.12.2019
	BGN '000	BGN '000
Financial assets at fair value through other comprehensive income, incl.:	11,607	9,621
<i>Equity investments</i>	<i>11,607</i>	<i>9,621</i>
Financial assets at amortised cost, incl.:	210,604	234,941
<i>Receivables and loans granted</i>	<i>206,828</i>	<i>230,982</i>
Long-term receivables from related parties	59,725	91,794
Other long-term receivables	11,105	9,897
Receivables from related parties	113,901	97,014
Trade receivables	17,843	26,114
Loans to third parties	3,903	6,044
Other current receivables	351	119
<i>Cash and cash equivalents</i>	<i>3,776</i>	<i>3,959</i>
Total financial assets	222,211	244,562

<i>Financial liabilities</i>	31.12.2020	31.12.2019
	BGN '000	BGN '000
Financial liabilities at amortised cost, incl.:		
<i>Long-term and short-term bank loans</i>	75,754	109,938
<i>Lease liabilities to related parties</i>	-	2,609
<i>Lease liabilities to third parties</i>	3,434	1,677
<i>Other loans and liabilities, incl.</i>	<u>8,917</u>	<u>14,764</u>
Trade payables	7,016	5,472
Payables to related parties	1,273	5,605
Other current payables	<u>628</u>	<u>3,687</u>
Total financial liabilities	<u>88,105</u>	<u>128,988</u>

At 31 December 2020, recognised liabilities under financial guarantees amount at BGN 427 thousand (31 December 2019: BGN 381 thousand) (Note 40).

The impairment losses, net of reversed, related to financial assets and financial guarantees recognised in the statement of comprehensive income are as follows:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Receivables from clients	873	(214)
Loans granted at amortised cost	3,551	526
Dividend receivables	1,293	-
Financial guarantees granted	46	54
Cash at amortised cost	<u>(12)</u>	<u>-</u>
Total	<u>5,751</u>	<u>366</u>

Credit risk

Credit risk is the risk that any of the Company's clients will fail to discharge in full and within the normally envisaged terms the amounts due.

The Company's credit risk arises both from its operating activities, through its trade receivables, and from its financing activities, including granting loans to related and third parties, commitments undertaken under loans and guarantees, and bank deposits. The Company has developed policies, procedures and rules for credit risk control and monitoring.

Trade receivables

In its commercial practice, the Company has applied different distribution schemes until arriving at the current effective approach that takes into consideration the market operational condition, the various payment methods, and the inclusion of sales rebates. The Company works with counterparts with whom it has a history on its main markets, and partners with over 70 Bulgarian and foreign licensed distributors of medicinal products.

Work with the NHSSO and with distributors working with state hospitals also require the adoption of a deferred payment policy. In this sense, even though credit risk concentration exists, this risk is controlled by means of selection, ongoing monitoring of the liquidity and financial stability of sales partners, as well as direct communication therewith and seeking quick measures upon indications for problems.

The Company's credit policy envisages assessing each new customer's creditworthiness before proposing standard delivery and payment conditions.

Expected credit losses are calculated at the date of each reporting period.

The Company uses provisioning matrixes to calculate expected credit losses from trade receivables and contract assets. The latter are grouped into groups (portfolios) from various client segments sharing similar characteristics, incl. for credit risk.

The percentages applied in the provisioning matrix are based on days past due for each portfolio. Each matrix percentage is initially determined based on historical data observed by the Company for a period of three years. The method is based on analysis of the history and assessing behaviour for each invoice within a group issued over at least the last three years, including pays past due, going period by period among the different past due ranges, payments and outstanding receivables, etc. Based on that, the loss percentage is determined as bad debt for the given group of factors versus past due invoices by days. The Company does not have a practice to request collateral of trade receivables, and does not insure them.

Second, the Company makes the impairment provisioning matrixes for each portfolio precise by adjusting certain percentages based on historical data for the behaviour of payments under the invoices issued and historical losses from bad debt, by including scenarios and forecast information about certain macro factors. Historical percentages are adjusted to reflect the effect of the future behaviour of macroeconomic factors for which a statistical dependence has been identified and which are considered to impact the customers' ability to service and settle their payables.

In view of the short-term horizon of receivables and the forecasts of international institutions (EC, IMF, World Bank) for the next 2021 for the development of the Bulgarian and global economy, the management's analysis of scenarios shows that the impact of changes in the macroeconomic environment on the provisioning matrix are insignificant in their amount as at 31 December 2020.

Court and awarded receivables

Upon determining the collectability of court and awarded receivables, the management analyses on an individual basis the overall exposure from each counterpart (counterpart type) in order to determine the actual likelihood of their collection. Upon establishing it is highly unlikely to collect a given receivable (group of receivables), it is assessed what portion thereof is secured (pledge, mortgage, guarantors, bank security) to thus guarantee collectability (through potential future realisation of the collateral or payment by the guarantor).

The receivables or portion thereof for which the management determines are highly unlikely to be collected, are 100% impaired.

Loans and financial guarantees granted

The assessment of each credit exposure for the management's purposes is a process that requires the use of models to reflect impact on exposure by changes in market conditions and the debtor's operation, estimated cash flows and time left to maturity. The assessment of the credit risk of loans granted leads to further judgement on the possibility of default, on the loss coefficients related to this judgement and to correlation between counterparts. The Company measures credit risk by using probability of default (PD), exposure at default (EAD) and loss given default (LGD).

To determine the credit risk of loans and financial guarantees granted, and of certain individual trade receivables, the Company's management has developed a methodology that includes two main components: determining the debtor's credit rating, and statistical models for calculating marginal PR by year for each rating. With respect to the rating, it uses internal credit ratings of its counterparts based on the global methodologies of world's leading rating agencies. The rating reflects financial indebtedness, liquidity, profitability ratios, etc. quantitative (for instance, sales volumes) and qualitative (for instance, financial policy, diversifications, etc.) criteria depending on the respective methodology and industry.

By means of statistical models based on historical global data about probability of default (PD) and transitions between different ratings, as well as forecasts for key macroeconomic indicators (GDP growth, inflation, etc.), the necessary marginal PD are determined by year for each rating.

Based on the specific rating established and the analysis of the debtor's characteristics and the loan/guarantee, incl. changes which have occurred therein compared to the prior period, the instrument's stage is determined (Stage 1, Stage 2, and Stage 3). The Company considers that a certain financial instrument has undergone a significant increase in credit risk when one or more of the following quantitative or qualitative criteria are met:

Quantitative criteria:

- An increase in the probability of default (PD) for the financial instrument's lifetime at the reporting date versus the possibility of default for the instrument's lifetime at the date on which the asset was initially recognised
- Payment is past due for over 30 days, but less than 90 days, past due
- An actual or expected significant adverse change in the debtor's operating result, above the permissible change range, measured based on the debtor's main financial and operating indicators
- A significant change in the value of the collateral, which is expected to increase the loss and risk of default.

Qualitative criteria:

- Significant adverse changes in the business, financial and/or economic conditions of the debtor;
- Actual or expected adverse changes in the debtor's operating results;
- A significant change in the collateral quality, which is expected to increase the risk of default;
- Early signs of cash flow/liquidity issues, such as delays in servicing trade creditors/bank loans.

The criteria used to identify a substantial increase in credit risk are monitored, and their viability is reviewed on a periodic basis by the Company's Finance Director.

The Company designates a financial instrument as *non*-performing and the credit loss as incurred, when it meets one or more of the following criteria:

Quantitative criteria

- The debtor's contract payments are over 90 days past due
- Significant adverse changes have occurred or are expected in the debtor's business, financial conditions and economic environment, manifest in a serious decrease in the debtor's main financial and operational indicators;
- The debtor states a number of losses and negative net assets;
- Significant adverse changes have occurred or are expected in value of the loan's key collateral, incl. loss of collateral.

Qualitative criteria

The debtor is unable to pay due to significant financial difficulties. This includes cases when:

- The debtor is in default of the financial contract, for instance with respect to interest payments, collaterals and/or another significant contract, including for financing;
- Adverse changes in the debtor's business, market, environment, and regulations;
- Concessions and reliefs have been made in relation to the debtor's financial difficulties;
- There is probability that the debtor declares insolvency.

The default definition is subsequently applied to modelling the probability of default (PD), the exposure at default (EAD), and the loss given default (LGD) determined through calculation of the Company's expected credit losses.

Expected credit losses have been determined by discounting the product of: the probability of default (PD), exposure at default (EAD), and the loss given default (LGD), determined as follows:

- PD is the probability of the debtor not meeting their financial obligations, either over the next 12 months, or over the financial asset's lifetime (lifetime PD) determined based on public PD data from generally accepted sources and statistical models of the impact of forecast macroeconomic factors. Moreover, the Company's management has conducted historical analysis and has identified the main economic variables impacting credit risk and expected credit losses per loan (portfolio) type.
- EAD is the amount payable to the Company by the debtor at default, over the next 12 months or over the remaining period of the loan, determined in accordance with the specific instrument's characteristics (amount due, repayment plans, interest, term, etc.).
- LGD is the Company's expectation for the amount of loss from a non-performing exposure. LGD varies depending on the type of counterpart, the type and superiority of the claim and the presence of collateral or other credit support. LGD is measured as a loss percentage for an open exposure at default.
- The discount rate used to calculate expected credit losses (ECL) is the instrument's initial effective interest or in the case of financial guarantees and other instruments without an applicable interest rate – the risk-free rate for the respective period, currency, etc.

The Company applies a number of policies and practices to lower the credit risk from loans granted. Most frequently, it accepts collateral. The Company assigns valuation to external experts – independent valuers, of the collateral received, as part of the process of granting loans. This valuation is reviewed on a periodic basis, but at least once per year.

The table below presents the quality of the Company's financial assets, contract assets and financial guarantee contracts, as well as the maximum exposure to credit risk according to the credit rating adopted as at 31 December 2020:

<i>Financial assets</i>	<i>Notes</i>	<i>Internal credit risk categorisation</i>	<i>Expected credit losses (IFRS 9)</i>	<i>Gross carrying amount</i>	<i>Impairment loss (allowance)</i>	<i>Carrying amount at 31 December 2020</i>
				<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Trade receivables from related parties	24	N/A	<i>For a 12-month period</i>	102,760	(2,634)	100,126
Long-term loans granted to related parties	21	Regular Stage 1	<i>Lifetime (credit-impaired)</i>	59,843	(118)	59,725
Trade receivables from third parties	22,25	N/A	<i>For a 12-month period</i>	23,329	(1,989)	21,340
Short-term loans granted to related parties	24	Renegotiated Stage 2	<i>Lifetime (credit-impaired)</i>	13,176	(35)	13,141
Long-term loans granted to third parties	22	Renegotiated Stage 2	<i>Lifetime (credit-impaired)</i>	7,620	(12)	7,608
Short-term loans granted to third parties	26 (a)	Regular Stage 1	<i>Lifetime (credit-impaired)</i>	3,158	-	3,158
Short-term loans granted to third parties	26 (a)	Renegotiated Stage 2	<i>Lifetime (credit-impaired)</i>	642	-	642
Receivables under issued and granted guarantees	24	N/A	<i>For a 12-month period</i>	368	-	368
Short-term loans granted to related parties	24	Regular Stage 1	<i>Lifetime (credit-impaired)</i>	266	-	266
Short-term loans granted to third parties	26 (a)	Underperforming Stage 3	<i>Lifetime (credit-impaired)</i>	103	-	103
Short-term loans granted to related parties	24	Underperforming Stage 3	<i>Lifetime (credit-impaired)</i>	5,672	(5,672)	-
Dividend receivables from related parties	24	N/A	<i>For a 12-month period</i>	1,293	(1,293)	-
Total:				218,230	(11,753)	206,477

The table below presents the quality of the Company's financial assets, contract assets and financial guarantee contracts, as well as the maximum exposure to credit risk according to the credit rating adopted as at 31 December 2019:

Financial assets	<i>Note</i>	<i>Internal credit risk categorisation</i>	<i>Expected credit losses (IFRS 9)</i>	<i>Gross carrying amount at 31 December 2019</i> <i>BGN '000</i>	<i>Impairment loss (allowance) at 31 December 2019</i> <i>BGN '000</i>	<i>Carrying amount</i> <i>BGN '000</i>
Long-term loans to related parties	21	Regular Stage 1	<i>Lifetime (credit-impaired)</i>	82,109	(110)	81,999
Short-term loans to related parties	24	Renegotiated Stage 2	<i>Lifetime (credit-impaired)</i>	14,198	(14)	14,184
Long-term loans to related parties	21	Renegotiated Stage 2	<i>Lifetime (credit-impaired)</i>	9,614	(8)	9,606
Long-term loans to third parties	22	Renegotiated Stage 2	<i>Lifetime (credit-impaired)</i>	6,431	(148)	6,283
Short-term loans to related parties	24	Underperforming Stage 3	<i>Lifetime (credit-impaired)</i>	5,440	(1,997)	3,443
Short-term loans to third parties	26 (a)	Regular Stage 1	<i>Lifetime (credit-impaired)</i>	4,554	(5)	4,549
Short-term loans to third parties	26 (a)	Renegotiated Stage 2	<i>Lifetime (credit-impaired)</i>	1,388	(3)	1,385
Short-term loans to third parties	26 (a)	Underperforming Stage 3	<i>Lifetime (credit-impaired)</i>	110	-	110
Long-term loans to third parties	22	Regular Stage 1	<i>Lifetime (credit-impaired)</i>	16	(1)	15
Trade receivables from related parties	21,24	N/A	<i>For a 12-month period</i>	80,397	(2,114)	78,283
Trade receivables from third parties	22,25	N/A	<i>For a 12-month period</i>	31,477	(1,764)	29,713
Total:				235,734	(6,164)	229,570

The table below presents the quality of the Company's financial assets, contract assets and financial guarantee contracts, as well as the maximum exposure to credit risk according to the credit rating adopted as at 31 December 2020:

<i>Category</i>	<i>Internal credit risk categorisation</i>	<i>Expected credit losses (IFRS 9)</i>	<i>Gross carrying amount</i> <i>BGN '000</i>	<i>Impairment loss (allowance) at 31 December 2020</i> <i>BGN '000</i>
Regular trade receivables (Stage 1)	<i>N/A</i>	3.67%	126,089	(4,623)
Regular loans (Stage 1)	B3	0.20%	58,704	(118)
Renegotiated loans (Stage 2)	B3	0.23%	15,383	(36)
Underperforming loans (Stage 3)	Caa1	98.22%	5,775	(5,672)
Renegotiated loans (Stage 2)	B2	0.20%	5,366	(11)
Regular loans (Stage 1)	B2	0.00%	3,158	-
Regular loans (Stage 1)	Ba2	0.00%	1,405	-
Renegotiated loans (Stage 2)	Ba2	0.00%	443	-
Receivables under issued and granted guarantees	<i>N/A</i>	0.00%	368	-
Renegotiated loans (Stage 2)	Ba3	0.00%	246	-
Uncollectable dividend receivables	<i>N/A</i>	100.00%	1,293	(1,293)
Uncollectable trade receivables (court and awarded receivables)	<i>N/A</i>	100.00%	20	(20)
Total:			218,250	(11,773)

The table below provides information about the Company's exposure to credit risk and the impairment of credit losses for loans granted and trade receivables as at 31 December 2019:

<i>Category</i>	<i>Correlation to an external credit rating</i>	<i>Average percentage of expected impairment loss</i>	<i>Gross carrying amount at 31 December 2019</i> <i>BGN '000</i>	<i>Impairment loss (allowance) at 31 December 2019</i> <i>BGN '000</i>
Performing trade receivables (Stage 1)	<i>N/A</i>	3.47%	111,875	(3,878)
Performing loans (Stage 1)	B3	0.14%	82,125	(111)
Renegotiated loans (Stage 2)	B2	0.12%	15,122	(18)
Renegotiated loans (Stage 2)	B3	0.71%	13,246	(154)
Under-performing loans (Stage 3)	B1	36.71%	5,440	(1,997)
Performing loans (Stage 1)	B2	0.11%	4,554	(5)
Renegotiated loans (Stage 2)	Ba2	0.04%	2,717	(1)
Renegotiated loans (Stage 2)	Ba2	0.00%	496	-
Under-performing loans (Stage 3)	Caa1	0.00%	110	-
Renegotiated loans (Stage 2)	Ba3	0.00%	49	-
Non-performing trade receivables (court and awarded receivables)	<i>N/A</i>	100.00%	5	(5)
			235,739	(6,169)

The Company has concentration of receivables from related parties (trade receivables and loans), as follows:

	31.12.2020	31.12.2019
	BGN '000	BGN '000
Client 1	42%	35%
Client 2	38%	52%
Client 3	-	3%

The Company monitors concentration of receivables from related parties on a current basis by applying credit limits and additional collaterals in the form of pledge on securities and other assets and applying promissory notes.

The Company has concentration of trade receivables from a client who is not a related party, amounting to 66.59% of all trade receivables (31 December 2019: 84.42%) (*Note 25*).

Cash

The Company's cash and payment operations are concentrated in different first-class banks. To calculate expected credit losses for cash and cash equivalents, it applies a model based on the bank's public ratings as determined by internationally recognised rating firms like Moody's, Fitch, S&P, BCRA and Bloomberg and the reference public data about PD referring to the rating of the respective bank. The management monitors changes in a bank's rating on an ongoing basis in order to assess the presence of increased credit risk, ensure the current management of incoming and outgoing cash flows and the allocation of cash in the bank accounts and banks.

Foreign currency risk

The Company performs its activities with an active exchange with foreign suppliers and clients. Therefore, it is exposed to currency risk mainly in respect of USD. The Company supplies part of its basic raw and other materials in USD. The currency risk is related with the adverse floating of the exchange rate of USD against BGN in future business transactions as to the recognised assets and liabilities denominated in foreign currency and as to the net investments in foreign companies.

The remaining part of Company's operations is usually denominated in BGN and/or EUR. The Company sells a significant part of its finished goods in Euro and thus eliminates the currency risk. The accounts and balances with the subsidiaries in Ukraine are also denominated in Euro. Nevertheless, in relation with the instability in the country and the devaluation of the Ukrainian Hryvnia, for the purpose of mitigating the currency risk the Company, through its subsidiaries, exercises currency policy that includes the immediate translation in EUR of proceeds in a local currency as well as using higher trade margins to compensate eventual future devaluation of the Hryvnia.

To control foreign currency risk, the Company has introduced a system for planning import supplies, sales in foreign currency as well as procedures for daily monitoring of US dollar exchange rate movements and control on pending payments.

The assets and liabilities denominated in BGN and foreign currency are presented as follows:

<i>31 December 2020</i>	in USD	in EUR	in BGN	in other currency	Total
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Equity investments	23	1,533	10,051	-	11,607
Receivables and loans granted	5,092	52,313	149,420	3	206,828
Cash and cash equivalents	281	1,542	1,925	28	3,776
Total financial assets	5,396	55,388	161,396	31	222,211
Long-term and short-term bank loans	-	13,735	61,989	30	75,754
Lease liabilities to third parties	152	3,107	107	68	3,434
Other loans and payables	2,486	2,469	3,956	6	8,917
Total financial liabilities	2,638	19,311	66,052	104	88,105
<i>31 December 2019</i>	in USD	in EUR	in BGN	in other currency	Total
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Equity investments	44	1,587	7,990	-	9,621
Receivables and loans granted	5,568	54,484	170,929	1	230,982
Cash and cash equivalents	784	617	2,532	26	3,959
Total financial assets	6,396	56,688	181,451	27	244,562
Long-term and short-term bank loans	-	34,483	75,422	33	109,938
Lease liabilities to related parties	-	2,609	-	-	2,609
Lease liabilities to third parties	107	1,343	166	61	1,677
Other loans and payables	1,609	2,725	10,368	62	14,764
Total financial liabilities	1,716	41,160	85,956	156	128,988

Foreign currency sensitivity analysis

The effect of Company's sensitivity to 10% increase/decrease in current exchange rates of BGN to USD and to other currency exposures, based on the structure of foreign currency assets and liabilities at 31 December and on the assumption that the influence of all other variables is ignored, is presented below. The final effect has been measured and presented as impact on the post-tax financial result and on the equity.

		USD	
		31.12.2020	31.12.2019
		BGN '000	BGN '000
Financial result	+	248	421
Accumulated profits	+	248	421
Financial result	-	(248)	(421)
Accumulated profits	-	(248)	(421)

In case of 10% increase in the exchange rate of USD to BGN, the final effect on post-tax profit of the Company for 2020 would be an increase by BGN 248 thousand (0.87%) (2019: increase at the amount of BGN 421 thousand) (1.04%). The same effect in terms of value would be seen on equity – 'retained earnings' component.

On 10% decrease in the exchange rate of USD to BGN, the ultimate impact on the (post-tax) profit of the Company would be equal and reciprocal of the stated above.

The impact of the remaining currencies (other than USD) on 10 % increase in their exchange rates to BGN on Company's (post-tax) profit is insignificant. The ultimate effect thereon for 2020 is a decrease by BGN 31 thousand (-0,11%) (2019: a decrease by BGN 52 thousand (-0,13%). The effect on equity is of the same amount and in a direction of increase / decrease and reflects in the component 'retained earnings'.

The management is of the opinion that the presented above currency sensitivity analysis, based on the balance sheet structure of foreign currency denominated assets and liabilities, is representative for the currency sensitivity of the Company for the year.

Price risk

On the one hand, the Company is exposed to price risk due to two main factors:

- (a) contingent increase of supplier prices of raw and starting materials, since more than 80% of the raw and starting materials are imported and they represent 50% on the average of all production costs; and
- (b) growing competition on the Bulgarian pharmaceutical market is also reflected in drug prices.

For the purpose of mitigating this influence, the Company applies a strategy aimed at optimization of production costs, validation of alternative suppliers that offer beneficial commercial conditions, expanding product range by means of new generic products development and last but not least, adoption of a flexible marketing and price policy. Price policy is a function of three main factors – structure of expenses, prices of competitors and purchasing capacity of customers.

On the other hand, the Company is exposed to a price risk related to the held thereby shares, classified as other long-term equity investments. For this purpose, the management monitors and analyses all changes in security markets and also uses consulting services of one of the most authoritative in the country investments intermediaries. At this stage, because of the economic and financial crisis, the management has taken a decision for a significant reduction in its operations on stock markets, retaining of the purchased shares for longer periods with current monitoring of the reported by the respective issuer financial and business indicators.

Liquidity risk

Liquidity risk is the adverse situation when the Company encounters difficulty in meeting unconditionally all of its obligations within their maturity.

The Company generates and maintains a sufficient volume of liquid funds. An internal source of liquid funds for the Company is its main economic activity generating sufficient operational flows. Banks and other permanent counterparts represent external sources of funding. To isolate any possible liquidity risk, the Company implements a system of alternative mechanisms of acts and prognoses, the final aim being to

maintain good liquidity and, respectively, ability to finance its economic activities. This is complemented by the monitoring of due dates and maturity of assets and liabilities as well as control of cash outflows.

Maturity analysis

The table below presents the financial non-derivative liabilities of the Company, grouped by remaining term to maturity, determined against the contractual maturity at the reporting date. The table is prepared on the basis of undiscounted cash flows and the earliest date on which a payable becomes due for payment. The amounts include principal and interest.

<i>31 December 2020</i>	up to 1 month	1 to 3 months	3 to 6 months	6 to 12 months	1 to 2 years	2 to 5 years	Total
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Long-term and short-term bank loans	18,349	1,340	15,252	41,334	12	5	76,292
Lease liabilities to third parties	171	387	469	938	1,266	351	3,582
Other loans and payables	4,850	3,391	15	661	-	-	8,917
Total liabilities	23,370	5,118	15,736	42,933	1,278	356	88,791
<i>31 December 2019</i>	up to 1 month	1 to 3 months	3 to 6 months	6 to 12 months	1 to 2 years	2 to 5 years	Total
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Long-term and short-term bank loans	783	44,746	32,614	30,154	2,418	2	110,717
Lease liabilities to related parties	86	172	257	515	1,030	605	2,665
Lease liabilities to third parties	66	125	188	382	617	356	1,734
Other loans and payables	3,911	10,458	12	383	-	-	14,764
Total liabilities	4,846	55,501	33,071	31,434	4,065	963	129,880

Risk of interest-bearing cash flows

Interest-bearing assets are presented in the structure of Company's assets by cash, bank deposits and loans granted, which are with fixed interest rate. Company's borrowings in the form of long-term and short-term loans are usually with a floating interest rate. Operating lease liabilities have both variable and fixed interest rates. This circumstance makes the cash flows of the Company partially dependent on interest risk. This risk is covered in two ways:

- (a) optimisation of the sources of credit resources for achieving relatively lower price of attracted funds; and
- (b) combined structure of interest rates on loans comprising two components – a permanent one and a variable one, the correlation between them, as well as their absolute value, can be achieved and maintained in a proportion favourable for the Company. The fixed component has a relatively low absolute value and sufficiently high relative share in the total interest rate. This circumstance eliminates the probability of a

significant change in interest rate levels in case of variable component updating. Thus the probability for an unfavourable change of cash flows is reduced to a minimum.

The Company's management currently monitors and analyses its exposure to changes in interest rates. Simulations are carried out for various scenarios of refinancing, renewal of existing positions, and alternative financing. The impact of a defined interest rate shift, expressed in points or percentage, on the financial result and equity is calculated based on these scenarios. For each simulation, the same assumption for interest rate shift is used for all major currencies. The calculations are made for major interest-bearing positions.

<i>31 December 2020</i>	interest-free	with floating interest %	with fixed interest %	Total
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Equity investments	11,607	-	-	11,607
Receivables and loans granted	123,601	-	83,227	206,828
Cash and cash equivalents	108	3,668	-	3,776
Total financial assets	135,316	3,668	83,227	222,211
Long-term and short-term loans	-	75,724	30	75,754
Lease liabilities to third parties	-	120	3,314	3,434
Other loans and liabilities	8,917	-	-	8,917
Total financial liabilities	8,917	75,844	3,344	88,105
<i>31 December 2019</i>	interest-free	with floating interest %	with fixed interest %	Total
	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>	<i>BGN '000</i>
Equity investments	9,621	-	-	9,621
Receivables and loans granted	109,838	-	121,144	230,982
Cash and cash equivalents	63	3,896	-	3,959
Total financial assets	119,522	3,896	121,144	244,562
Long-term and short-term loans	-	109,905	33	109,938
Lease liabilities to related parties	-	-	2,609	2,609
Lease liabilities to third parties	-	65	1,612	1,677
Other loans and liabilities	14,764	-	-	14,764
Total financial liabilities	14,764	109,970	4,254	128,988

The table below demonstrates the Company's sensitivity to possible changes in interest rates by 0.50 points based on the structure of assets and liabilities as at 31 December and with the assumption that the influence of all other variables is ignored. The effect is measured and presented as impact on the financial result after taxes and on equity.

<i>2020</i>	<i>Increase/ decrease in interest rate</i>	<i>Impact on post-tax financial result profit/(loss)</i>	<i>Impact on equity increase/(decrease)</i>
EUR	Increase	(76)	(76)
BGN	Increase	(280)	(280)
USD	Increase	(1)	(1)
EUR	Decrease	76	76
BGN	Decrease	280	280
USD	Increase	1	1
<i>2019</i>	<i>Increase/ decrease in interest rate</i>	<i>Impact on post-tax financial result profit/(loss)</i>	<i>Impact on equity increase/(decrease)</i>
EUR	Increase	(173)	(173)
BGN	Increase	(348)	(348)
EUR	Decrease	173	173
BGN	Decrease	348	348

Capital risk management

The capital management objectives of the Company are to build and maintain capabilities to continue its operation as a going concern and to provide return on the investments of shareholders and economic benefits to other stakeholders and participants in its business as well as to maintain an optimal capital structure to reduce the cost of capital.

The Company currently monitors capital availability and structure on the basis of the gearing ratio. This ratio is calculated as net debt divided by the total amount of employed capital. Net debt is calculated as the difference between total borrowings, as presented in the statement of financial position, and cash and cash equivalents. Total employed capital is calculated as the sum of equity and net debt.

In 2020, the strategy of the Company management was to maintain the ratio about 10%-15% (2019: 15% – 20%).

The table below shows the gearing ratios based on capital structure:

	<i>2020</i> <i>BGN '000</i>	<i>2019</i> <i>BGN '000</i>
Total borrowings, including:	79,188	114,224
<i>bank loans</i>	<i>75,754</i>	<i>109,938</i>
<i>lease liabilities</i>	<i>3,434</i>	<i>4,286</i>
Less: Cash and cash equivalents	(3,776)	(3,959)
Net debt	75,412	110,265
Total equity	536,988	522,644
Total capital	612,400	632,909
Gearing ratio	0.12	0.17

The cash and liabilities shown in the table are disclosed in *Notes 27, 29, 32, 33, 35, 37 and 40*.

Fair value measurement

The fair value concept presumes realisation of financial assets through a sale based on the position, assumptions and judgments of independent market participants in a principal or most advantageous market for a particular asset or liability. The Company acknowledges as a principal market for its financial assets and liabilities the financial market in Bulgaria – the Bulgarian Stock Exchange, the large commercial banks – dealers, and for some specific instruments – direct transactions between the parties. However, in most cases especially in regard of trade receivables and payables as well as loans and deposits, the Company expects to realise these financial assets also through their total refund or respectively, settlement over time. Therefore, they are presented at amortised cost.

In addition, a large part of the financial assets and liabilities are either short-term in their nature (trade receivables and payables, short-term loans) or are presented in the statement of financial position at market value determined by applying a particular valuation method (investments in securities, loans with floating interest rate) and therefore, their fair value is almost equal to their carrying amount. Therefore, they are presented at acquisition cost (cost). With regard to loans, extended with fixed interest rate, the method used for setting this rate uses as a starting point for the calculations the current observations of the Company with regard to the market interest levels.

As far as the Bulgarian market of various financial instruments is still not sufficiently active – with stability, satisfactory volumes and liquidity for purchases and sales of certain financial assets and liabilities – there are no sufficient and reliable market price quotations for them, and for this reason, the Company uses other alternative valuation methods and techniques.

Company's management is of the opinion that the estimates of the financial assets and liabilities presented in the statement of financial position are as reliable, adequate and trustworthy as possible for financial reporting purposes under the existing circumstances.

43. SEGMENT REPORTING

Company's segment reporting is organised on the basis of the production of main groups of finished goods:

- Tablet dosage forms
- Ampoule dosage forms
- Medical products
- Other dosage forms
- Other revenue

Medical products include: plasters, sanitary and hygienic products, dressings, and medical cosmetics.

The other dosage forms include: lyophilic products, ointments, syrups, drops, suppositories, inhalers, haemodialysis concentrates, sachets and substances.

Other revenue includes revenue from assets leased and revenue from agricultural production.

Segment revenue, expenses and results include:

	<i>Tablet dosage forms</i>		<i>Ampoule dosage forms</i>		<i>Other forms</i>		<i>Medical products</i>		<i>Other revenue</i>		<i>Total</i>	
	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Segment revenue	142,086	159,485	23,666	28,670	27,689	29,317	11,105	11,442	2,191	1,777	206,737	230,691
Segment cost	(67,838)	(75,661)	(15,890)	(18,189)	(19,283)	(21,171)	(7,889)	(7,783)	(735)	(31)	(111,635)	(122,835)
Segment result	74,248	83,824	7,776	10,481	8,406	8,146	3,216	3,659	1,456	1,746	95,102	107,856
Non-allocated operating income											4,188	4,134
Non-allocated operating expenses											(66,467)	(65,952)
Profit from operations											32,823	46,038
Impairment of non-current assets outside the scope of IFRS 9											(7,373)	(15,135)
Finance income/(costs), net											6,315	14,355
Profit before income tax											31,765	45,258
Income tax expense											(3,101)	(4,876)
Net profit for the year											28,664	40,382

SOPHARMA AD
NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

Segment assets include:

	<i>Tablet dosage forms</i>		<i>Ampoule dosage forms</i>		<i>Other dosage forms</i>		<i>Medical products</i>		<i>Other revenue</i>		<i>Total</i>	
	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Property, plant and equipment	74,466	74,934	19,070	20,671	20,100	20,805	2,829	3,079	-	-	116,465	119,489
Investment property	-	-	-	-	-	-	-	-	44,759	39,329	44,759	39,329
Inventories	35,244	34,262	14,798	13,493	12,689	8,295	3,500	3,513	-	88	66,231	59,651
Segment assets	109,710	109,196	33,868	34,164	32,789	29,100	6,329	6,592	44,759	39,417	227,455	218,469
Non-allocated assets											422,883	460,296
Total assets											650,338	678,765

Segment liabilities include:

	<i>Tablet dosage forms</i>		<i>Ampoule dosage forms</i>		<i>Other dosage forms</i>		<i>Medical products</i>		<i>Other revenue</i>		<i>Total</i>	
	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Government grants	2,780	3,088	1,900	2,100	85	108	92	102	-	-	4,857	5,398
Payables to personnel	401	336	182	161	341	306	47	52	-	-	971	855
Social security payables	168	223	100	126	178	213	27	38	-	-	473	600
Segment liabilities	3,349	3,647	2,182	2,387	604	627	166	192	-	-	6,301	6,853
Non-allocated liabilities											107,049	149,268
Total liabilities											113,350	156,121

The capital expenditures, depreciation/amortisation and non-monetary expenses other than depreciation/amortisation by business segment include:

	<i>Tablet dosage forms</i>		<i>Ampoule dosage forms</i>		<i>Other dosage forms</i>		<i>Medical products</i>		<i>Other revenue</i>		<i>Total</i>	
	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>	<i>2020</i>	<i>2019</i>
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Capital expenditures	3,748	2,510	439	161	1,710	1,628	-	-	5,522	1,962	11,419	6,261
Depreciation and amortisation	5,813	5,803	2,149	2,189	1,767	1,846	287	290	109	13	10,125	10,141
Non-monetary expenses, other than depreciation and amortisation	1,879	1,044	425	362	426	258	83	268	92	99	2,905	2,031

44. RELATED PARTY TRANSACTIONS

The companies related to Sopharma AD and the type of their relationship are as follows:

<i>Related parties</i>	<i>Relation type</i>	<i>Relation period</i>
Donev Investments Holding AD	Shareholder with significant influence	2019 and 2020
Telecomplex Invest AD	Shareholder with significant influence	2019 and 2020
Sopharma Trading AD	Subsidiary company	2019 and 2020
Pharmalogistica AD	Subsidiary company	2019 and 2020
Sopharma Poland OOD – in liquidation	Subsidiary company	2019 and 2020
Electroncommerce EOOD	Subsidiary company	2019 and 2020
Biopharm Engineering AD	Subsidiary company	2019 and 2020
Vitamina AD	Subsidiary company	2019 and 2020
Sopharma Buildings REIT	Subsidiary company	2019 and 2020
Momina Krepost AD	Subsidiary company	2019 and 2020
Briz SIA	Subsidiary company	2019 and 2020
Sopharma Warsaw EOOD	Subsidiary company	2019 and 2020
Sopharma Ukraine EOOD	Subsidiary company	2019 and 2020
TOO Sopharma Kazakhstan, Kazakhstan	Subsidiary company	2019 and 2020
Phyto Palauzovo AD	Subsidiary company	2019 and 2020
Veta Pharma AD	Subsidiary company	2019 and 2020
Rap Pharma International OOD	Subsidiary company	2019 and 2020
Aromania OOD	Subsidiary company	2019 and until 23 December 2020
Pharmachim EOOD	Subsidiary company	as from 14 April 2020
Sopharmacy EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 2 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 3 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 4 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 5 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 6 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 7 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 8 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 9 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 10 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 11 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 12 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 13 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 14 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 15 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 16 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 17 EOOD	Subsidiary company through Sopharma Trading AD	2019 and 2020
Sopharmacy 18 EOOD	Subsidiary company through Sopharma Trading AD	as from 28 February 2019 and 2020
Sopharma Trading Pharmaceuticals (Sopharma Trading Belgrade doo)	Subsidiary company through Sopharma Trading AD	2019 and until 3 August 2020
Sopharma Trading doo (Lekovit doo)	Subsidiary company through Sopharma Trading AD	2019 and 2020
Valentina Vassileva – Lyulin EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020

SOPHARMA AD**NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020**

Vasilka Lilovska EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Venera Mutashka EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Veselka Vassileva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Victoria Angelova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Desislava Yordanova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Dimka Vladeva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Donka Chivganova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Ekaterina Mihaylova – Shumen 1 EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Elka Neykova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Emilia Angelova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Zhuliana Kotova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Ivan Ivanov-1 EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Iliana Kalushkova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Irina Toncheva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Kapka Nikolova – Voenna Bolnica EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Kostadin Gorchev EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Krasimira Shunina EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Lora Doncheva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Lyudmila Zlatkova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Lyudmila Kovacheva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Manik Burhazyan EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Mariyka Zhaygarova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Maria Agova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Maria Gancheva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Maria Kenova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Maria Hristova – Motopista EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Mariana Markova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Mery Ivanova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Nelly Stavreva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Preslava Becheva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Rayna Madzharova – St. Georgi Sofiyski EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Rumyana Ignatova – Gancheva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Sashka Todorova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Svetlana Harizanova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Svetlana Pirpidonova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Seiba-Blagoevgrad-1 EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Silvia Veneva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Siyana Milanova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Stoyanka Radenkova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Ana Avdzhieva EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Radina Bekova EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Rumen Raynov EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Hani Modhi EOOD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
SCS Francise EAD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Sanita Franchising AD	Subsidiary company through Sopharma Trading AD	as from 1 October 2020
Brititrade COOO	Subsidiary company through Briz OOD	2019 and 2020
OOO Tabina	Subsidiary company through Briz OOD	2019 and 2020
ZAO Interpharm	Subsidiary company through Briz OOD	2019 and 2020
SOOO Brizpharm	Subsidiary company through Briz OOD	2019 and until 31 January 2020
OOO Farmacevt Plus	Subsidiary company through Briz OOD	2019 and 2020

SOPHARMA AD**NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020**

ZAO UAB TBS Pharma	Subsidiary company through Briz OOD	until 27 December 2019
B000 SpetzApharmacia	Subsidiary through Briz OOD	2019 and 2020
000 Med-dent	Subsidiary through Briz OOD	until 2 January 2019
000 Bellerophon	Joint venture through Briz OOD	until 6 March 2019
000 Bellerophon	Subsidiary company through Briz OOD	from 7 March 2019 and 2020
Alenpharm Plus ODO	Subsidiary company through Briz OOD	2019 and 2020
ODO Salyus Line	Subsidiary company through Briz OOD	2019 and 2020
ODO Medjel	Subsidiary company through Briz OOD	2019 and 2020
000 GalenaPharm	Subsidiary company through Briz OOD	2019 and 2020
000 NPFK Ariens	Subsidiary company through Briz OOD	until 19 September 2019
000 Ivem & K	Subsidiary company through Briz OOD	until 19 September 2019
Zdorovey OOO	Subsidiary company through Briz OOD	2019 and 2020
000 Farmatea	Subsidiary company through Briz OOD	until 19 September 2019
Zabotlivaya Apteka OOO	Subsidiary company through Briz OOD	until 19 September 2019
UAB Recessus	Subsidiary company through Briz OOD	From 26 September 2019 and 2020
Zdorovey Pharm OOO	Subsidiary company through Briz OOD	as from 2 March 2020
Doverie Obedinen Holding AD	Associate	2019 and 2020
Companies at DOH Group	Companies controlled by an associate	2019 and 2020
Elpharma AD – in liquidation	Company related through key management personnel	2019 and until 28 August 2020
Telecomplect AD	Company related through key management personnel	2019
Sopharma Properties REIT	Company controlled by a shareholder with significant influence	2019
Sofprint Group AD	Company controlled by a shareholder with significant influence	2019
Sofprint Group AD	Company related through key management personnel	2020
Sofconsult Group AD	Company related through key management personnel	2020
VES Electroinvest Systems EOOD	Company related through key management personnel	2019 and 2020
Eco Solar Invest OOD	Company related through key management personnel	2019 and 2020
Sirius OOD	Company related through key management personnel	2019 and 2020
Melnitsa Stefanovo EOOD	Company related through key management personnel	2019 and 2020
OKP Investments OOD	Company related through key management personnel	2019 and 2020
Alpha In EOOD	Company related through key management personnel	2019 and 2020

The sales performed by Sopharma AD to the related companies at 31 December are as follows:

<i>Sales to related parties</i>	<i>2020</i>	<i>2019</i>
	<i>BGN '000</i>	<i>BGN '000</i>
<i>Sales of finished goods to:</i>		
Subsidiaries	114,701	132,394
	114,701	132,394
<i>Sales of services to:</i>		
Subsidiaries	2,706	2,467
Companies related through key management personnel	63	8
Associates	7	8
Companies related through a shareholder with significant influence	-	59
	2,776	2,542
<i>Sales of goods and materials to:</i>		
Companies related through a key management personnel	912	-
Subsidiaries	654	645
Companies controlled by an associate	2	1
Companies related through shareholding companies with significant influence	-	826
	1,568	1,472
<i>Interest on loans granted to:</i>		
Companies controlled by an associate	2,194	2,136
Subsidiaries	554	602
Associates	75	353
Companies related through key managing personnel	-	26
	2,823	3,117
<i>Dividend income from:</i>		
Subsidiaries	9,179	10,493
Companies related through shareholding companies with significant influence	-	100
	9,179	10,593
<i>Income under issued and granted guarantees:</i>		
Subsidiaries	368	-
	368	-
<i>Sales of non-current assets to:</i>		
Companies related through key managing personnel	1	-
Companies controlled by an associate	1	10
	2	10
Total sales to related parties	131,417	150,128

The supplies performed to Sopharma AD by the related companies as at 31 December are as follows:

<i>Supplies from related parties</i>	2020	2019
	BGN '000	BGN '000
Supply of inventories from:		
Companies related through key management personnel	10,420	37
Companies controlled by an associate	62	59
Subsidiaries	55	82
Companies related through shareholding companies with significant influence	-	10,227
	10,537	10,405
Supply of services from:		
Subsidiaries	5,062	9,183
Companies controlled by an associate	1,076	896
Shareholding companies with significant influence	368	326
Companies related through key managing personnel	230	3,027
Companies related through shareholding companies with significant influence	-	362
	6,736	13,794
Investments acquired in:		
Subsidiaries	3,474	9,337
Companies related through shareholding companies with significant influence	-	322
	3,474	9,659
Dividends accrued to:		
Shareholding companies with significant influence	6,883	3,107
Key management personnel	157	98
Companies related through key managing personnel	-	-
	7,040	3,205
Other supplies from:		
Companies controlled by an associate	104	-
Shareholding companies with significant influence	6	6
Subsidiaries	2	-
	112	6
Supplies related to lease assets:		
Companies related through shareholding companies with significant influence	-	1,038
	-	1,038
Supplies for acquisition of PPE from:		
Companies related through key managing personnel	-	20
	-	20

	2020	2019
	<i>BGN '000</i>	<i>BGN '000</i>
<i>Supplies for acquisition of investment property from:</i>		
Companies related through key managing personnel	-	251
Subsidiaries	-	53
	<u>-</u>	<u>304</u>
<i>Supplies of non-current assets from:</i>		
Companies related through key managing personnel	-	96
	<u>-</u>	<u>96</u>
Total	<u>27,899</u>	<u>38,527</u>

The terms and conditions of these transactions do not deviate from the market ones for similar transactions. The accounts and balances with related parties are presented in *Notes 21, 24, 32 and 37*. The members of the key personnel are disclosed in *Note 1*.

Salaries and other short-term benefits of key managing personnel at the amount of BGN 1,321 thousand (2019: BGN 1,242 thousand) are as follows:

- current wages and salaries – BGN – 917 thousand (2019: BGN 909 thousand);
- tantieme – BGN 404 thousand (2019: BGN 333 thousand).

45. EVENTS AFTER THE REPORTING PERIOD

After the end of the reporting period, the following change took place in the subsidiaries of Sopharma Trading AD acquired on 1 October 2020:

- the new management address of all companies is: Sofia, 5, Lachezar Stanchev St., Sopharma Business Powers, Building A, floor 13;
- the companies' names are changed, as follows:

<i>Old name</i>	<i>New name</i>	<i>Date of change</i>
Valentina Vassileva – Lyulin EOOD	Sopharmacy 19 EOOD	28.01.2021
Vasilka Lilovska EOOD	Sopharmacy 20 EOOD	17.02.2021
Venera Mutashka EOOD	Sopharmacy 21 EOOD	05.02.2021
Veselka Vassileva EOOD	Sopharmacy 22 EOOD	18.02.2021
Victoria Angelova EOOD	Sopharmacy 23 EOOD	18.02.2021
Desislava Yordanova EOOD	Sopharmacy 24 EOOD	05.02.2021
Dimka Vladeva EOOD	Sopharmacy 25 EOOD	09.02.2021
Donka Chivganova EOOD	Sopharmacy 26 EOOD	05.02.2021
Ekaterina Mihaylova – Shumen 1 EOOD	Sopharmacy 27 EOOD	19.02.2021
Elka Neykova EOOD	Sopharmacy 28 EOOD	28.01.2021

SOPHARMA AD**NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020**

Emilia Angelova EOOD	Sopharmacy 29 EOOD	18.02.2021
Zhuliana Kotova EOOD	Sopharmacy 30 EOOD	28.01.2021
Ivan Ivanov-1 EOOD	Sopharmacy 31 EOOD	28.01.2021
Iliana Kalushkova EOOD	Sopharmacy 32 EOOD	20.01.2021
Irina Toncheva EOOD	Sopharmacy 33 EOOD	28.01.2021
Kapka Nikolova – Voenna Bolnica EOOD	Sopharmacy 34 EOOD	18.02.2021
Kostadin Gorchev EOOD	Sopharmacy 35 EOOD	17.02.2021
Krasimira Shunina EOOD	Sopharmacy 36 EOOD	05.02.2021
Lora Doncheva EOOD	Sopharmacy 37 EOOD	05.02.2021
Lyudmila Zlatkova EOOD	Sopharmacy 38 EOOD	05.02.2021
Lyudmila Kovacheva EOOD	Sopharmacy 39 EOOD	17.02.2021
Manik Burhazyan EOOD	Sopharmacy 40 EOOD	19.01.2021
Mariyka Zhaygarova EOOD	Sopharmacy 41 EOOD	28.01.2021
Maria Agova EOOD	Sopharmacy 42 EOOD	18.02.2021
Maria Gancheva EOOD	Sopharmacy 43 EOOD	05.02.2021
Maria Kenova EOOD	Sopharmacy 44 EOOD	05.02.2021
Maria Hristova – Motopista EOOD	Sopharmacy 45 EOOD	05.02.2021
Mariana Markova EOOD	Sopharmacy 46 EOOD	18.02.2021
Mery Ivanova EOOD	Sopharmacy 47 EOOD	18.02.2021
Nelly Stavreva EOOD	Sopharmacy 48 EOOD	28.01.2021
Preslava Becheva EOOD	Sopharmacy 49 EOOD	05.02.2021
Rayna Madzharova – St. Georgi Sofiyski EOOD	Sopharmacy 50 EOOD	28.01.2021
Rumyana Ignatova – Gancheva EOOD	Sopharmacy 51 EOOD	28.01.2021
Sashka Todorova EOOD	Sopharmacy 52 EOOD	18.02.2021
Svetlana Harizanova EOOD	Sopharmacy 53 EOOD	08.02.2021
Svetlana Pirpidonova EOOD	Sopharmacy 54 EOOD	18.02.2021
Seiba-Blagoevgrad-1 EOOD	Sopharmacy 55 EOOD	28.01.2021
Silvia Veneva EOOD	Sopharmacy 56 EOOD	18.02.2021
Siyana Milanova EOOD	Sopharmacy 57 EOOD	19.02.2021
Stoyanka Radenkova EOOD	Sopharmacy 58 EOOD	28.01.2021
Ana Avdzhieva EOOD	Sopharmacy 59 EOOD	09.02.2021
Radina Bekova EOOD	Sopharmacy 60 EOOD	19.01.2021
Rumen Raynov EOOD	Sopharmacy 61 EOOD	19.01.2021
Hani Modhi EOOD	Sopharmacy 62 EOOD	19.01.2021
SCS Francise EAD	Sopharmacy 63 EAD	03.02.2021

On 10 March 2021, the Company sold 396,600 of its shares in the capital of Momina Krepost AD, as a result of which the share of ownership of Sopharma AD became 37.46%.

On 15.03.2021 an agreement was concluded between Sopharma AD and Medical Consumables OOD for a common policy in the management of Momina Krepost AD through joint exercise of voting rights.

There are no other events after the date of the statement of financial position that require disclosure in these separate financial statements.